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FOREWORD 
 
 
The year 2013 marked the end of the 
first phase of the Innovative Medicines 
Initiative (IMI) during which 11 Calls for 
proposals were launched. This will lead to the 
establishment of over 50 public-private 
consortia. IMI is now a mature organisation 
that is recognised worldwide as a model 
public-private partnership (PPP) in healthcare. 
 As this report demonstrates, 2013 was 
IMI’s most fruitful year since its launch. The 
projects supported by IMI continue to address 
issues of great relevance to European citizens 
such as antimicrobial resistance, dementia 
and diabetes. More broadly, by creating new 
relationships between the multiple 
stakeholders in healthcare, IMI exerts a 
significant influence on pharmaceutical 
research and development for the common 
benefit of industry and society. 
 Importantly, the added value of IMI 
for the European Union (EU) has been 
documented by the second interim review 
conducted by independent experts on behalf 
of the European Commission (EC). 
 
 
 
 
Furthermore, the entire budget has 
been executed, ensuring that the public and 
private resources are invested in the best 
interest of all parties. 
 On this solid basis, it is now time to 
prepare for IMI 2, the new PPP dedicated to 
research and innovation in healthcare under 
Horizon 2020. With its efficient and highly-
motivated staff, the IMI Executive Office is 
fully committed to continuing its mission of 
facilitator to achieve the ambitious goals set 
for IMI 2, which should result in concrete 
improvements in the standard of care across 
the EU. 
 All this has been and will be possible 
owing to the efficient collaboration between 
the EC services and the European Federation 
of Pharmaceutical Industries and Associations 
(EFPIA), with the essential support of the IMI 
Scientific Committee and the IMI States 
Representatives Group (SRG). Furthermore, 
tribute should be paid to the over 6 000 
scientists who every day contribute to IMI’s 
reputation as a European flagship for 
pharmaceutical research. 
 
 
14 February 2014 
Michel Goldman, MD, PhD 
IMI Executive Director 
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 1. ACHIEVING IMI’S STRATEGIC OBJECTIVES 
 
IMI, the largest PPP in the life sciences, was 
set up in 2008 with the important goal of 
significantly improving the efficiency and 
effectiveness of the drug development 
process and thereby helping to bring more 
effective and safer innovative medicines to 
patients. 
At the end of its first phase, the programme 
has reached maturity and therefore its 
performance, impact on, and value to the 
stakeholders can be better assessed.  
However, developing metrics to measure a 
PPP’s performance is challenging. To quote 
from the recent ‘Consortiopedia’ report by 
FasterCures Milken Institute, there are 
currently ‘no systematic methods that can be 
used to compare across consortia, with many 
organisations relying on those used by 
academic researchers to assess the impact of 
interdisciplinary collaborations such as 
number of patents, number of publications 
and the quality of journals, or number of 
citations’1. The report concludes: ‘There is a 
need to move beyond these metrics and 
develop more quantitative measures of 
output that are meaningful to the audiences 
interested in the consortium.’ 
IMI’s efforts to measure and analyse its output 
have evolved considerably since the initial key 
performance indicator (KPI) framework set 
out in 2011, and today IMI applies a mixture 
of metrics and qualitative assessments to 
measure the performance and impact of the 
programme, see the following table. These 
reflect the strategic objectives that were set 
out by the Council Regulation at the inception 
of IMI, notably to support coordinated ‘non-
competitive pharmaceutical research and 
development (R&D)’ to overcome the 
research bottlenecks in the drug development 
process, by: 
 increasing the research investment in the 
biopharmaceutical sector; 
 pooling resources and fostering 
collaboration between the public and 
private sectors; 
1 http://www.fastercures.org/reports/view/39  
 promoting the involvement of small and 
medium-sized enterprises (SMEs) in its 
activities; 
 implementing the research priorities as 
set out in the Strategic Research Agenda 
(SRA). 
Nevertheless, IMI is convinced that its metrics 
can be developed and optimised further, and 
in collaboration with leaders in the field, is 
working on producing a reliable assessment 
framework that would be suitable to a new 
public-private and multi-sector collaboration 
model such as IMI. 
 
Assessment of project achievements 
An extensive analysis of IMI’s ongoing projects 
has been performed by extracting project 
achievements from progress reports of the 
projects, interim reviews, and scientific 
publications resulting from the projects. These 
achievements support the following messages 
that have been and will be conveyed to the 
relevant audiences: 
 IMI enhances EU competitiveness in the 
pharmaceutical sector by promoting a 
new ecosystem based on open innovation; 
 IMI fosters European scientific leadership 
in the medical sciences by creating 
collaborative intelligence networks; 
 IMI accelerates the development of drugs 
for major unmet public health needs and 
the access of patients to innovative 
medicines; 
 IMI offers new business opportunities to 
SMEs active in the pharmaceutical sector; 
 IMI develops innovative tools and 
educates scientists and patients to 
optimise data sharing and the analysis of 
‘big data’ for the benefit of patients and 
industry. 
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No. KPI 
Reinforce pharmaceutical R&D in Europe by 
addressing bottlenecks and gaps in drug research 
Target 2013 Results 
1 The extent to which IMI projects cover the value chain of drug development Qualitative assessment 
Analysis was performed and results are 
reported in section 1.1 
2 
Percentage of projects achieving 75% of pre-set 
milestones within the first two years from the launch 
of the projects 
 ≥90% 
 68% 
This shows the status at the end of the 
first two reporting periods of Calls 1 
and 2 projects and at the end of the 
first reporting period for the more 
recently launched projects in Calls 3 
and 4. 
3 
Measurable outputs in terms of: 
 biomarkers, tools and models qualified for use 
in drug development; 
 validated standards, measurements, 
methodologies, models, simulation 
technologies, tools and platforms successfully 
integrated in the R&D process; 
 Students/scientists enrolled in education and 
training activities. 
Quantitative and qualitative assessment 
Analysis was performed and results are 
reported in section 1.2.2 
4 Bibliometric indicator: Citation scores of project publications Quantitative and qualitative assessment 
Analysis was performed and results are 
reported in section 1.2.1 
5 
 Percentage of participants in signed Grant 
Agreements that are SMEs 
 Percentage of overall budget for projects 
allocated to SMEs 
 ≥13% 
 
 ≥15% 
 15.2% 
 
 18.5% 
6 
Number of new ventures/collaborations, business 
activities, patents and licenses resulting from 
projects 
Quantitative and qualitative assessment 
Analysis was performed and results are 
reported in section 1.2.3 and 1.4 
7 Impact on societal and healthcare challenges 
Collect preliminary indications on the 
impact on society and healthcare from 
ongoing projects 
Analysis was performed and results are 
reported in section 1.2.4 
Maximise the Efficiency and Effectiveness of the 
Executive Office 
Target 2013 
Results 
8 Average Time to Pay  
 Pre-financing payments: ≤15 days 
 Interim payments to beneficiaries: 
≤45 days 
 18 days 
 66 days 
9 Average Time to Grant  
 ≤290 days  279  (from EOI submission to GA 
signature) 
 149 (from FPP submission to GA 
signature 
10 Average monthly visitors to the IMI website   ≥7 000 unique users  11 081 
11 Percentage of filled positions  100%  100% 
12 Annual budget execution 
Running costs: 
 100% commitment and payment 
appropriations 
Operational costs: 
 commitment appropriations as close 
as possible to 100% but ≥95% 
 payment appropriations as close as 
possible to 100% but ≥90% 
Running costs: 
 Commitment 84.7% 
 Payment  69.6% 
Operational costs: 
Commitment 100% 
Payment 99.4% 
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  Implementation of the Strategic Research Agenda of IMI 1.1
 
The first IMI Call for proposals was launched in April 2008. Since then IMI has launched 11 Calls for 
proposals and committed its entire budget envelope. Currently, there are 46 ongoing projects; once 
the last projects from the 11th Call are launched, IMI will have created a total of 59 projects. A key 
mission, and achievement, of the Executive Office team (36 people) has been to facilitate the 
mobilisation of the stakeholders and the creation of the networks behind these projects. It is 
estimated that these projects involve more than 6 000 scientists and 1 296 teams.  
 
 
The content of IMI portfolio, as envisioned in the initial IMI Strategic Research Agenda (SRA) 
developed in 2007, includes projects focused on drug discovery and the early stages of the drug 
development process, as well as on education and training (E&T). However the trend towards later 
phases of the value chain such as clinical development and risk-benefit assessment, as well as an 
expansion into chemical development and pharmaceutical science, becomes more visible with Calls 
launched after the update of the SRA in 2011. From Call 5 onward there has been a shift towards 
‘think big’ projects such as the European Lead Factory (ELF), and the antimicrobial resistance 
programme New Drugs for Bad Bugs (ND4BB). Moreover, efforts have been made towards creation 
of focused platforms where projects active in the same area work collaboratively in a legal 
framework that fosters synergies, complementarities and lessons learnt to optimise impact and 
resource exploitation. The figure below represents a mapping of current IMI activities according to 
the value chain of drug development and scientific or disease areas. 
Extent to which IMI projects cover the value chain of drug development 
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The IMI portfolio is broad and comprehensively covers the full spectrum of the R&D value chain as 
well as many key disease and interest areas. The following figure2 presents the breakdown of the IMI 
budget by the scientific areas supported and the ratio of IMI funding versus in kind contribution from 
EFPIA companies, as well as the list of industrial partners involved in the top three research areas.   
 
 IMI project output assessment 1.2
1.2.1 Bibliometric outputs 
One of the traditional ways of measuring scientific output is via bibliometric analysis, which analyses 
how many scientific papers have been produced by a given group (in this case, IMI projects), what 
journals they were published in, and how often they have been cited by other researchers in 
subsequent publications. IMI conducts these analyses with the assistance of Thomson Reuters. The 
latest data has been is based on publications resulting from IMI project up to 31 December 2013. 
 
The results show that the overall volume of IMI project research has increased rapidly since 2009 and 
the initiative continues to show rapid growth, as illustrated in the graph below. By 31 December 
2013, IMI projects had produced 657 publications (629 of which are indexed in the Web of Science), 
half of which were published in 2013. It is expected that publication output will continue to raise as 
the number of projects increases and those projects yield results for publication. 
2 This diagram is adapted from Nature Medicine 20, 5 (2014) |News –‘Infectious disease leads in first phase of Europe’s IMI 
effort’ published online on 07 January 2014 at http://www.nature.com/nm/journal/v20/n1/full/nm0114-5.html. 
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Source: Thomson Reuters analysis 2014
 IMI project publications have been 
published in a total of 301 journals, and 74.4% 
of papers were published in top quartile 
journals (determined by journal impact 
factor), including JAMA (the Journal of the 
American Medical Association), Science and 
Nature Publishing Group titles.  
 The analysis also reveals that 24.4% of 
papers from IMI projects are ‘highly cited’, 
meaning they are in the top 10% of papers by 
journal category and year of publication. 
 The average journal impact factor of all 
the journals in which IMI project publications 
have been published is 6.05. 
 The citation impact of papers associated 
with IMI projects is internationally influential, 
with an average citation impact average of 
2.05 for the four-year period 2010-2013 
(compared to the world baseline of 1.0). This 
is a substantial increase since 2012 (when the 
average citation impact was 1.55) and 
indicates that the quality of IMI research has 
not only been maintained but has increased 
while output has grown. In comparison, the 
EU’s average citation impact relative to world 
baseline for the same four-year period in 
similar research fields was 1.15. 
 IMI project research published in, clinical 
neurology and genetics & heredity, research & 
experimental medicine as well as psychiatry is 
exceptionally well cited, with average citation 
impact well above the European and world 
benchmarks. This performance is driven by 
multiple highly-cited papers, as well as 
publications identified as a ‘hot papers’ in the 
Thomson Reuters databases. Hot papers are 
those which gather citations at a faster than 
average rate and may represent 
breakthroughs in the field(s) to which they 
relate.
0
50
100
150
200
250
300
350
2009 2010 2011 2012 2013
Number of publications per year 
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Source: Thomson Reuters analysis 2014 
IMI project research also compares well to research supported by the Wellcome Trust, an established 
funding organisation. Research from both funders is internationally influential with a citation impact 
twice the world average and with just under one fifth of papers being highly cited, as shown in the 
table below. 
 
  
Number of papers  
2010-2013 
Citation impact 
(normalised) 
Percentage of 
highly-cited papers 
IMI project research 599 2.05 24.4% 
Wellcome Trust research 21 421 1.95 23.4% 
Source: Thomson Reuters analysis 2014 
 
  
0.0 1.0 2.0 3.0
Clinical Neurology
Genetics & Heredity
Research & Experimental Medicine
Psychiatry
Pharmacology & Pharmacy
Neurosciences
Rheumatology
Biochemistry & Molecular Biology
Oncology
Mathematical & Computational Biology
Endocrinology & Metabolism
Overall
Citation impact by research field 
IMI papers EU papers
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  In order to compare the research 
performance of individual projects, the 
number of papers, four-year average citation 
impact and share of highly-cited papers were 
calculated. Projects from Calls 1-3 with at least 
10 publications during the time period 2010-
2013 were included in the analysis. 
 The average citation impact of all 14 
projects is above world citation impact (1.0) 
Research associated with 9 of these 14 
projects (Europain, MARCAR, NEWMEDS, 
Pharma-Cog, PROTECT, U-BIOPRED, QuIC-
ConCePT, OncoTrack, and EU-AIMS) is very 
well cited, with a citation impact of at least 
twice the world average or even higher. 
 Research associated with the PROTECT 
and EU-AIMS projects is exceptionally well 
cited (3.91 and 3.96 respectively). Both 
projects citation impact are nearly four times 
the world average and well above the average 
for all IMI projects.  
 From Call 1 NEWMEDS is the most prolific 
project, followed by EUROPAIN, both cited 
more than twice world average.   
 BTCure is the most prolific among Call 2 
projects with 107 publications and its papers 
are cited nearly twice world average (1.90). 
 
Source: Thomson Reuters analysis 2014 
Trends in the normalised citation impact (i.e. the citation impact that has been adjusted to take 
account of differences between research fields) and raw citation impact (which does not take 
account of differences between research fields) have been analysed and visualised in the graph 
below. The graph demonstrates that the quality of IMI projects’ published work, as indexed by 
citation impacts, as well as the percentage of highly-cited papers, has not only been maintained since 
the first report in October 2012 (R1), but has increased while output has grown (as measured in 
second and third reports, R2 and R3 respectively). 
eTOX 
EUROPAIN 
MARCAR 
NEWMEDS 
Pharma-Cog 
PROTECT 
SUMMIT 
U-BIOPRED 
BTCure 
IMIDIA 
scale = 10% highly-
cited papers 
Onco Track 
Open  
PHACTS 
Quick-Concept 
EU-AIMS 
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
10 25 40 55 70 85 100 115
Citation  
impact  
Number of papers 
Research performance analysis 
IMI (all projects) 
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Source: ‘Bibliometric analysis of ongoing projects’, Thomson Reuters Third Report - October 2013  
 
 
1.2.2 Research and development related outputs 
The R&D-related outputs resulting from ongoing projects have been classified according to the 
following nine categories: 
1. Identification and validation of new drug targets and novel hit and lead discovery 
2. Establishment of robust, validated tools for preclinical drug development  
3. Development of biomarkers and tools predictive of clinical outcomes (efficacy and safety) 
4. Clinical trials - improved design and process 
5. ‘Big data’ solutions to leverage knowledge 
6. Implementation of data standards  
7. Impact on regulatory framework  
8. Implementation of project results inside industry  
9. Education and training for a new generation of R&D scientists  
 
The following table describes in detail many important results that are being delivered by IMI 
projects. These advances have a great potential to improve global healthcare and provide novel, 
more effective treatments to patients faster. 
 
Significant progress has already been made to better understand the disease mechanisms and 
therefore enable development of better treatment in diabetes, lung disorders, autism, 
neuropsychiatric disorders, cancer and chronic pain. 
 
IMI researchers are developing tools that will accelerate the medicines development process as well 
as reduce the time and cost of clinical trials to produce treatments that more precisely target each 
disease. 
 
Safety of medicines is another area of high importance and it is being tackled by multidisciplinary 
approaches such as development of safety markers that could be detected by a simple blood test; 
computer modelling and predicting potential toxicity of compounds before considering them as drug 
candidates; development of improved methods for monitoring adverse effects of medicines that is 
already available to patients in order to identify problems early and prevent serious complications. 
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 Other benefits from IMI projects include tools that will result in the replacement, reduction or 
refinement (3Rs) of animal use in drug development, as recognised by the Fund for the Replacement 
of Animal Research in Medical Experiments3. 
 
Many of these achievements are completely novel, unprecedented, unique in scale, or moved earlier 
results to another stage. 
 
Brief descriptions of the project outputs and objectives are set out as follows. The table below lists 
the new developments that have taken place in 2013. Earlier achievements are listed in the Annual 
Activity Report 2012. 
 
 
Project Area Results  
1. Identification and validation of new drug targets and novel hit and lead discovery 
Listed achievements contribute to better understanding of disease and therefore providing 
accelerated pathways towards new or improved treatments for various diseases in areas of unmet 
medical need. Furthermore the discovery programs assemble and screen large, unique compound 
collections therefore enabling identification of new potent molecules that might lead to novel 
medicines for rare or neglected diseases. 
Europain chronic pain 
Established the Pain Networks web database 
(www.painnetworks.org) that will allow the sharing of next-
generation sequence data and the further integration of genetic data 
globally.  
SUMMIT diabetes 
Determination that Nuclear Factor of Activated T-Cells (NFAT) 
signalling may be a novel and attractive approach for the treatment 
of diabetic macrovascular complications. 
BTCure 
rheumatoid 
arthritis 
Identification of new targets for therapy, including 6 potential 
microRNA targets that are translatable between mice and RA 
patients. 
ELF 
drug discovery in 
rare or neglected  
diseases  
326 486 unique and non-commercially available compounds received 
from the EFPIA partners and reformatted into screening plates and 
transferred to the relevant screening facilities at EFPIA partners and 
Pivot Park Screening Centre. 
Screening Selection Committee installed and 41 public target 
proposals received, of which 17 have been approved. 24 EFPIA 
targets nominated and approved. 
9 high throughput screening (HTS) campaigns on public targets 
completed and at least 10 HTS campaigns on EFPIA targets 
completed. 
Collected 170 proposals for new libraries from the chemistry public 
partners (academic and SMEs), of which 140 have been approved, 26 
have been rejected, and 4 are under consideration. Of the approved 
proposals, 31 are in production (average expected size is 500 
compounds/library, which would result in 15 000 compounds being 
generated for the public compound collection). 
3 Balls, M. (2012) ‘FRAME and the Pharmaceutical Industry’, ATLA 40, pp. 295-300. 
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Project Area Results  
2. Establishment of robust, validated tools for preclinical drug discovery & 
development 
Listed achievements contribute to speeding up the development of new medicines by providing 
improved tools that more precisely predict whether given candidate molecule will be effective in 
patients before they are progressed into clinical development. The tools include unique in vitro or 
animal models that are more closely reproduce the patient reality, non-invasive imaging techniques, 
as well as computer models that allow efficacy prediction without the need to expose the patients or 
even animals test compounds. 
Europain chronic pain 
Development of three colonies of genetically modified-mice carrying 
clinically-relevant SCN9a mutations as novel surrogate models of 
spontaneous pain. 
Development of seven new rodent models of pain, including the 
Zucker diabetic fatty (ZDF) rat, the most viable and clinically-relevant 
animal model of painful diabetic neuropathy to have been described 
to date. 
NEWMEDS 
schizophrenia, 
depression 
Publication of three Nature protocols describing assays developed 
within the NEWMEDS touchscreen platform to measure various 
aspects of executive and cognitive function in rodents. 
Demonstration of the test–retest reliability of the positron emission 
tomography (PET) tracer [11C]AZ10419369 binding to 5-HT1B 
receptors in the human brain. 
Development of a mouse model that recapitulates key features of the 
15q13.3 microdeletion syndrome including schizophrenia- and 
epilepsy-related alterations. 
Establishment (by a novel application of multivariate analysis across 
the whole brain) of the modulation of the ketamine pharmacological 
magnetic resonance imaging (phMRI) response as a tool to 
investigate the mechanistic action of novel compounds relevant for 
psychiatric disorders such as schizophrenia and depression. 
Demonstration that cognitive and neural abnormalities observed in 
schizophrenia are also found in control carriers of CNVs (copy 
number variations) that confer a high risk of the disease. Findings 
published in Nature. 
IMIDIA diabetes 
Validation of the efficiency and specificity of EnvKA-pseudotyped 
lentiviral vectors and definition of the best route to perform in vivo 
labelling of beta cells. 
Establishment of the largest collection of human islets from control 
individuals and type 2 diabetic patients, characterised by 
computational analysis of the genome, transcriptome, lipidome and 
morphological and physiological characteristics. 
U-BIOPRED asthma 
Establishment of a new animal model of severe asthma by combining 
exposure to the house dust mite with exposure to a virus, which 
produces a model that is less responsive to standard therapy.  
Development of a human in vivo model of asthma exacerbations 
using a source rhinovirus inoculum produced according to good 
manufacturing practice (GMP). 
ANNUAL ACTIVITY REPORT 2013 INNOVATIVE MEDICINES INITIATIVE  page 14 of 118 
 
 
 EU-AIMS autism 
Generation of an inventory of applied rodent behavioural testing 
paradigms relevant to autism spectrum disorders (ASD).  
Demonstration of the high relevance of Nlgn4 null mutant mice as an 
ASD model with both construct and face validity and development of 
a gender-specific autism severity composite score.  
PREDECT cancer 
Development of novel test models (in vitro models, genetically-
engineered mouse models (GEMMs) and patient-derived xenograph 
(PDX) models) of prostate, breast and lung cancer.  
Characterisation of three-dimensional (3D) and slice platforms and 
development of guidelines on their use and limits for industry and 
academia - preventing the waste of resources on uncharacterised 
platforms. 
MARCAR cancer 
Discovery of DNA modifications in liver cells representing fingerprints, 
termed an EPICODE, of exposure to non-genotoxic carcinogenic 
(NGC) compounds. 
Development of ‘InCroMAP’, a new tool for the automated mapping 
of relationships between biological processes at a molecular level. It 
allows the analysis and visualisation of high-level microarray data 
from individual or multiple platforms. The tool is open access at 
http://www.ra.cs.uni-tuebingen.de/software/InCroMAP/.  
BTCure 
rheumatoid 
arthritis 
Development of standardised, multiplex assays for the analysis of 
auto-antibodies specific for rheumatoid arthritis (RA). The platform 
has been used to describe the emerging immune response that 
occurs before the development of arthritis and provides a basis for 
future clinical trials on pre-RA individuals. 
Enhanced tools and methods for the imaging of migrating 
lymphocytes in animal models of RA. This will form the basis for 
testing new drugs in animal models, when these drugs are directed 
towards molecules of importance for T- and B-cell migration. 
Standardisation of four mouse models for arthritis with an emphasis 
on the most clinically-relevant animal models described so far. 
OncoTrack cancer 
Establishment of all the technologies and procedures required to 
generate and analyse the data for in silico modelling as well as for 
biomarker discovery using clinically-relevant samples. 
Established 70 novel xenograft models that can be used to explore 
response to treatment. 
Established 50 canceroid cell cultures established for investigation of 
tumour progenitor cell biology. 
Established drug sensitivity testing in high throughput screening (HTS) 
format established. 
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Project Area Results  
3. Development of biomarkers and tools predictive of clinical outcomes  
(efficacy and safety) 
Listed achievements contribute to speeding up the development of new medicines by providing 
improved tools that will predict whether the studied medicine candidates will benefit the patents, 
whether they are safe and should be taken further into development process. The tools include 
markers that could be detected by a simple blood test, imaging technique or patient reported 
outcomes. Ultimately those reliable measures or tools will help eliminate ineffective or unsafe 
compounds early in the development process and therefore avoid unnecessarily exposing patients or 
investing in unnecessary development programmes. 
NEWMEDS 
schizophrenia,  
depression 
Demonstration by genome-wide association study (GWAS) in a cohort 
of 2 897 individuals of European ancestry that is not possible to 
associate a single common genetic variant with antidepressant 
response at a clinically-relevant level. 
Identification by whole-exome sequencing of a polymorphism in the 
BMP5 gene associated with response to selective serotonin reuptake 
inhibitor (SSRI) treatment for major depression. 
Establishment that DNA methylation in interleukin-11 predicts clinical 
response to antidepressants. 
Pharma-Cog 
Alzheimer’s 
disease 
Development of the analysis of electroencephalographic (EEG) 
rhythms in rodents as a translational biomarker of cognitive 
impairment. 
Demonstration that cortical resting state EEG in Alzheimer’s disease 
(AD) patients is sensitive to pharmacological treatment with 
acetylcholine esterase inhibitors (AchEis) and memantine, and it is a 
marker of disease progression in mild cognitive impairment (MCI). 
Contribution of structural imaging data to the C-Path Coalition 
Against Major Diseases (CAMD) consortium for further validation by 
the United States (US) Food and Drug Administration (FDA) on the 
use of hippocampal volume as a marker of enrichment in clinical 
trials. 
Europain chronic pain 
Demonstration by magnetic resonance imaging (MRI) that after 
repetitive pain exposure, healthy pain sensitizers exhibit grey matter 
changes similar to those seen in chronic pain patients.  
Demonstration that multi-arterial spin labelling functional magnetic 
resonance imaging (ASL-FMRI) has excellent reproducibility to 
investigate functional changes in brain activation both in surrogate 
pain models and chronic pain patients. 
PROactive COPD 
Development of patient-reported outcome (PRO) tools to capture 
physical activity for patients with chronic obstructive pulmonary 
disease (COPD). Finalisation of the protocols of a set of collaborative 
studies to gather sufficient data on the robustness of the PROs with 
the view to the qualification of the tools.  
SUMMIT diabetes 
Assembly of one of the largest, homogeneous population samples of 
European ancestry subjects with type 1 diabetes (more than 6 000 
subjects), and identification by GWAS of novel susceptibility sites 
associated with diabetes neuropathy (DN). 
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 IMIDIA diabetes 
Discovery of a lipid signature in the serum of mice fed with a high-fat 
diet that correlates with physiological readouts – a potential novel 
biomarker for diabetes. 
EU-AIMS autism 
Demonstration that babies aged 4-6 months at risk of autism show a 
reduced response to social cues and different brain activity patterns 
compared to other babies. 
EMIF-AD 
Alzheimer’s 
disease 
Development of a comprehensive study protocol allowing the 
collection of the full range of AD biomarkers (including blood, 
cerebrospinal fluid (CSF), imaging, cognitive status, etc.) in 300 
healthy elderly subjects.  
Development of a detailed questionnaire to characterise AD cohorts 
across Europe and collection of data from 23 cohorts out of 52. All 
information on the AD cohorts is made available in an EMIF browser 
to allow selection of relevant cohorts for further studies. 
Development of a flow diagram for MCI and AD to operationalise 
revised international and NIA-AA (National Institute on Aging–
Alzheimer's Association) diagnostic criteria. This will allow the use of 
the criteria to tackle the investigation work of the project on the 
prevalence and risk factors for dementia in Europe.   
Setting up of a generic taxonomy for dementia cohorts. Data 
uploaded in tranSMART for the first AD cohorts. This is a key step 
towards the validation of the project’s efforts on to define extreme 
phenotypes and discover new biomarkers. 
EMIF-Metabolic 
metabolic 
syndromes 
Review and catalogue developed of all available industry data 
resources (electronic health records (EHRs) and clinical trials). 
Medium-size obese cohorts have been selected as well as internal 
EFPIA data resources (EHRs and clinical trials) so that questions on 
the predictors of the complications of obesity can start to be 
interrogated. 
EMIF 
AD & metabolic 
syndromes 
Establishment of clinical protocol for a joint AD/metabolic study and 
start of patient recruitment. 
SAFE-T safety 
Completed the evaluation of 153 potential biomarker candidates for 
drug-induced injury of the kidney, liver and vascular system. 79 have 
been selected for qualification studies.  
Assays for around 65 biomarkers developed; assay validation 95% 
complete. 
e-TOX 
knowledge 
management, 
safety 
Released the first beta version of eTOXsys to the consortium. This 
application combines the outputs mentioned below to allow the 
querying of the eTOX database through standard chemical and text-
based searches and gives a prediction of first-order toxicity for 65 
endpoints. 
Has built a unique toxicology information database utilising legacy 
reports from industry partners and public data to develop better in 
silico tools for toxicology prediction of new compounds. This 
database contains 2 859 preclinical reports from the participating 
pharmaceutical companies available for predictive modelling with a 
further 3 030 reports being processed.  
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Assembled a second database of publically-available data covering 
169 000 compounds annotated to over 400 targets with more than 
650 000 activities extracted from over 11 000 publications. 
Developed 89 in silico models and established a workflow for their 
formal documentation, verification and validation. 
Has built a series of ontologies to harmonise the verbatim terms 
compiled in the project database. More than 1.5 million terms have 
been curated. 
MARCAR safety 
Gained novel insights into early mechanisms of non getotoxic 
carcinogens (NGCs) that might lead to novel target identification. 
  
Identification of novel genes that may be able to predict whether 
potential drugs have cancer-inducing properties. 
PROTECT pharmacovigilance 
Establishment of the Drug Consumption Databases in Europe using 
data from European national sources and data from IMS Health for 17 
countries– publically available. 
Establishment of the database of adverse drug reactions (ADRs) of 
centrally authorised medicinal products with 45 298 ADRs for 654 
medicines – publically available. 
Developed a method to calculate the population exposed to drugs. 
RAPP-ID infectious diseases 
Development of conceptual point of care test (POCT) platforms for 
community-acquired pneumonia, influenza, tuberculosis. 
Designed conceptual POCTs for the detection of antibiotic resistance 
for ventilator-associated pneumonia and tuberculosis. 
BTCure 
rheumatoid 
arthritis 
Identification of biomarkers for response to therapy. 
Production of monoclonal human antibodies to autoantigenic targets 
in RA: these were generated in academia, produced by industry, and 
are now used by the entire consortium. 
QuIC-ConCePT cancer 
Development and technical validation of 5 new cancer imaging 
biomarkers for tumour cell proliferation, cell death, apoptosis and 
invasion. Two of the biomarkers are moving into the biological 
validation studies with a goal to incorporate them into  decision-
making in Phase I trials of investigational cancer therapies by October 
2016. 
PREDECT cancer 
Set up of a central IHC (immunohistochemistry)/TMA (tissue 
microarray) platform as the common molecular pathology platform 
to assess the different models. TMA biobanking set up with over 
1 071 samples. 
OncoTrack cancer 
Design of a selector assay targeting 28 genes commonly mutated in 
solid tumours. 
Discovered over 170 potential biomarkers able to predict tumour 
sensitivity to certain drugs. 
U-BIOPRED asthma 
‘Omic’ platforms completed and preliminary fingerprints and 
handprints generated through an interim analysis on limited subsets 
of various types of high-dimensional data aiming at better defining 
severe asthma.  
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Project Area Results  
4. Clinical trials - improved design & process 
Listed achievements contribute to speeding up the development of new medicines by investigating 
novel clinical trial design that better reflect real life situations, relevant to the disease and its 
progression. Proposed new paradigms require less patients and time but at the same time generate 
more robust information/evidence. Various projects have made efforts to also improve patient 
recruitment, for example by utilizing of healthcare records or creating well characterised patient 
registries, to focus clinical trials on more precisely characterised patient population. 
NEWMEDS 
schizophrenia 
depression 
Demonstrated that it is possible to increase the power of a clinical 
study by combining into a single statistic the drug effect in those who 
complete a trial and the proportion of patients in each treatment 
group who complete a trial. This approach is more sensitive to the 
effects of an experimental treatment versus active controls (but not 
placebo) than the standard approach. 
Development of consensus criteria for the optimisation of clinical 
trials of pharmacological agents for treating negative symptoms in 
schizophrenia. Started informal consultation with regulatory 
authorities (FDA & European Medicines Agency (EMA)). 
Pharma-Cog 
Alzheimer’s  
disease 
Recruitment completed of 156 MCI patients for the clinical validation 
of the utility of the Pharma-Cog biomarker matrix to follow disease 
progression. 
Europain chronic pain 
Improved description of pathogenic mechanisms and subgrouping of 
patients with persistent pain after previous hernia surgery, breast 
cancer surgery and pulmonary surgery. 
EU-AIMS autism 
Development of a clinical network of over 40 partners across Europe. 
Development of an online survey tool to establish an inventory of 
ASD patient characteristics and clinical measures routinely used 
across Europe. 
Started recruitment of the to-date two largest European multi-site 
genetic/imaging/behavioural clinical studies on ASD: a high-risk infant 
sibling study, and an accelerated longitudinal clinical study. 
Discovered that autism affects different parts of the brain in males 
and females with high-functioning autism, suggesting that 
researchers should stratify their results by gender and avoid 
assuming that results found in males also apply to females. 
U-BIOPRED asthma 
Completed recruitment of the cohorts of adult and paediatric 
patients with severe asthma, and appropriate controls (1 029 
patients: 730 adults including severe smokers and 299 paediatric 
patients including pre-school children). 
Established a central registry of adults and children with severe 
asthma which can be used for future studies. Biobank of baseline 
samples established: Sample numbers over 100 000. 
BTCure 
rheumatoid 
arthritis 
Identified and characterised cohorts and biobanks for different stages 
of RA (33 cohorts, more than 10 000 biosamples), to enable 
identification of factors for RA development in high-risk individuals. 
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EH4CR 
knowledge 
management 
Business modelling implementing exploitation of electronic health 
records for clinical research has been initiated.  
Released a reference implementation of the protocol feasibility 
service/demonstrator; currently nine hospitals in three countries are 
using actual anonymised EHR data. 
Ran pilots on identification and assessment of eligible patients 
through EHRs.   
Stakeholder environment scan published. Held a stakeholder 
awareness session for potential service providers with a 
demonstration of the tools.  
Assessment of the protocol feasibility services. Overall 373 free-text 
eligibility criteria were reviewed by clinical trial experts. 175 
feasibility criteria were transformed into computable representation. 
Pilot sites mapped approximately 300 data fields from their local 
terminologies.  
ND4BB - 
COMBACTE 
antibiotics 
Creation of a high quality, pan-European clinical trial network of 
hospitals prepared for and experienced in performing high-quality 
clinical studies with new antimicrobials against resistant bacterial 
pathogens (CLIN-Net), supported by a high-quality laboratory 
surveillance network (LAB-NET). 290 clinical sites in 33 countries are 
already candidates for joining CLIN-Net. 
U-BIOPRED asthma 
Great involvement of patients in activities of the projects through the 
Ethics Board, Safety Monitoring Board and Patient Input Platform, 
allowing the inclusion of patients’ perspective in project activities 
(clinical trial design, PRO development, informed consent form 
drafting, patient information forms), helping ensure project 
outcomes are more relevant for people with the disease.  
PROactive COPD 
GetReal 
relative 
effectiveness 
Created for the first time a public-private consortium bringing 
together all key stakeholders (namely industry, academia, regulatory 
agencies, reimbursement agencies, healthcare budget holders, and 
patient groups), who are not used to working together, to share their 
insights and know-how, with the view to developing new approaches 
for incorporating real-life data into drug development. 
 
 
Project Area Results  
5. ‘Big data’ solutions to leverage knowledge 
Listed achievements contribute to speeding up the development of new medicines by providing 
solutions to best take advantage of existing or newly generated data. By pooling , linking and then 
analysing various vast collections of data one can make important discoveries that will further improve 
our understanding of disease, predict how test compounds will behave once administered to patients, 
or help best design clinical trials. 
Open PHACTS 
knowledge 
management 
Integrated 13 pharmacological information sources into a modular 
platform to facilitate queries and analysis of data. The Open PHACTS 
infrastructure can support many different scientific domains and 
questions. 
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 12 applications for advanced analytics and prediction are using the 
Open PHACTS service. 
Setting up of a subscription-based, not-for-profit entity, the Open 
PHACTS Foundation, to ensure sustainability of the data integration 
services and data quality. The services will also be useful to current 
and future IMI projects.    
EMIF 
knowledge 
management 
Completed curation of information from five AD cohorts, and 
uploaded three into EMIF-tranSMART; the other two are awaiting 
completion of contracts.   
Piloted the Private Remote Research Environment (a PRRE allows 
access to electronic health records in a secure manner for a given 
research question). 
Demographic and follow-up profiles have been summarised for all 13 
EHR data sources covering 48 million patients in 7 European 
countries. A prototype fingerprint browser has been developed. 
eTRIKS 
knowledge 
management 
Replaced a component of the open source tranSMART platform with 
an open source component, reducing the cost of software licenses for 
the user. Collaborating with the tranSMART Foundation to share 
platform development work.    
Supporting five collaborative projects with design and 
implementation of knowledge management solutions with four 
eTRIKS/tranSMART deployments. Preparing to support another four 
consortia. 
Established a public tranSMART version containing open access data 
from 22 subject-level translational studies and aggregated summary 
results from 1 400 Gene Expression Atlas studies. 
DDMoRe 
knowledge 
management 
Clinical trial simulator (2nd release) and model-based adaptive 
optimal design tool (1st release) delivered. 
Initial version of modelling language standards (modelling description 
language (MDL) and pharmacometrics markup language (PharmML)) 
including an MDL editor released publicly on www.ddmore.eu. New 
standards will facilitate exchange/re-use of drug and disease 
modelling to guide quantitative decision-making. 
Piloted an interoperability framework that supports execution of 30 
drug/disease models in diabetes, oncology, central nervous system 
(CNS), infectious diseases, and inflammatory diseases.  
OrBiTo drug delivery 
Design and population of an OrBiTo database with historical in vivo 
pharmacokinetic data for novel compounds (so far over80 active 
pharmaceutical ingredients (APIs) and about 450 in vivo studies) from 
the EFPIA partners, which is a core resource for continued work in the 
project to improve and validate predictive methods. 
K4DD drug discovery 
Defined selection criteria for target-related data harvesting from 
industry programmes. 
Completed a list of agreed targets to be shared among industry and 
public partners of the consortium including 14 fully-approved targets 
covering different classes of targets, as well as 31 partially-approved 
targets. 
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OncoTrack cancer 
The ‘OncoTrack DB’ (data-integration platform for systems biology 
collaborations) has been set up and expanded significantly. 
tranSMART (data warehouse and data mining infrastructure for 
hypothesis generation and testing) has been implemented. 
U-BIOPRED asthma 
Severe asthma patient registry established from the baseline data 
collected. This relates to Adult Cohorts A (307 patients) and B (106 
patients) and Paediatric Cohorts A (93) and C (81), after exclusion of 
screen failures, dropouts and violators.  
 
Project Area Results  
6. Implementation of data standards 
In an era of increased transparency and data sharing as well as large scale pooling and analyses of data 
from multiple origins, data standards are essential to ensure accuracy, reproducibility and scientific 
integrity. Quality of data is an essential pre-requisite for implementation of new research and 
regulatory paradigms 
eTRIKS 
knowledge 
management 
Developed and adopted translational information standards. Adopted 
the Clinical Data Interchange Standards Consortium (CDISC) data 
standards for clinical research data. Evaluation of standards for non-
clinical data is ongoing. 
BioVacSafe vaccines 
Implemented CDISC-CDASH (Clinical Data Acquisition Standards 
Harmonisation) for data collection in two large cohorts covering more 
than 4 600 disease episodes of the cohorts. The resulting data 
extracted is being transformed into CDISC-SDTM (Study Data 
Tabulation Model) format for the purpose of the data analysis. Full 
mapping and harmonisation with the BRIDG UML (Biomedical 
Research Integrated Domain Group unified modelling language). 
model will support the interoperability with EHRs and other data 
formats. Will be developing a vaccine-specific data standard in 
compliance with regulatory requirements and publicly reviewed as 
part of the CDISC/Critical Path Institute (C-Path) therapeutic area 
standards development effort for wide adoption. 
SAFE-T drug safety 
Implemented the CDISC-SDTM to combine the clinical data and 
biomarker screening results as the common content standard for 
data management checks and statistical analysis.  
EMIF 
Alzheimer’s  
disease 
CDISC data standards were adopted and adapted to match additional 
AD neuropsychological tests available in the AD cohorts. 
EU-AIMS autism 
Started evaluation of whether CDISC standards can be used/further 
developed by the project. Currently no data standards are available 
for autism. 
PreDiCT-TB tuberculosis 
Contributed to the development of tuberculosis (TB) research data 
standard with CDISC and the C-Path CPTR (Critical Path to TB Drug 
Regimens) consortium. 
EHR4CR 
knowledge 
management 
A first version of the EHR4CR information model (a platform-
independent conceptual model) has been developed based on 
generic reference models for representing clinical data, such as 
standards developed by the International Organization for 
Standardization (ISO) Health Level Seven International (HL7), and 
CDISC. 
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 Project Area Results  
7. Impact on regulatory framework 
Most IMI projects address questions in areas of emerging and innovative sciences and are intended to 
result in novel tools, methodologies and standards that can impact medicines development efficiency 
as well as regulatory standards, guidance and practice for the benefit of public health. A number of 
projects have already taken steps to obtain advice from regulators on qualifying the tools, 
methodologies or standards resulting from their work. In addition, some projects have been 
instrumental in triggering the development of regulatory guidelines. 
PROactive COPD Qualification advice completed at the EMA. 
EU-AIMS autism 
Started EMA formal scientific advice procedure for qualification of 5 
biomarkers in ASD.  
eTOX drug safety 
Provided an update on the eTOX database and the prediction system 
to the EMA’s Committee for Medicinal Products for Human Use 
(CHMP) Safety Working Party (SWP). The main focus was to develop a 
common understanding on the use of the system and expectation for 
validation of the systems. National representatives of the SWP 
expressed interest in accessing the database. In order to explore ways 
of cooperating between eTOX and regulatory authorities, a decision 
was taken to start a Scientific Advice Procedure. 
MARCAR cancer 
Has developed new biomarkers, technologies, and alternative test 
systems that help explain or predict animal and/or human 
carcinogenic pathways and mechanisms for non-genotoxic 
carcinogenesis. This will provide enhanced scientific rationale for 
Carcinogenicity Assessment Document (CAD) submissions, with 
potential impact for revisions of the guideline on carcinogenicity 
testing of pharmaceuticals of the International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH).  
SAFE-T drug safety 
Developed and progressed towards an aligned EMA/FDA qualification 
of a set of novel safety biomarkers for drug-induced kidney, liver, and 
vascular injury.  
DDMoRe 
knowledge 
management 
In May 2012 an advisory meeting with EMA and FDA representatives 
was held. Through a Modelling Review Group, DDMoRe is in regular 
contact with both the EMA and FDA regarding the qualification of the 
content of the project’s model library.  
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Project Area Results 
8. Implementation of project results inside industry 
Listed achievements are examples of project results that have already been implemented in the 
internal processes and decision making of pharmaceutical companies, therefore speeding up the 
development of new medicines in a number of diseases.  
IMIDIA diabetes 
The human beta cell line EndoC BetaH1 has been further validated by 
Endocells and three pharmaceutical partners, confirming their initial 
insulin secretion capacity. These cells have been successfully 
transferred as a research tool for drug discovery to industrial 
partners.  
DDMoRe 
knowledge 
management 
Several drug/disease models identified by DDMoRe have been 
adopted or are being further developed inside the industry. 
eTRIKS 
knowledge 
management 
Adoption of the eTRIKS results (tranSMART deployments) in five 
pharmaceutical companies. Adoption of a company-developed 
curation tool in eTRIKS. 
Europain chronic pain 
Developed, standardised and validated a preclinical model of 
spontaneous pain behaviour in rodents across several laboratories 
and pain models, in rats and mice. This model, which was previously 
lacking, is already being used for internal decision-making in the drug 
development process. The ultraviolet B (UVB) pain model has also 
started to be used for in-house R&D. 
 
Project Area Results  
9. Education and training for a new generation of R&D scientists 
IMI education and training programmes are meant to address the gaps in the required biomedical 
research and development expertise by training new generation of highly qualified individuals that will 
strengthen the position of the European scientific community in global drug research arena.  
EMTRAIN 
E&T, 
networking 
Catalogued over 5 000 masters, PhD, continuing professional 
development (CPD) courses, and short courses taught in 21 
languages, from 39 countries, covering over 60 scientific, therapeutic 
and biomedical areas from about 1 000 universities. 
SafeSciMET 
E&T in safety 
sciences  
Successfully completed its second cycle of courses in 2013, with 
participants giving very positive feedback. More than 320 students 
participated (55% from EFPIA companies). 
Provided 20 new courses in drug safety sciences. 
Eu2P 
E&T in pharmaco-
vigilance and 
pharmaco-
epidemiology 
58 students are following the flexible and fully e-learning programme 
covering medicines risk identification and quantification, medicines 
and public health, medicine risk communication, assessing the 
benefits of medicines, and regulatory processes. 
PharmaTrain 
E&T in 
pharmaceutical 
medicine 
685 trainees have been following various courses (28% from EFPIA 
companies). 
Assembled a network of 24 universities and 16 affiliates. 
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 CHEM21 green chemistry 
Performed a gap analysis on green chemistry in the industry. 
Reviewed 6 200 relevant chemical transformations from EFPIA 
members and nearly 400 significant publications. 
Produced and disseminated 'green' metrics and a prototype of a 
reaction database and solvent guide to assess the sustainability of 
chemical processes used by industry in synthesis and manufacturing 
practices. These metrics are also part of the academic partners’ 
training programmes in sustainable chemistry. 
 
 
1.2.3 Business-related outputs 
 
Based on the first analysis of IMI projects’ outputs, EFPIA and the European Commission felt it 
necessary to identify where projects might have missed market opportunities and value creation for 
follow-up research geared towards product development and launch, patents, creation of joint 
ventures/spin-off companies, etc. 
The Katholieke Universiteit Leuven (KU Leuven) was commissioned to perform a case study to: 
 assess the effectiveness of PPPs; 
 identify intellectual property (IP) and business opportunities; 
 provide an evidence-based approach to evaluate these; 
 identify successful components and characteristics to apply in future biomedical PPPs.  
Due to the size of the projects, time constraints and the number of partners involved, the analysis 
was performed only on a selected sample of projects working in different areas: neuroscience 
(NEWMEDS), metabolic diseases (SUMMIT, IMIDIA), respiratory diseases (U-BIOPRED), knowledge 
management projects such as development of platforms for toxicity prediction (eTOX) and integrated 
pharmacologic data (Open PHACTS). 
KU Leuven identified a range of valuable assets (innovative research tools, databases and 
knowledge), not all were being exploited or exploitable yet; these are listed in table below. 
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Conclusions of the study 
IMI projects reflect successful partnerships 
towards innovative scientific research built 
upon trust. 
 IMI portrays the important paradigm shift 
in business models at companies and in 
academia (e.g. IP strategy). 
 
 Sharing resources and outcomes creates 
a multiplication effect in terms of scientific 
and business outcomes. 
 The value of IMI projects for SMEs is high, 
however, the incentive for participation could 
be further enhanced. 
 
Report recommendations 
Report 
recommendations 
IMI action(s) Timeline 
Creation of a forum to 
exchange best 
practices and 
dissemination of 
existing knowledge on 
the legal and 
regulatory landscape 
Interactions between projects and sharing of lessons 
learnt best practices (including on sustainability 
plans) have been and will be promoted by organising 
joint and cross-projects meetings and/or using 
various other channels (e.g. the IMI Group on 
LinkedIn). 
In December 2013, IMI commissioned a consultancy 
service to set up a platform for stakeholder 
involvement to optimise the exploitation of IP and 
value generated in its projects (see below). 
On-going and to be 
continued in 2014 
Stimulation of positive 
peer pressure by 
public declaration and 
dissemination of 
expertise and 
commitment to the 
consortium 
IMI, together with EFPIA, are promoting more 
strategic approaches to IMI portfolio management 
by setting advisory groups involving all healthcare-
related stakeholders having then an overview on 
each scientific research area. 
On-going and to be 
continued in 2014 
Creation of 
sustainable legacy 
mechanisms 
IMI will launch a tender procedure to make available 
the necessary legal and financial expertise and 
support to projects. 
2014 
Expansion of IMI’s 
track record of 
success as Europe’s 
largest PPP 
IMI JU is exploring possible expansions (e.g. through 
a tender procedure) of the KUL case study notably 
by including a macroeconomic perspective. 
2014 
Organisation of 
dedicated workshops 
for SMEs 
In order to promote the participation of SMEs in its 
activities, IMI is offering support to SMEs interested 
in applying for IMI projects. This has been primarily 
through an SME-dedicated contact person, via the 
SME webpage, and through interactions with 
Europe-wide umbrella organisations. 
Moreover, IMI is preparing dedicated workshops, 
notably with venture capitals in order to explore 
other funding opportunities across Europe. 
On-going and to be 
continued in 2014 
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 Report 
recommendations 
IMI action(s) Timeline 
Stimulation of 
dialogue between 
researchers and 
patients 
From June 2013, IMI has organised a pilot patient 
group meeting which will lead to two Patient Focus 
Meetings in 2014: one session on diabetes together 
with the Juvenile Diabetes Research Foundation 
(JDRF), and the second one around overall 
challenges facing patients regardless of the disease 
they are suffering from. 
Moreover, the IMI JU will invest in improving the 
patients and lay community understanding of what 
IMI delivers and how it might impact their lives by 
developing a patient-dedicated section on IMI's 
website, translating outputs from IMI projects into 
lay language, including patient sessions in IMI 
stakeholder forum and organising other dedicated 
patient meetings. 
On-going and to be 
continued in 2014 
Creation of incentives 
to attract young 
scientists 
Besides the launch of competitive calls for proposals, 
IMI will explore any other necessary procedures to 
evaluate proposals and award funding to projects 
involving young scientists. 
IMI will further invest in the partnering and 
networking tool and/or events (in collaboration with 
the States Representatives Group). 
2014 
 
 
 
Follow-up to the KU Leuven pilot case study 
These results provide a basis for designing 
means to optimise the exploitation of IP and 
value generated in a number of selected IMI 
projects. However, other areas of focus not 
necessarily directly linked to IP and 
commercial exploitation should be analysed to 
assure that the impact of IMI projects can be 
maximised and that the results are 
sustainable. 
 
To help maximise the translation of project 
outputs into standard of care (new practices 
and processes leading to improved 
healthcare), all key stakeholders, including the 
clinical community (e.g. clinicians, physicians, 
nurses, pharmacists) and patients, should be 
brought together in a multi-stakeholder 
Exploitation of Results Forum.  
 
The consultancy service to set up a platform 
for stakeholder involvement to optimise 
project outcomes was selected in December 
2013 (see Section 5.4). 
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 Stakeholder engagement4 1.3
IMI attracts participants from all key stakeholder groups, such as academia, research organisations, 
the pharmaceutical industry, SMEs, patient organisations, and regulatory bodies. This creates an 
integrated and collaborative approach leveraging the strengths and input of all stakeholders in the 
health system with the shared goal of delivering effective and sustainable healthcare solutions for 
society. The figure below shows the total number of participations by different stakeholders. 
 
1.3.1 SME involvement 
Throughout 2013, IMI continued to promote the participation of SMEs in IMI and offer support to 
SMEs interested in applying for IMI projects. This has been primarily through an SME-dedicated 
contact person, via the SME webpage, and through interactions with Europe-wide umbrella 
organisations.  
Thanks to these efforts, SMEs now account for 15% of all beneficiaries (135 out of 886 in total) 
involved in projects up to and including Call 8. The SMEs involved in IMI projects also receive 
proportionally more funding compared to other IMI beneficiaries, although they only make up 15% 
of project partners, they receive 18.4% of the budget (€133 million out of a total committed by Call 8 
of €723 million).  
The IMI Executive Office has also been exploring other means to provide support to SMEs. This has 
most notably been in the form of providing more information on and access to additional sources of 
funding. This approach has focused on two main avenues. The first has been to explore other 
initiatives directed towards SMEs such as those within the European Cooperation in Science and 
Technology (COST) action, or how IMI’s activities could be complemented with what is happening in 
other areas, e.g. vaccines. In addition, the availability of European Commission SME-specific financial 
instruments has been explored. While this is of great interest to SMEs due to the start date of 
Horizon 2020, it was not possible to align IMI approaches with the specific financial instruments 
currently available. However, this will be revisited in 2014 now that Horizon 2020 has been launched.  
 
4 For the purposes of the Annual Activity Report, figures on the total number of participations in IMI projects may count the 
same organisation multiple times, when involved in several projects. 
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 The second approach has been to engage with 
venture capital (VC) funders and facilitate 
dialogue between VC funds and SMEs involved 
in IMI projects. VC funds are very interested 
and a series of meetings were held with 
representatives from organisations such as 
the International Venture Club (IVC), Vesalius 
Biocapital and FlandersBio to explore possible 
approaches. The output of these discussions is 
to be a SME-funding meeting to be held the 
first quarter of 2014, at which SMEs involved 
in IMI projects will be able to interact with VC 
funds, pharmaceutical company investors, and 
business development professionals with the 
aim of identifying other sources of financial 
support. 
 
 
 
 
 
 
Overall, SME involvement in IMI (for Call 1 to 8) represents 15.2% of beneficiaries and 18.4% of IMI 
JU funding. 
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1.3.2 Patient involvement 
 
At IMI patients are key stakeholders. IMI 
research is ‘patient-centric’ and IMI provides, 
and will continue to do so, a valuable 
opportunity for patient groups to participate 
in various activities to influence the 
development of new partnerships that aim to 
address current bottlenecks in pharmaceutical 
R&D. During the last year we have intensified 
our patient involvement efforts. The 1st 
Patient Focus Meeting was successfully held in 
June, 2013. Patients and patient organizations 
have expressed a lot of enthusiasm bout IMI 
and willingness to engage further as a result of 
our efforts.  
The current status of patient involvement in 
IMI projects has been assessed. The Executive 
Office, with the support of the London School 
of Economics (LSE) conducted a short survey 
among ongoing projects. The survey was 
designed to determine which projects 
currently involve patients, how they are 
involved, and the related benefits and 
challenges. 
 Responses were received from 39 out of 
40 projects surveyed (Calls 1-6). Of these, 24 
(61%) currently have some form of patient 
participation, mostly through clinical trials or 
research where patient samples are required.  
 Less frequently, patient organisations are 
part of the project consortium or members of 
ethical boards. The most common reason 
given for not involving patients is that it was 
not envisaged in the project’s scope, although 
a small number of respondents stated there is 
no clear benefit to involving patients, or that 
there are budgetary constraints. 
 
 The benefits of involving patients 
generally revolve around the unique 
perspective patients can bring to a project, 
and patients’ ability to improve dissemination, 
especially outside the scientific community. 
From the patients’ perspective, participating 
in an IMI project helps them to build networks 
and better understand their conditions.  
 The barriers to greater patient involved 
included the burden on the patient in terms of 
finance, time and energy; the logistical, ethical 
and legal requirements associated with 
involving patients, particularly across 
countries; language issues; and ensuring 
representativeness when involving a relatively 
small proportion of patients with a given 
condition. 
In order to further improve the patient 
involvement at IMI the following primary 
objectives have been identified: 
 Improving the patients and lay community 
understanding of what IMI delivers and 
how it will impact their lives - this will 
ensure the continued support to IMI/IMI2 
 Improving on how IMI draws on the 
patient’s expertise by enrolling patients 
into defining and executing projects   
 Provide forum for discussion and 
interaction between the patients, the 
researchers and other interested 
stakeholders  
Next important meeting, jointly organised 
between IMI and JDRF, will be held in May of 
2014 and will focus on diabetes. The goal of 
the meeting is to focus on identifying research 
& development gaps in the diabetes area from 
the perspective of patient needs and 
challenges.  Ultimately we envision that this 
input will guide decisions on future topics on 
diabetes in IMI2 and in JDRF’s activities. 
Putting patients in the centre and leading the 
discussion with researchers and industry will 
give them the opportunity to become an 
influential force for priority setting in disease 
research. 
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 1.3.3 Interactions and involvement with regulatory authorities 
IMI has embarked on a number of initiatives 
to enhance interaction between regulators 
and its projects to ensure the translation of 
project outcomes into regulatory and clinical 
practice.  
On 23 May 2013, IMI and EFPIA, together with 
the EMA and FDA, organised an information 
session for project coordinators on the 
processes for drug development tools advice 
and qualification5. 
On 30 October 2013, IMI hosted the third IMI 
regulatory summit meeting attended by 
representatives of EMA, FDA, Japan’s 
Pharmaceuticals and Medical Devices Agency 
(PMDA), the EC, EFPIA, and relevant project 
coordinators. One of the outcomes of this 
meeting is continuous IMI support to the 
projects in engaging as early as possible with 
regulators for input on the strategy for the 
project work plan with a view to developing 
tools that would be accepted by regulators. 
The importance of involving regulators at the 
time of idea generation (topic development) 
was also highlighted. In this respect IMI has 
already taken steps to have representatives of 
the EMA attending workshops for the 
preparation of the topics for the 10th and 11th 
Calls for proposals. 
In addition, IMI representatives attended 
several multi-stakeholder meetings, including 
regulators, aiming at exploring whether an IMI 
Call topic could be developed to move 
towards adaptive licensing, also referred to as 
‘medicines adaptive pathways to patients’ 
(MAPP). There are already a number of 
5www.imi.europa.eu/content/documents#regulators 
outputs from IMI projects that could be help 
to support moving from a traditional, linear 
approach to drug development and 
registration to an approach that allows 
progressive patient access to new medicines 
based on a prospective plan agreed by all 
stakeholders. To this end, in December 2013 a 
consultancy service was contracted to set up a 
multi-stakeholder Exploitation of Results 
Forum to facilitate the relevant stakeholder 
involvement to optimise project outcomes 
(see Section 5.4). 
 
In terms of involvement in IMI consortia, 
regulators participate in IMI projects either as 
participants or on advisory boards. For 
instance, the EMA is a partner in four IMI 
projects, including one, PROTECT, as 
coordinator. Other EU national authorities 
participate in eight projects. Representatives 
of regulatory agencies, including the FDA, are 
represented in the Scientific Advisory Boards 
of half of all IMI projects.  
Moreover, the EMA’s Work Programme 2013 
includes specific objectives concerning IMI. 
These relate to facilitating biomarker 
development and strengthening research 
supporting safety monitoring as well as other 
novel approaches. 
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 Measures of collaboration – the added value of PPPs 1.4
 
1.4.1 Collaboration measured based on bibliometric outputs 
It has been recognised that “deciphering the complexity of human diseases and finding safe, cost-
effective solutions that help people live healthier lives requires collaboration across scientific and 
medical communities throughout the health care ecosystem.”6 
As illustrated in the previous section, IMI is successfully bringing together the key stakeholders 
involved in IMI projects with a view to impact the productivity and success of the projects. Now we 
would like to know how well those stakeholders are working together. 
How collaborative are IMI projects? 
International research collaboration is a rapidly growing element of research activity.7 In addition, 
international collaboration has been shown to be associated with an increase in the number of 
citations received by research papers, although this may vary across countries.8  Co-authorship is 
likely to be a good indicator of collaboration, therefore co-authorship on IMI project publications has 
been analysed. The following table and graph compare the output and citation impact of IMI project 
papers that are co-authored between different sectors, institutions and countries.  
 
 The data shows that IMI project research is 
collaborative at sector, institution and country 
level. Well over half (64%) of all IMI project papers 
have been published by researchers affiliated with 
different sectors (such as researchers with 
academia publishing together with researchers 
from industry or SMEs). Moreover within those 
cross-sector collaborative publications nearly one-
third (32.6%) are between the public sector and 
industry. Three quarters (75%) of IMI project 
papers involve collaboration between institutions. 
Half (51%) of all IMI project papers have are 
internationally collaborative.  
 The collaborative IMI publications are 
internationally influential, with a citation impact 
well over twice the world average (1.0). Within 
IMI project research, there is a clear difference in 
average citation impact between collaborative 
and non-collaborative publications.  his supports 
the hypothesis that collaboration has a positive 
impact on the quality of research performed. 
6 Zerhouni, E. A. (2014) ‘Turning the Titanic’ Science Translational Medicine, vol. 6, pp 221ed2. 
7 Adams, J. (2013) ‘Collaborations: the fourth age of research’ Nature, Vol. 497, pp. 557-560. 
8 Adams, J., Gurney, K., & Marshall, S., Patterns of international collaboration for the UK and leading partners, Evidence Ltd, 
Leeds, 2007. 
Source: Thomson Reuters analysis 2014 
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 Collaboration by sector Collaboration by disease area 
How collaborative are IMI researchers? 
 An expanded collaboration analysis was 
carried out on the basis of co-authorship 
between IMI-supported researchers as well as 
between their co-authors. For this purpose, 
4 861 individual researchers participating in 36 
IMI projects from Calls 1-5 were identified. Of 
these, 2 659 researchers have published 
documents that were indexed in the Web of 
Science and over two thirds (76%) of these 
researchers collaborated (co-authored) with 
at least one other IMI researcher during the 
period January 2007 - December 2013. 
 The patterns and frequency of 
collaborative activities are shown in the 
following figures, where each individual is 
represented as a single node coloured with 
respect to the sector of their organisation (left 
pane) or according to the disease in which 
their project is active (right pane). Lines 
between researchers mark instances where 
co-authorship has occurred in a published 
work. The distance between the nodes 
correlates to the frequency of co-authorship. 
 As expected, co-authorship is more 
common among researchers in the same 
sector than among researchers in different 
sectors. 
 However, there are also substantial co-
authorship activities among researchers from 
different sectors, accounting for 40% of all co-
authorship activities during IMI’s lifetime so 
far. 
 
 
 
 
 
  
Source: Thomson Reuters analysis 2014 
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IMI facilitates widespread collaborations 
between researchers involved in IMI projects. 
This is illustrated by the collaborative 
networks in the figure below where 
collaborative publications among IMI 
researchers have been mapped across Europe. 
The data covers all IMI participants in Europe 
from 37 projects from Calls 1-5 and includes 
more than 29 064 publications published since 
2007 by those researchers.  
In order to determine whether participation in 
an IMI project has a positive effect on 
collaborative activities; co-authorship patterns 
were compared for the periods before and 
after the IMI grant award.  
Geographical maps of collaboration among 
IMI researchers show that IMI research has 
led to an increase in the level of co-authorship 
between researchers both within individual 
countries and between countries.  
The map visualises: 
− The mean degree of collaboration – the 
average number of other researchers each 
researcher is co-authoring with – for 
researchers internally within each country 
(shaded from white to blue).  Countries with 
no contributing output are shaded in grey. 
− The mean degree of collaboration for 
researchers externally between pairs of 
countries (shaded from white to orange).  For 
each pair of countries, the degree was 
calculated based only for researchers in one 
country who co-authored with researchers in 
the other country. 
− The red dot indicates the approximate 
middle of each country. 
  Source: Thomson Reuters analysis 2014 
Mapping Collaborative Research Links within and between countries prior to and after IMI funding award 
for IMI researchers in Calls 1-5 
            
 
Pre IMI funding 
 
Post IMI funding 
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 Collaboration by research area 
Another way to assess the influence of IMI 
participation on collaboration between 
researchers is to look at the number of 
investigators and co-authorships by disease 
area, and also the average degree and average 
weighted degree of each author both pre and 
post the earliest IMI funding awarded.  Below 
figure shows the average degree for the same 
two areas.  The degree of an author is the 
number of distinct co-authors that author has; 
so a researcher who has written publications 
with, at most, three other researchers has a 
degree of three.  
For most disease areas, the average number 
of co-authors for each researcher has 
increased since the researcher first received 
IMI funding; sustainable chemistry (the 
CHEM21 project) is the only exception.  Four 
“disease” areas (data management, drug 
safety, lung diseases and metabolic disorders) 
have all experience a more than three-fold 
increase in mean degree since IMI funding 
began. 
 
 
 
 
 
Source: Thomson Reuters analysis 2014 
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Collaboration between public and private sectors 
Finally it is of high interest to assess 
collaboration between IMI researchers coming 
from different sectors, e.g. academia, 
pharmaceutical industry, SMEs, patient 
organisations, etc. For that purpose the 
number of collaboration pairs between the 
different sectors, both ‘pre-IMI’ and ‘post-IMI’ 
funding have been analysed.  
The following figure illustrates a substantial 
increase in the number of co-authorships, 
both within sector and cross-sector as 
measeured by mean collaboration degree. The 
mean collaboration degree between 
researchers from the same sector is the 
average number of co-authors each author 
has who are from their sector; and “from 
different sectors” is the average number of 
those co-authors who are from the other 
specified sector. 
The data suggest that IMI funding award has 
contributed to more than doubled academic-
academic collaboration (2.91 to 6.12); 
corporate-corporate collaboration has nearly 
trebled (0.49 to 1.41); and academic-
corporate collaboration has nearly quadrupled 
(0.25 to 0.96). 
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1.4.2 Collaboration among consortia and with external bodies within and beyond IMI 
 
In order to ensure synergies between existing project from IMI and outside, inter-consortia 
collaboration is strongly encouraged. Many IMI projects have initiated collaboration with other 
consortia and a number of these resulted in signatures of formal memoranda of understanding 
(MoUs). Key collaborative activity areas have been: diabetes, CNS disorders, tuberculosis, patient 
reported outcomes, cancer, preclinical safety, and education and training.  
 
Moreover IMI has signed horizontal agreements with C-Path, the Juvenile Diabetes Research 
Foundation (JDRF), and CDISC.  
 
 
Collaboration with C-Path  
The first-ever public conference co-sponsored 
by IMI and C-Path was held in March 2013 in 
Brussels. It featured cross-sector participants 
discussing challenges and opportunities in the 
rapidly-evolving PPP space, focusing on drug 
development in Alzheimer’s disease and 
tuberculosis. IMI and C-Path have 
complementary activities in the areas of 
tuberculosis (C-Path CPTR consortium and IMI 
PreDiCT-TB project) and Alzheimer’s disease 
(C-Path CAMD consortium and IMI Pharma-
Cog and EMIF-AD projects). Under the 
umbrella of the IMI-C-Path MoU, IMI has 
facilitated interactions between these 
initiatives.  
 
 
Collaboration with the National Institutes of Health (NIH) 
On 29 October 2013, IMI organised a meeting 
to review IMI’s safety projects (see section on 
cross-project collaborations) and consider 
their impact on regulators. The meeting also 
represented an opportunity for IMI projects to 
establish links with US initiatives in the safety 
area, such as the NIH National Center for 
Advancing Translational Sciences (NCATS) and 
C-Path’s Predictive Safety Testing Consortium 
(PSTC). The scope of IMI and US-based 
projects are broadly complementary, offering 
opportunities for collaboration. To coordinate 
efforts and avoid duplication, IMI and NCATS 
agreed to develop a white paper on innovative 
advances in the predictive safety area, 
identifying gaps for future research and 
setting out a framework for collaborative 
support.  
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CDISC 
Collaboration with CDISC continued in 2013. 
Benefits of this collaboration for IMI project 
participants include access to CDISC’s training 
activities. In addition, IMI was invited to join 
the Scientific Advisory Committee of the 
Coalition for Accelerating Standards and 
Therapies (CFAST), a joint initiative of C-Path 
and CDISC that aims to accelerate clinical 
research and medical product development by 
facilitating the establishment and 
maintenance of data standards, tools and 
methods for conducting research in 
therapeutic areas important to public health. 
As many therapeutic area standards under 
development relate to areas covered by IMI 
projects such as oncology, diabetes etc., being 
part of the CFAST Scientific Advisory 
Committee provides good opportunities for 
establishing synergies with IMI projects on the 
development of the standards. 
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 2. MANAGEMENT OF ONGOING PROJECTS 
 
 Interim reviews for Call 2 projects 2.1
In 2013, IMI conducted six project interim reviews of Call 2 projects as shown in the table below. 
 
IMI project 
acronym Full project name 
Interim review 
date 
BTCure Be the cure for rheumatoid arthritis 07/05/2013 
DDMoRE Drug disease model resources 31/05/2013 
RAPP-ID Development of rapid point-of-care test platforms for infectious diseases 04/06/2013 
EHR4CR Electronic health records systems for clinical research 07/06/2013 
OncoTrack Methods for systematic next generation oncology biomarker development 05/07/2013 
PREDECT New models for preclinical evaluation of drug efficacy in common solid tumours 02/10/2013 
 
The expert reviewer panel consisted of at least 
three experts: one from the Scientific 
Committee, one from the original full project 
proposal evaluation panel, and one selected 
from suggestions provided by the consortium. 
These experts were appointed by the IMI 
Executive Office following screening of 
existing or potential conflict of interest. 
Overall, the reviewers were satisfied with the 
progress made by the projects. The consortia 
have completed the majority of the 
milestones set and are now on track for the 
final, critical steps of the projects such as 
clinical and validation studies.  
In most cases, the reviewers had some 
recommendations aimed at ensuring the 
delivery tangible achievements by the end of 
the funding period. 
 
Recommendations were shared with the 
consortia, which are now in the process of 
responding to them by proposing appropriate 
actions and/or amending the work planned for 
the remainder of the project. 
 
 Cross-project meetings and collaborations 2.2
 
In 2013, IMI increased its focus on fostering cross-project interactions and collaborations, particularly 
with regards to promoting collaboration beyond IMI and Europe to achieve a global impact. Key IMI 
activity areas have been: diabetes, CNS disorders, tuberculosis, preclinical safety, education and 
training, knowledge management, and antimicrobial resistance. 
 
Diabetes 
The IMI portfolio includes 
three projects working on 
diabetes: The Call 1 projects 
SUMMIT and IMIDIA started 
in late 2009 and early 2010 
respectively, while the Call 3 
project DIRECT started at the 
beginning of 2012. The 3 projects have a 
combined budget of over €100 million. IMIDIA 
focuses on studying the pancreatic beta cells 
to develop new therapeutic strategies, while 
SUMMIT’s work addresses the vascular, renal 
and ocular complications of diabetes. 
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Finally, DIRECT takes a personalised medicine 
approach to diabetes.  
A MoU that covers the transfer of knowledge 
and materials and the handling of intellectual 
property was signed in 2012 between 
SUMMIT and IMIDIA. In September 2013 
SUMMIT, IMIDIA & DIRECT announced the 
signature of a new MoU that provides the 
framework for taking collaborative activities 
between the three projects one step further – 
formally implementing the IMI Diabetes 
Platform and bundling of expertise, 
knowledge and findings across the projects. 
 The 1st Symposium of the IMI 
Diabetes Platform was hold on the occasion of 
the 2013 annual meeting of the European 
Association for the Study of Diabetes (EASD) in 
Barcelona9. The three projects jointly 
presented their latest research on diabetic 
complications, the pancreatic beta cell, and 
personalised medicines to the public. 
 
CNS disorders 
 The IMI portfolio includes five projects 
focusing on CNS disorders. Europain, Pharma-
Cog and NEWMEDS arose from IMI’s 1st Call 
for proposals in 2009 and were launched in 
late 2009/early 2010. EU-AIMS, which started 
mid-2012, was generated from IMI’s 3rd Call in 
2010. Finally, EMIF-AD (which is part of the 
wider EMIF project), arose from IMI’s 4th Call 
of 2011 and started working in January 2013. 
The total budget of the projects is over €160 
million. The Europain project focuses on 
chronic pain; Pharma-Cog and EMIF-AD focus 
on Alzheimer’s disease (AD); NEWMEDS 
focuses on schizophrenia and depression; and 
EU-AIMS focuses on Autism Spectrum 
Disorders (ASD). 
 On 6 March 2013 the lead players of the 
Pharma-Cog and EMIF-AD projects met with 
the representatives of the C-Path CAMD 
initiative to identify areas of common interest 
and synergy. The output of the meeting was 
the creation of joint working groups in the 
areas of biomarkers, data modelling and 
9 http://2013.easd-industry.com/industry-
programme/symposia-programme/symposium-
details/imi-diabetes-platform.html 
simulation, data standardisation and 
remapping, cognition and integrative 
approaches to AD. 
 On 13 May 2013 the IMI CNS coordinators 
met in Brussels to discuss project 
achievements, address major challenges, and 
explore synergies. The meeting was also 
attended by an EMA representative. Areas 
where the projects agreed it would be 
important to work together are: 
 
1) Consolidation of project outputs with 
those of other initiatives active globally to 
avoid duplication of efforts and ensure 
synergy (e.g. standardisation of clinical 
end points at global level in ASD, disease 
modelling in AD) 
 
2) Creation of an environment for ensuring 
harmonisation and acceptance of results 
not only by EMA, but also FDA. 
 
3) Improve and enhance the involvement of 
SMEs as they can represent ideal exit 
solutions for output of the projects. 
 
4) As there are clear commonalities in the 
issues and challenges faced by the 
different CNS disease areas, it is necessary 
to create synergies and learn from each 
other to further optimise use of resources 
and allow for cross-fertilisation. 
 
5) Provide ways to better link the projects to 
the in-house strategies and portfolios of 
the industrial partners. 
 
6) Focus more on training to create a 
workforce that is able to work cross-
sector. 
 
 The EU-AIMS project is also continuing its 
collaboration with the Neuroscience 
Steering Committee of the Foundation for 
the NIH Biomarker Consortium to 
maintain an open dialogue and alignment 
between initiatives in the area on the two 
sides of the Atlantic. 
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Tuberculosis 
The IMI portfolio includes one project focusing 
on tuberculosis, PreDiCT-TB, which resulted 
from IMI’s 3rd Call for proposals of 2010 and 
started in mid-2012. PreDiCT-TB is a 
multidisciplinary consortium bringing together 
experts in microbiology, pharmacology, 
engineering, mathematical modelling, and 
clinical trials to create a new integrated 
framework for TB drug development, making 
optimal use of preclinical information to 
design the most efficient clinical trials. 
 
 On 8 March 2013 the lead scientists from 
PreDiCT-TB and the C-Path CPTR project held a 
very fruitful meeting in Brussels. Both 
consortia shared ideas and resources that 
could significantly strengthen the fight against 
TB. Initial priorities included building a 
comprehensive database of TB clinical trials, 
and developing more effective modelling 
approaches using preclinical and clinical data. 
 
 The meeting paved the way for the signing 
on 14 March 2013 of a MoU between the two 
consortia, which will help them to tackle 
important obstacles to developing 
combinations of old and new anti-TB drugs 
that could shorten the length of TB treatment. 
 
Safety 
IMI has a rich portfolio of pre-clinical safety 
projects including the ABIRISK, BioVacSafe, 
eTOX, MARCAR, MIP-DILI, SafeSciMET, and 
SAFE-T. Furthermore, the project 
StemBANCC includes activities for the 
development of stem-cell-based assays of 
novel drugs and predictive toxicology. 
 
 An IMI Safety Projects Review meeting 
was held on 29 October 2013 in Brussels. The 
meeting reviewed the progress to date of 
IMI’s safety projects with particular reference 
to their expected regulatory impact and 
therefore their current interaction with 
regulators. In addition, this meeting aimed to 
explore the areas for and means of 
establishing effective collaborations between 
IMI and the NIH (and other major global 
initiatives), ensuring synergy and avoiding 
duplication of effort in the safety sciences 
area. The key output from this meeting, the 
current and expected regulatory impact, was 
presented the following day at IMI’s 
Regulatory Summit.  
The meeting was well attended by 
coordinators of IMI’s safety projects, 
representatives from the regulatory agencies 
EMA, FDA, and PMDA, representatives from 
the European Commission, and senior 
managers in the safety area of EFPIA 
companies. In addition, the meeting also 
heard from both NCATS and PSTC with a view 
to exploring how to further develop 
interactions between IMI’s safety projects and 
their US counterparts. 
 
 SAFE-T established a formal 
collaboration with C-Path’s PSTC on drug-
induced liver and vascular injury (DILI and 
DIVI). In September 2013, SAFE-T and PSTC 
finalised their joint work plans for 
collaborative studies. The work plans define 
specific areas of collaboration that will help 
advance the objectives of both consortia and 
include deliverables. Specific areas of 
collaboration for DILI are: biomarker assay 
development, pre-clinical and clinical assay 
validation and performance, biomarker 
translation strategy, and regulatory strategy. 
 
 SAFE-T also established a 
collaboration with the NIH Foundation 
Biomarkers Consortium entitled ‘Clinical 
Evaluation and Qualification of Kidney Safety 
Biomarkers’, for the study of drug-induced 
kidney injury (DIKI). In September 2013, the 
two projects signed a confidential disclosure 
agreement (CDA).  
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Education and training 
IMI’s five education & training (E&T) projects 
EMTRAIN, Eu2P, EUPATI, PharmaTrain, and 
SafeSciMET increased their collaboration 
during 2013.  
 
 On 6 March 2013, the Drug Information 
Association (DIA) EuroMeeting featured an 
entire theme dedicated to IMI’s five E&T 
projects. The sessions highlighted the latest 
news from the projects and demonstrated 
how they are collaborating and helping to 
advance education in the biomedical sector in 
Europe. 
 
 As a result of the collaboration, the 
EMTRAIN, SafeSciMET, PharmaTrain10, and 
Eu2P projects submitted a joint, cross-project 
Exploring New Scientific Opportunities (ENSO) 
application for the last ENSO Call of 2013. 
 
Knowledge management 
2013 was an active year for IMI’s knowledge 
management projects as demonstrated by 
their achievements (see previous chapter) and 
cross-project and collaborative meetings. 
 A two-day workshop entitled 
‘Translational Knowledge Management in 
Pharmaceutical R&D’ was organised in 
Brussels on 11-12 July 2013 to review the 
state of play in the area. The workshop was 
organised in collaboration with the 
INBIOMEDvision project, which is funded 
under the EU’s Seventh Framework 
Programme (FP7) under grant agreement no. 
270107. 
 
10 The PharmaTrain project ends in April 2014. 
Sustainability is a key deliverable of PharmaTrain., and 
the PharmaTrain Federation has been established to this 
end as the successor organisation. The PharmaTrain 
Federation will become a new partner in the EMTRAIN 
consortium and therefore is part of the ENSO 
application. With the E&T cross-project activities 
platform, the four IMI E&T projects have developed a 
unique collaborative and synergistic effort which is 
reflected in the cross-project ENSO application. 
 
 
 Open PHACTS, DDMoRe and eTOX 
project members held a workshop on tissue 
knowledge management on 30-31 October 
2013 to discuss resources (data, information 
and knowledge) and standards to support 
physiology based modelling and simulation.  
 
 On 21 November 2013, six IMI 
projects attended the meeting ‘Global 
approach to accelerating medical research’, 
during which the CDISC standards were 
presented. The training was appreciated by 
the participants and deemed very useful. 
 
 The eTRIKS project supports 
collaborative projects with the design and 
implementation of knowledge management 
solutions. eTRIKS is currently actively 
supporting four IMI projects (ABIRISK, 
OncoTrack, PreDiCT-TB, U-BIOPRED) and the 
Medical Research Council (MRC) project (RA-
MAP). This support includes assistance with 
four local eTRIKS/tranSMART deployments 
and one centrally-hosted deployment. All 
five projects received tranSMART training. 
eTRIKS provides curation support for three 
projects, enhancements to the tranSMART 
platform in terms of data types covered and 
cross-study querying/analysis. eTRIKS is 
preparing to support a further four 
consortia. 
 
 eTRIKS is also collaborating with the 
tranSMART Foundation and the Translational 
Research Information Technology (TraIT) 
project11 to share user experience of the 
current tranSMART deployments and the 
development the next generation of 
tranSMART. TraIT is another informatics and 
analytics knowledge management project 
supporting collaborative projects funded by 
the Center for Translational Molecular 
Medicine (CTMM12). The result will be one 
global informatics-based analysis and pre-
11http://www.ctmm.nl/en/projecten/translational-
research-it-trait/translationele-research-it-
trait?set_language=en 
12 http://www.ctmm.nl/en/over-ctmm 
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 competitive data-sharing platform for clinical 
and translational research.  
 Several IMI projects eTRIKS, EHR4CR, 
PREDICT-TB worked on a draft ‘Code to re-use 
health data in collaborative scientific research 
projects’. The draft guidance is of general 
interest to multiple IMI projects as well as 
other collaborative projects in FP7. 
 
 eTRIKS in collaboration with 
OncoTrack developed a key data loading 
module for variant call format (VCF) data. VCF-
formatted data is a standard technical format 
(.doc; .xls; .pdf; .xml are technical formats) for 
storing the differences between for example 
the genome of a cancer cell as compared to 
the genome of a normal cell of a patient (of 
note, there can be up to 30 000 variants in a 
cancer genome and thus a special storage 
format exists). The data load module will be 
made available to all tranSMART installations 
and users as part of version 1.2 which is 
scheduled for public release in the 1st quarter 
of 2014. 
 
 
Antimicrobial resistance 
2013 represented the first year of activities for 
the antimicrobial resistance platform, New 
Drugs for Bad Bugs (ND4BB). 
 TRANSLOCATION and COMBACTE, the 
first two antimicrobial resistance projects of the 
ND4BB programme signed a MoU in November 
2013 to facilitate their collaboration. The MoU 
covers issues such as data sharing (and 
confidentiality), communication and 
coordination, and the creation of a shared 
Ethics Committee. 
 
 
 
Other areas 
 In the area of respiratory diseases, the 
project PROactive signed in July 2013 a MoU 
on the use of PROactive’s daily patient 
reported outcomes (PROs) with COPDMAP. 
COPDMAP is supported by the Inflammation 
and Immunology Initiative of the MRC and the 
Association of the British Pharmaceutical 
Industry (ABPI).  
 In addition, PROactive signed a MoU 
with the Urban Training study Catalonia for 
the use of the PROactive clinical visit PRO. 
 
 The European Lead Factory project is 
preparing a MoU to allow collaboration with 
the European initiative EU-OPENSCREEN. 
 The European Lead Factory has also 
initiated collaboration with the IMI project 
Open PHACTS. 
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3. IMPLEMENTATION OF THE 7th TO 11th CALLS FOR PROPOSALS 
 
 
 In 2013 the new process of continuous Call 
launches was maintained. 
 
 In addition to the implementation of the 
final stages of Calls 7 and 8, three new Calls 
were launched (Calls 9 to 11) and two ENSO 
deadlines reached (ENSO-2 and ENSO-3) in 
2013. 
 
 An overview of these activities is displayed 
in the chart below (2012 – 2014). 
 
 
 
 
 
Most of the experts (57 of 76) involved in the review of proposals submitted in response to Calls 7, 8 
and 9 and the ENSO-1 and ENSO-2 Calls came from EU and FP7 associated countries. 
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  Implementation of the 7th Call for proposals 3.1
 
The 7th Call for proposals included two topics: 
1. Developing a framework for rapid 
assessment of vaccination benefit/risk in 
Europe  
2.  Incorporating real-life clinical data into 
drug development  
 
 Following the approval of the 
recommendations of the Expression of 
Interest (EoI) evaluation panels by the 
Governing Board in 2012, the two first-ranked 
EoIs were invited to prepare a Full Project 
Proposal (FPP) together with the pre-
established EFPIA consortium. The deadline 
for submission of the FPP was 7 March 2013.  
 
 The evaluation of the resulting two FPPs 
was conducted by the external experts 
working initially remotely and then at a 
consensus panel meeting.  
 
 Both FPPs, ADVANCE and GetReal were 
recommended for funding by IMI and 
approved by the Governing Board. 
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The Grant Agreements for both ADVANCE and GetReal were signed in 2013 and both projects also 
received pre-financing. 
 
The two 7th Call projects pre-financed in 2013 (in EUR) 
 
 
 
 Implementation of the 8th Call projects 3.2
 
The 8th Call for proposals included the 
following five topics:  
1. ND4BB Subtopic 1C: Conduct of clinical 
studies supporting the development of 
MEDI4893, a monoclonal antibody targeting 
Staphylococcus aureus alpha toxin.  
2. ND4BB Topic 3: Discovery and development 
of new drugs combating Gram-negative 
infections. 
3. Developing an aetiology-based taxonomy of 
human disease: A new classification for 
systemic lupus erythematosus (SLE) and 
related connective tissue disorders and 
rheumatoid arthritis (RA).  
4. Developing an aetiology-based taxonomy of 
human disease: A new classification for 
neurodegenerative disorders with a focus on 
Alzheimer’s disease and Parkinson’s disease.  
5. European induced pluripotent stem cell 
bank.  
 ND4BB Subtopic 1C in Call 8 is part of Topic 
1 of IMI Call 6 and aims at reinforcing the 
clinical investigator network in Europe. The 
resulting project was planned to run under the 
same Grant Agreement as the COMBACTE 
project of Call 6 as mentioned in the 8th Call 
for Proposals 201213.  
 The 8th Call for proposals was launched by 
the IMI on 17 December 2012 with a deadline 
for submission of EoIs of 19 March 2013. 
 The Call launch was widely promoted in 
December 2012 and January 2013 via the IMI 
Newsletter, the IMI website, a press release, 
webinars, targeted and general emails, 
network organisations and IMI ambassadors 
at various events.  
 26 EoIs were received by the submission 
deadline, all of which were eligible for 
evaluation.  
 Analysis of the applicants revealed that 
333 legal entities took part; of which 242 
(73%) were academic and non-profit 
organisations and 81 (24%) were SMEs. On 
average, there were 12.8 entities per EoI. Key 
figures regarding the EoIs are presented 
below. 
13http://www.imi.europa.eu/sites/default/files/upl
oads/documents/8th_Call/IMI_8thCallText_FINAL.
pdf (p.14-15) 
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 The in-house evaluation of the EoIs was conducted by separate panels of independent experts 
mainly from Europe.  The first ranked EoI consortia were merged with the EFPIA consortia and 
invited to submit their FPPs by 26 July 2013. 
 The FPP evaluations were successfully completed during August 2013 with the Expert Panel 
recommending to the IMI Governing Board that the all five consortia progress to the negotiation 
stage. 
 The negotiations for the Call 8 projects were concluded in December 2013. The Grant 
Agreement14 signatures took place and pre-financing was released in December 2013. The projects 
are scheduled to begin in the first quarter of 2014. 
 The key figures of the participants in the Call 8 projects are presented below. 
 
 
 
 
 
14 For Topic 1, the applicant consortium merged with the Call 6 project, COMBACTE, via an amendment to the Grant 
Agreement. 
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 The four 8th Call projects pre-financed in 2013 (in EUR) 
 
 
 Launch of the 9th Call for proposals 3.3
 
The 9th Call for proposals included the 
following topics:  
1. WEBAE – Leveraging emerging technologies 
for pharmacovigilance 
2. Developing innovative therapeutic 
interventions against physical frailty and 
sarcopenia (ITI-PF&S) as a prototype geriatric 
indication 
3. ND4BB Topic 4: Driving re-investment in 
R&D and responsible use of antibiotics 
4. ND4BB Topic 5: Clinical development of 
antibacterial agents for Gram-negative 
antibiotic resistant pathogens 
 Workshops were held by the IMI Executive 
Office in May 2013 in Brussels to discuss the 
proposed topics. The topics discussed were:  
- Developing innovative therapeutic 
interventions Against physical 
frailty/sarcopenia 
- Driving re-investment in R&D and 
responsible use of antibiotics 
- Correlates of protection for influenza 
vaccines 
 As with previous workshops, members of 
the Scientific Committee chaired the sessions, 
and for each topic the EFPIA coordinator made 
a presentation, after which there was a 
discussion with a panel of invited experts. 
These experts were selected based on 
recommendations from Scientific Committee 
members, members of the SRG, and also the 
EFPIA project teams. The output from the 
workshop was a report detailing advice and 
recommendations to be incorporated into the 
topic text prior to the start of the final 
consultation of the SRG and Scientific 
Committee. 
 Topic 1, WEBAE had been the subject of 
previous workshop in 2012. The IMI 
antimicrobial resistance programme (ND4BB 
Topic 5) had also been the subject of a 
workshop dedicated to this programme in 
2011. Therefore these two topics were not on 
the agenda of the May workshop.  
 As a result of the workshop and further 
discussions amongst the EFPIA companies, it 
became apparent that an extended period of 
time was required to ensure the topic 
‘Correlates of protection for influenza 
vaccines’ would meet its full potential. It was, 
therefore, decided to delay this topic to a 
future Call.  
 The final text of the Call 9 topics was sent 
for consultation on 28 May 2013, and 
following Governing Board approval, the 9th 
Call for proposals was launched on 9 July 
2013. The deadline for submission of EoIs was 
9 October 2013.  
 The launch of the 9th Call was announced 
to the media with a press release entitled ‘IMI 
9th Call For proposals: Focus On frailty, use of 
social media to monitor drug safety, and 
antibiotic development’. 
 Webinars were held in early July 2013 to 
present the topics to potential applicants. The 
EFPIA in kind contribution committed to the 
9th Call projects was €72.25 million and the IMI 
JU contribution was €63.12 million. 
 37 EoIs were received by the submission 
deadline, 33 of which were eligible for 
evaluation.  
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 Analysis of the eligible EoI applicants 
revealed that 365 legal entities took part; 232 
(64%) were academic and non-profit 
organisations and 73 (20%) were SMEs. On 
average, there were 11.1 entities per EoI.  
 
 
Key figures regarding submitted EoIs are 
presented below. 
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 The evaluation of the EoIs was conducted 
by panels of independent experts from Europe 
and the US working initially remotely and then 
at a consensus meeting. 26 external experts 
worked in 4 panels (1 panel per topic) 
moderated by IMI’s Scientific Officers.  
 
 
 
 
 
 
 
 Following the approval of the 
recommendations of the evaluation panels by 
the Governing Board, the four first-ranked 
EoIs were invited to prepare FPPs together 
with the pre-established EFPIA consortia.  
The deadline for submission of the FPPs is 4 
March 2014. The evaluation of the resulting 
FPPs will be conducted in 2014.  
 
 Key figures of the first-ranked EoIs are 
presented below. 
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*UN resolution 
 
 
 Launch of the 10th Call for proposals 3.4
 
The 10th Call for proposals included the topic 
on Immunological assay standardisation and 
development for use in assessments of 
correlates of protection for influenza vaccines. 
 The consultative workshop had previously 
been held in the IMI Executive Office 
alongside the Call 9 topics in May 2013.  
 The final text of the Call 10 Topic was sent 
for consultation on 12 September 2013, and 
following Governing Board approval, the 10th 
Call for Proposals was launched on 29 October 
2013. The deadline for submission of EoIs was 
28 January 2014.  
 The launch of the 10th Call was announced 
to the media with a press release entitled ‘IMI 
launches Call for proposals with focus on flu 
vaccines’ 
 A webinar was held on 24 October 2013 to 
present the topic to potential applicants. 
 The EFPIA in kind contribution committed 
to the 10th Call projects is €6.1 million and the 
IMI JU contribution is also €6.1 million. 
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  Launch of the 11th Call for proposals 3.5
 
The 11th Call for proposals included following 
topics:  
1. Applied public-private research enabling 
osteoarthritis clinical headway (APPROACH) 
2. European platform to facilitate proof of 
concept for prevention in Alzheimer’s disease 
(EPOC-AD) 
3. Blood-based biomarker assays for 
personalised tumour therapy: value of latest 
circulating biomarkers 
4. Zoonoses anticipation and preparedness 
initiative (ZAPI) 
5. Generation of research tools to enable the 
translation of genomic discoveries into drug 
discovery projects 
6A. ND4BB Subtopic 6A: Epidemiology 
research and clinical development of a novel 
bispecific IgG antibody, BiS4αPa, for the 
prevention of serious Pseudomonas 
aeruginosa disease 
6B. ND4BB Subtopic 6B: Clinical development 
of a novel resistance-breaking beta-lactam 
antibiotic, AIC499, in combination with a beta-
lactamase inhibitor (BLI) against severe 
bacterial infections due to Gram-negative 
pathogens. 
7. ND4BB Topic 7: Development of novel 
inhaled antibiotic regimens in patients with 
cystic fibrosis (CF) and patients with non-CF 
Bronchiectasis (BE) 
8. Ecorisk prediction (ERP) 
 Consultative workshops for all topics were 
held during October 2013. A workshop was 
also held for an additional topic, ‘Remote 
assessment of disease and relapse’, however, 
following discussions among the EFPIA 
companies, it became apparent that extra 
time would be needed to further develop the 
topic. It was, therefore, decided to delay this 
topic to a future Call. 
 
 
 
 
 In order to facilitate the Call launch in 
December 2013, the consultation workshops 
were held via web conference and were 
chaired by the IMI Scientific Officer. The EFPIA 
coordinators presented the topics, and this 
was followed by a discussion with a panel of 
invited experts. These experts were selected 
based on recommendations from Scientific 
Committee members, members of the SRG, 
and also the EFPIA project teams. The output 
from the workshop was a report detailing 
advice and recommendations to be 
incorporated into the topic text prior the start 
of the final consultation of the SRG and 
Scientific Committee. 
 The final text of the Call 11 topics was sent 
for consultation on 7 November 2013, and 
following Governing Board approval, the 11th 
Call for proposals was launched on 11 
December 2013.  The deadline for submission 
EoIs is 8 April 2014.  
 The launch of the 11th Call was timed to 
coincide with the G8 health ministers meeting 
in London, and was announced to the media 
with a press release entitled ‘IMI launches 
€371 million Call with focus on Alzheimer’s, 
arthritis, cancer, and more’. 
 Webinars to present the topics to 
potential applicants will be held in January 
2014. 
 The EFPIA in kind contribution committed 
to the 11th Call projects is €201.1 million and 
the IMI JU contribution is €171.4 million. 
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  Implementation of ENSO Calls for proposals 3.6
 The rolling Call for proposals inviting 
ongoing projects to submit applications to 
Explore New Scientific Opportunities (ENSO) 
was launched in August 2012.  
 The deadlines were 15 December 2012, 31 
May 2013, and 15 December 2013. 
 To promote the ENSO Call among IMI 
project participants and clarify the key points 
a question and answer (Q&A) document on 
the ENSO Call was published and updated on 
the ENSO web page15. Presentations were 
given to the projects via webinar on 24 April 
2013 and 7 November 2013. 
 
ENSO-1: 15 December 2012 deadline 
In total, five applications were submitted by 
the following projects for the 15 December 
2012 deadline: eTOX, IMIDIA, PREDECT, 
BTCure, EHR4CR. The evaluations were held in 
January and February 2013.  
 The evaluation of the five applications was 
conducted by a single panel of five 
independent experts working initially 
independently and then at a consensus 
telephone conference. 
 Following the approval of the 
recommendations of the evaluation panels by 
the Governing Board, all five applicant 
proposals were invited to negotiate an 
amendment to the Grant Agreement to 
incorporate the new ENSO activities.  All 
amendments were signed, and the projects 
pre-financed in 2013. 
15 http://www.imi.europa.eu/content/new-
opportunities 
ENSO-2: 31 May 2013 deadline 
 One application was received from the U-
BIOPRED project by the 31 May 2013 
deadline.  The evaluation was held in June 
2013 
 The evaluation of the application was 
conducted by a single panel of three 
independent experts working initially 
independently and then at a consensus 
telephone conference. 
 Following the approval of the 
recommendation of the evaluation panels by 
the Governing Board, the successful proposal 
was invited to negotiate an amendment to the 
Grant Agreement to incorporate the new 
ENSO activities. The amendment was signed, 
and the project pre-financed in 2013. 
 The remaining unspent budget earmarked 
for this cut-off date became part of the total 
available IMI budget of €7.5 million for the 
following cut-off date of 15 December 2013. 
 
 
ENSO-3: 15 December 2013 deadline 
 8 applications were submitted by the 15 
December 2013 deadline. The evaluations are 
scheduled for January and February 2014. 
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 4. COMMUNICATION AND NETWORKING 
 
 
 Strategy and key messages 4.1
 
In 2013, IMI’s communication strategy 
focused on promoting IMI’s successes and 
attracting applicants for Calls for proposals. 
Hiring a public relations (PR) agency helped 
IMI to formalise its Communication Strategy 
and refine its key messages for different 
target audiences. 
As the highlights below reveal, IMI achieved 
considerable visibility in both specialist and 
general media.  
Furthermore, the fact that a number of 
opinion leaders spontaneously cited IMI in 
various outlets demonstrates a high level of 
awareness of IMI among key stakeholders. 
IMI also continued to work on outreach to 
researchers in the newer EU Member States, 
and with the help of the PR agency Media 
Consulta, achieved considerable media 
coverage there. It should be noted that IMI’s 
communication successes in 2013 were 
boosted by the efforts of the European 
Commission and EFPIA, as well as the SRG, 
Scientific Committee, and the projects 
themselves. 
 Improving IMI outreach 4.2
 
Events 
 
In line with the Communication Strategy, IMI’s events in 2013 were designed to:  
 promote IMI’s successes and its Calls for proposals; 
 provide stakeholders with an opportunity to give feedback on IMI’s work; 
 facilitate networking between IMI stakeholders. 
 
Event Date & location Outcome 
Collaborating for cures - leveraging global 
public-private partnerships (PPPs) to 
accelerate biopharmaceuticals development 
 Joint event with C-Path on the benefits 
of and challenges faced by PPPs in 
health research 
7 March 2013 
Brussels, 
Belgium & 
online 
 Over 100 attendees, including 
policy makers, regulators, 
researchers, IP experts 
 Event broadcast over internet 
 High-level speakers from both 
sides of Atlantic 
 Lively debate on challenges 
faced by PPPs 
 Press coverage 
 
IMI and personalised medicine 
 Event organised in framework of 
conference ‘Innovation and patient 
access to personalised medicine’ 
organised by the European Alliance for 
Personalised Medicine (EAPM) under 
the auspices of the Irish Presidency of 
the EU Council. 
20 March 
2013 
Dublin, Ireland 
 Over 70 attendees, including 
researchers, patient groups, 
policy makers 
 IMI projects on personalised 
medicine presented to broad 
audience 
 Chapter on IMI in report on 
main event. 
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Event Date & location Outcome 
IMI Stakeholder Forum 2013 
 Morning dedicated to brain research (in 
line with broader EU Month of the 
Brain initiative) 
 Afternoon focused on IMI in the 
European Research Area 
 High-level speakers included 
immunologist and Nobel laureate Rolf 
Zinkernagel, Richard Frackowiak of the 
Human Brain Project, and Françoise 
Grossetête MEP (Member of the 
European Parliament) 
 
13 May 2013 
Brussels, 
Belgium & 
online 
 Over 250 attendees, including 
policy makers, patient 
groups, researchers, 
regulators 
 
 Event broadcast over internet 
 IMI projects given high 
visibility 
 Press coverage 
 Networking opportunities 
Info Session: funding opportunities with the 
Innovative Medicines Initiative 
 Event held in framework of Health 
Management & Clinical Innovation 
Forum (MIHealth) 
 Focus on 9th Call for proposals and 
other future topics 
 Combined with SRG meeting 
 
28 June 2013 
Barcelona, 
Spain 
 Over 100 attendees, including 
academics and SMEs 
 Spotlight on, and tips from, 
local project participants 
 Networking opportunities 
 Local press coverage 
IMI 9th Call webinars 
 Webinars held on all Call topics plus 
IMI’s rules and procedures 
 
1-15 July 2013 
Online 
 Opportunity for potential 
applicants to discuss topics 
with coordinators 
IMI 2 proposal launch 
 Event organised by European 
Commission 
 IMI support re success stories, speakers 
 
10 July 2013 
Brussels, 
Belgium 
 Press coverage 
Moving translational immunology forward 
through public-private partnership 
 IMI symposium at the 15th International 
Congress of Immunology (ICI2013) 
26 August 
2013 
Milan, Italy 
 Over 200 attendees 
 Focus on contribution of PPPs 
to immunology research 
 Promotion of forthcoming IMI 
calls for proposals 
Innovation through collaboration - The role of 
public-private partnerships in translational 
medicine 
 IMI symposium at the 11th Congress of 
the European Association for Clinical 
Pharmacology and Therapeutics (EACPT 
2013) 
 
29 August 
2013 
Geneva, 
Switzerland 
 Over 100 attendees 
 Focus on IMI projects on 
autism, diabetes, and 
antimicrobial resistance 
The Innovative Medicines Initiative (IMI): 
Putting Europe at the forefront of innovation 
in drug development 
 Dinner debate at the European 
Parliament 
10 September 
2013 
Strasbourg, 
France 
 Attendees included 8 MEPs 
 Speakers included academic 
and patient representatives 
from IMI projects / 
committees 
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 Event Date & location Outcome 
Joint Technology Initiatives [JTIs] - Innovation 
in Action 
 Joint event with the other JTIs at the 
European Parliament 
 Week-long series of events included 
exhibition, press conference, debate 
 
30 September 
– 4 October 
2013 
Brussels, 
Belgium 
 Interactions with several 
MEPs and other key 
stakeholders 
 Press coverage 
IMI 10th Call webinars 
 Webinars held on all Call topics plus 
IMI’s rules and procedures 
 
24 October 
2013 
Online 
 Opportunity for potential 
applicants to discuss topics 
with coordinators 
Open Info Day - Horizon 2020 'Health, 
demographic change and wellbeing' 
 Event organised by European 
Commission 
 IMI stand at exhibition 
 
22 November 
2013 
Brussels, 
Belgium 
 Promotion of IMI’s 10th and 
11th Calls for proposals 
G8 Dementia Summit 
 Event organised by UK presidency of G8 
 Regular contact between organisers 
and IMI in run up to event 
 IMI contributed to speaking notes of 
relevant speakers 
IMI mentioned in event press materials 
11 December 
2013 
London, UK 
 Event attended by G8 health 
ministers, researchers, 
patient and carer 
representatives 
 High visibility of 11th Call 
Alzheimer’s disease topic 
thanks to announcements by 
Commissioner Tonio Borg, 
Paul Stoffels (J&J) and Michel 
Goldman 
 IMI mentioned in official 
summit communique  
 Press coverage 
 
Promoting IMI’s Calls for proposals 
IMI launched its 9th, 10th and 11th Calls for proposals in 2013. Calls were promoted via the following 
channels: 
 IMI website 
 Press release 
 Webinars (NB the 11th Call webinars are planned for January 2014) 
 IMI Newsletter 
 Social media (Twitter, LinkedIn) 
 Flyers 
 Events organised by others (e.g. SRG members) – for this, IMI often provided speakers and 
materials. 
 Direct e-mails to stakeholder organisations (e.g. academic societies, patient groups) and 
relevant individuals  
 IMI events 
 Presentations by IMI staff at external events 
 
IMI also held two webinars on the ENSO Call for proposals, one in April, the other in November. 
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Promoting IMI’s project successes 
The Communications Team promotes the successes of IMI projects through a variety of channels: 
 IMI newsletter 
 IMI website 
 Social media (Twitter, LinkedIn) 
 IMI press releases  
 Other organisations’ press materials (e.g. European Commission) 
 Press and scientific articles by the IMI office 
 Examples given to journalists writing about IMI 
 IMI events 
 Presentations by IMI staff and ambassadors at external events 
 
IMI website 
The IMI website continues to attract growing numbers of visits and visitors. 
 
Data source: Google Analytics, data downloaded on 6 January 2014. 
 
Infodesk 
In 2013, the IMI infodesk e-mail address, managed by the Communications team, received more than 
1 000 requests. The infodesk facilitated public interaction on key issues and improved awareness of 
IMI activities and processes.  
 
IMI Newsletter 
IMI sent out 10 newsletters in 2013, covering Call launches, new projects, IMI event announcements, 
news on IMI reports and publications, and news from the projects. At the end of 2013, there were 
over 3 000 newsletter subscribers. 
 
Social Media 
At the end of 2013, IMI’s LinkedIn group had 1 260 members, up from 784 at the end of 2012. 
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Data source: LinkedIn group statistics, accessed on 22 January 2014 
 
IMI continued to increase its Twitter activity throughout 2013, with regular tweets on project 
successes and press articles mentioning IMI. IMI also tweeted live from a number of events. By the 
end of the year, the @IMI_JU account had over 1 300 followers (data source: Twitter). 
 
 Key publications 4.3
 
Media highlights 
In collaboration with the PR agency, IMI expanded its press list in 2013 to take in more journalists 
from across Europe. In addition to sending out 15 press releases (on Calls for proposals, the launch of 
new projects, project results, and certain events), IMI invited journalists to some of its most 
important events. Media monitoring by Media Consulta revealed that IMI has achieved coverage in 
almost all EU Member States, and featured in some of Europe’s most influential news outlets. An 
analysis of the coverage by Media Consulta reveals that the tone of most articles is neutral or 
positive, with very little negative coverage. 
 
The following list sets out the top 10 media highlights from 2013. A more exhaustive list can be found 
in Annex D and on the Media Coverage page of the IMI website. 
 Wall Street Journal, 30 December 2013 
Researchers Aim to Speed Cures to Patients 
 Financial Times (UK), 6 December 2013 
Science: High-tech drug research gives us a fuller picture 
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 Financial Times (UK), 17 October 2013 
Doctor prescribes boost for biomedicine in EU 
 Science (US), 12 July 2013 
E.U. Commission Beefs up Research Partnerships with Industry 
 Euronews (European), 25 June 2013 
Developing a treatment for autism 
 Scrip (international), 21 April 2013 
INTERVIEW: Goldman's dreams of competitive collaboration as IMI 2 considered 
 Deutsche Welle – Spectrum (Germany), 4 March 2013 
Make drugs not war 
 Nature (UK), 7 February 2013 
Europe bets on drug discovery 
 Reuters (international), 7 February 2013 
Drugmakers, academics pool R&D in $265 mln EU project 
 BioCentury (US), 24 January 2013 
IMI's collaborative chemistry 
 
Spontaneous citations – a sign of growing awareness of IMI 
While the majority of press articles and scientific publications mentioning IMI came about as a result 
of efforts on the part of the IMI office, 2013 saw a number of cases where journalists and opinion 
leaders spontaneously mentioned IMI.  
 
Some of the most prominent examples of this are listed below: 
1. Nature Medicine, 5 December 2013 
Timeline of events: A brief history of what made news this year (highlights the launch of the 
European Lead Factory as a highlight in 2013) 
2. Science Translational Medicine, 28 August 2013 
Curing Consortium Fatigue (article discusses how to improve the way multi-stakeholder 
collaborations work) 
3. World Health Organization, 9 July 2013 
Priority Medicines for Europe and the World Update Report, 2013 (emphasises 
effectiveness of IMI and other PPPs in precompetitive research)  
4. Europe’s World, 1 June 2013 
Everything that’s wrong with the EU budget … and how to fix it (MEP and former Belgian 
Prime Minister Guy Verhofstadt cites IMI in section on importance of investing in research 
and innovation) 
5. Science, 12 April 2013 
Opening Industry-Academic Partnerships (section on IMI in article on academia-industry 
collaboration) 
6. Nature Careers, 17 April 2013 
Regulatory science: Researchers in the pipeline (mentions IMI’s PharmaTrain and Eu2P 
projects) 
7. Chief Medical Ofﬁcer for England, Dame Sally Davies, March 2013 
Annual Report of the Chief Medical Ofﬁcer - Infections and the rise of antimicrobial 
resistance (report cited IMI as an example of what is needed to tackle antimicrobial 
resistance, generating a lot of media coverage for IMI) 
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 8. The Guardian, 27 January 2013 
Science funding and the EU: you've got to be in it to win it (Nobel laureate and President of 
the UK’s Royal Society Sir Paul Nurse cited IMI in an article on the benefits to the UK research 
community of EU membership) 
9. Nature Reviews Drug Discovery, January 2013 
News and Analysis - 2012 in reflection (highlights the launch of the Calls for proposals on 
antimicrobial resistance and the European Lead Factory) 
 
IMI in scientific journals & reports 
 Science Translational Medicine, Vol. 5 (216) pp. 216ed22  
Goldman, M. (2013) New Frontiers for Collaborative Research 
 Computational and Structural Biotechnology Journal, Vol. 6 (7), e201303017 
Vaudano, E. (2013) The Innovative Medicines Initiative: a public private partnership model 
to foster drug discovery 
 Alternatives to Laboratory Animals (ATLA), Vol. 40 (6), pp. 307-312 
Gunn, M. et al. (2013) The rational use of animals in drug development: contribution of the 
innovative medicines initiative 
 European Journal of Immunology, Vol. 43 (2), pp. 298-302 
Goldman, M. et al. (2013) The Innovative Medicines Initiative moves translational 
immunology forward 
 Clinical and Translational Medicine, Vol. 2 (2), published online 15 January 2013 
Goldman, M. et al. (2013) Public-private partnerships as driving forces in the quest for 
innovative medicines 
 
 
 Support to Governance and Consultative bodies 4.4
IMI provided continuous support to its governance and consultative bodies. Efforts were made to 
improve communication and feedback on IMI’s existing and planned scientific activities, notably 
through the development of dedicated platforms and periodic newsletters. In addition, the 
consultation process of the Scientific Committee and the States Representatives Group on future Call 
topics was streamlined. 
 
Governing Board 
The Governing Board oversees the 
implementation of IMI’s activities. In April 
2013, Dr Rudolf Strohmeier (EC) became 
Chairman and Mr Roch Doliveux (EFPIA) 
became Vice-Chairman for a one-year 
mandate. The Governing Board met three 
times (in March, July, and October), adopting 
various decisions and reports that include the 
Annual Activity Report 2012, the Annual 
Implementation Plan for 2014, Call texts and 
budgets, and the outcome of evaluations. In 
addition, monthly teleconferences between 
the Chair, Vice-Chair and the Executive 
Director were held for information purposes.
 
Scientific Committee 
The Scientific Committee held three meetings 
in 2013 (in March, June, and November). They 
were chaired by Professor Christian Noë until 
the end of his term in June 2013.  
The composition of the Scientific Committed 
was partially renewed in September with the 
appointment of eight new members to 
replace those whose mandate ended in June. 
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By the end of the year, the Scientific 
Committee appointed its new Chair, Mrs 
Béatriz Da Silva Lima. 
 
Key activities included an update on IMI 
project achievements, notably on the occasion 
of the interim reviews of the Call 2 projects, 
and consultations on future and new Call 
topics. 
Furthermore, the Scientific Committee was 
periodically informed by the IMI founding 
members about the preparation of the IMI -2 
proposal within the new Framework 
Programme Horizon 2020. 
 
 
States Representatives Group SRG 
The SRG held four meetings (in February, 
June, October, and December) chaired by Dr 
Gunnar Sandberg. Detailed updates on IMI 
activities in terms of ongoing projects’ 
achievements were provided and 
consultations on future Calls were organised. 
Open discussions with the founding members 
provided the opportunity for SRG members to 
discuss the IMI 2 proposal and related ongoing 
debates. 
 
 
Stakeholder Forum 
Through its annual Stakeholder Forum, IMI 
engages key stakeholders in discussions about 
its activities. IMI held its 2013 Stakeholder 
Forum in Brussels on 13 May. As May was the 
European Month of the Brain, the morning 
session was dedicated to presentations by and 
discussions on IMI’s brain projects.  
The afternoon was devoted to a debate on 
IMI’s role in the European Research Area 
(ERA). High-level speakers included 
immunologist and Nobel laureate Rolf 
Zinkernagel, Richard Frackowiak of the Human 
Brain Project, and Françoise Grossetête MEP. 
The event attracted over 250 participants and 
was also broadcast over the internet. 
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 5. EXECUTIVE OFFICE MANAGEMENT 
 
 Budget and finance 5.1
 
Budget execution 
In 2013, the budget execution further improved, compared to 2011 and 2012, reaching 99.50% in 
commitment appropriations and 97.52% in payment appropriations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The graphs below show the difference in budget execution between operational activities (project-
related) and the running costs of the Executive Office (staff and infrastructures). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79.60% 
65.45% 
96.35% 94.90% 97.52% 99.50% 
Payment appropriation Commitment appropriation
Total budget execution  (%) 
2011 2012 2013
78.73% 
56.14% 
96.34% 
73.19% 
100.00% 
84.75% 
Operational activities Running costs
Budget execution  
Commitment appropriation  (%)   
2011 2012 2013
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Financial operations 
 
IMI handled a total of 1 714 financial files (payments, commitments, forecasts of revenue, recovery 
orders and budget transfers) in 2013. 
 
 
           
 
More detailed information is presented on the Annex A. 
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 Since January 2013, IMI has had to comply with the payment time limits set out in the new Financial 
Regulation. The table below shows the average time to pay, which is in all cases below the targets 
set. Average time to pay regarding operational payments in 2011 and 2012 is not mentioned as the 
payment limits were different than in 2013 and are therefore not comparable.  
Maximum payment time 
limit 
Average  
time to pay (days) 
Year 2011 2012 2013 
Administrative payments   
30 days 39 17 15 
45 days* 44 23 19 
60 days 47 25 14 
Operational payments  
30 days   18 
90 days    66 
                          *In 2013 the maximum payment time limit is 30 days  
Though the majority of processed files relate to payments for running costs, the payment 
appropriation is mainly executed through operational payments (IMI contribution to projects). In 
order to raise the quality of, and reduce errors in, periodic reports provided to IMI by the consortia, 
IMI organised four financial management workshops in 2013. In total, 124 representatives of IMI 
beneficiaries participated in three financial workshops for beneficiaries and 31 representatives of 
EFPIA companies attended the workshop for EFPIA companies. This initiative started in 2012 and will 
continue in 2014. 
State of play of founding members’ contribution 
The following table provides an overview of reported contributions for EFPIA companies and 
beneficiaries as at 28 January 2014. It shows that the balance between public funding and industry 
contribution has been maintained to date. 
 
Reported contributions include submitted claims reported but not yet accepted for Call 1 - period 4. 
 
Notes: 
 Call 8 resulted in five successful projects, of which one (APC) became an amendment to the existing Call 6 project COMBACTE. 
Accordingly, the commitment of that project has been included in Call 6 (which increased compared to last year’s commitment). 
 Call ENSO-3 amounts are based on the submitted proposals on 15 December 2013.  
Nbr of 
projects Committed Reported Committed Reported
Call 1 15 113 603 647 71 252 168 62.7% 148 604 419 88 229 618 59.4%
Call 2 8 82 796 204 27 594 996 33.3% 71 165 346 18 312 697 25.7%
Call 3 7 111 816 124 10 144 282 9.1% 70 953 085 5 422 543 7.6%
Call 4 7 97 943 541 6 367 511 6.5% 111 046 803 7 390 422 6.7%
Call 5 1 79 999 157 91 337 070
Call 6 2 125 417 213 142 058 215
Call 7 2 12 999 811 11 927 750
Call 8 4 98 732 937 49 163 653
Call 9 4 63 120 000 72 250 000
Call 10 1 6 100 000 6 100 000
Call 11 8 171 424 773 201 045 105
ENSO-3 6 471 146 6 497 305
59 970 424 553 115 358 957 11.9% 982 148 751 119 355 280 12.2%
EU (EUR) EFPIA (EUR)
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 Human resources 5.2
 
 
 The authorised maximum ceiling of 36 
staff members was reached on 1 July 2012. 
 
 Recruitment in 2013 was conducted in 
line with the Multi-Annual Staff Policy Plan 
approved by the Governing Board. Four new 
staff members joined IMI during the year 
following the departure of staff members. 
- Two administrative assistants joined the 
scientific team. 
- One Communication and Events Officer 
joined the communication team. 
- One Ex post Audit and Finance Officer 
(new position) joined the finance team. 
 
 
 
 
 
 
These new recruits enabled IMI to keep 
improving its geographical balance while the 
gender balance stayed the same as last year, 
as shown in the graphs below. 
 
 For the first year, IMI implemented its 
learning and development policy. The main 
areas covered were: 
- IT skills (on Microsoft office tools as well 
as IMI’s own IT tools); 
- Communication (public speaking and 
languages); 
- Ethics and integrity (follow up actions); 
- How to better work together? (Team-
building seminar organised in May 2013 
with a follow-up action plan implemented 
in the second half of the year). 
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  Information and communication technology 5.3
 
IMI’s strategic ICT objective is to deliver value to IMI business and to be a key enabler of new 
business initiatives with the goal of supporting and shaping the present and future of IMI.  
IMI’s ICT applications and infrastructure support the implementation of IMI’s strategy and business 
objectives with the aim of making all IMI processes simpler and more efficient. 
With a view to contributing to the effective operation of the IMI IT project environment, the IMI IT 
Manager achieved PM² (Project Management Methodology) certification  in 2013. 
PM² certification provides knowledge and tools customised for the EC. 
The year 2013 marked the technical consolidation and delivery of enhancements for integrated 
solutions across business processes as summarised in the table below.  
 
 
IMI Core Business 
SOFIA 
(Submission of Information 
Application) 
• Automatic export to CORDA (Common Research Data 
Warehouse) and eCORDA (External Common Research 
Data Warehouse) 
• Reporting application - QlikView - for IMI, EC, EFPIA, SRG 
• Industry Liaison Group (ILG) overview  
• Enhanced Annual Periodic Reporting 
• ENSO Calls 
• Ethics Review 
• 3rd login for Project Managers 
• Training and support to project participants 
Other IMI Business Applications 
Events Registration Application • Extended to manage events organised jointly by the five JUs (Joint Undertakings) 
IMI website and newsletter • Migration to new server and provider 
ICT Internal Support 
DORA 
(Document Repository Application) 
• Enhanced and extended to include annexes 
• Implemented integration with scanner 
ISA 
(Information System for Absences) 
• Enhanced and extended to manage additional types of 
absences: teleworking and part-time 
eCDR 
(electronic Career Development 
Report) 
• New web application for managing staff appraisals 
BIT 
(Booking of IT material) 
• New web application for managing the booking of IT 
materials 
ICT Internal Support to other Jus 
Vacancies and ISA • Two IMI web applications have been configured and 
made available to two other JUs 
 
 
 
 
  
ANNUAL ACTIVITY REPORT 2013 INNOVATIVE MEDICINES INITIATIVE  page 67 of 118 
 
 
 
 
Support to IMI core business 
SOFIA is a fully-integrated web application to support the management of the Call process and 
project life cycle. It is an important element of the simplification of IMI processes. In 2013 SOFIA was 
subject to significant development improvements described in the sections below.  
 
Back office 
 
 Front office 
Automatic export to CORDA and eCORDA  
Since the third quarter of 2013, IMI has been 
exporting its Call and project data from SOFIA 
to the EC’s Common Research Data warehouse 
(CORDA). The exports are done automatically 
and on a daily basis. The external CORDA data 
warehouse (eCORDA), for external stakeholder 
users, has also been updated with IMI data.  
 
 
 
 
 
 
 
 
 
 
 
 
This is a major achievement on the integration 
of SOFIA with the EC IT architecture for 
reporting of Call and project data which is now 
available in CORDA along with data from the 
other EC Framework Programmes for Research. 
 
Upload of past data 
Call 1 was managed before the set-up of the 
IMI online submission tool; therefore, non-
successful Call 1 EoIs and consensus reports 
were manually encoded in SOFIA. 
 
Generation and upload of negotiation letter 
SOFIA has been enhanced with functionality to 
generate the negotiation letter at the end of 
the negotiation process. After signature, the 
negotiation letter is uploaded in SOFIA. 
 
 
 
 
 
 
 
 Reporting application - QlikView - for IMI, EC 
and EFPIA 
During 2013, a statistics and KPI monitoring 
module, with a variety of tailor-made 
dashboards, was implemented using QlikView. 
It is integrated with SOFIA and enables the 
analysis of IMI scientific and financial Call and 
project data. In third quarter of 2013 it was 
made available to the IMI founding members 
and SRG for their real-time analysis of IMI data. 
 
ILG overview  
Following a request from EFPIA/ ILG members, 
SOFIA was enhanced with a report on project 
reporting deadlines. In addition the EFPIA/ILG 
members’ access to SOFIA was enhanced, 
allowing ILG members to update their own 
company’s administrative data for a specific 
project or across several projects and to view 
the budget of a project, including details of EU 
and non-EU in kind contributions. 
 
3rd login for project managers 
A 3rd login access per project for the project 
manager was made available in SOFIA, in 
addition to the login access of the Coordinator 
and of the Managing Entity.  
 
Enhanced annual Periodic Reporting 
In SOFIA, the annual reporting functionality has 
been enhanced to include the uploading of the 
signed Form C (Financial Statement and 
Adjustments to previous periods), CFS 
(Certificate of Financial Statement) and 
Periodic Report files, in PDF format. The upload 
functionality is available to project participants 
during submission of their annual Periodic 
Report.  
 
Training and support to project participants 
On the occasion of IMI financial workshops for 
project beneficiaries and EFPIA participants, IT 
trainings was provided on the use of SOFIA for 
reporting, namely for amendments and annual 
financial reporting.  
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 Back and front office 
 
ENSO Calls 
As of the beginning of 2013, project consortia could submit, via web form, applications for the ENSO 
Calls. In addition to this, the ENSO evaluation web form, to be used by the experts, was launched.  
 
Ethics Review 
The Ethics Review was integrated in SOFIA with the existing online Stage 2 evaluations by means of 
implementing a web form for submission by the experts of the remote review. The web form for 
generating the consolidated review by the rapporteur was also created. 
On a daily basis, any SOFIA user can receive online technical support via the helpdesk 
(sofia@imi.europa.eu), which is monitored by the IMI IT Manager. 
 
ICT internal support 
DORA (Document Repository Application) 
Training has been given to staff on the use of 
DORA. Several additional functionalities were 
implemented throughout the year (e.g. 
annexes area with versioning for existing 
documents; integration with IMI 
multifunctional printer and scanner). New 
functionalities were presented to staff in 
morning sessions which included staff 
feedback on current usage and useful future 
developments. 
 
ISA (Information System for Absences) 
ISA was extended to manage additional types 
of absences: teleworking and part-time. Also 
the status of leave 
requests is now clearly 
displayed in the 
application using a traffic 
light approach.  
 
BIT (Booking of IT material) 
A new web application was implemented to 
manage the booking of IT material that is 
taken by IMI staff when going on business 
trips or for meetings. This represented an 
efficiency gain for the Executive Office: an 
overview of available material is available in 
real-time, helping the staff with the planning 
of future needs for IT material. 
 
eCDR (electronic Career Development 
Report) 
A new web application was implemented to 
manage IMI staff appraisals. Both staff and 
line managers are guided through the 
different steps of the appraisal workflow. 
After completion, the appraisal is available for 
viewing online, and can also be saved in PDF 
format.   
 
 
ICT internal support to other JUs 
The year 2013 ended with close collaboration 
with other JUs. Two IMI web applications – 
ISA and Vacancies - of the IMI administrative 
platform for ICT internal support have been 
configured and made available to two other 
JUs – Fuel Cells and Hydrogen (FCH) and Clean 
Sky – which share the premises with IMI. 
 
The web applications in question are now 
common to the three Jus, with the advantage 
that there is a unique source code, while the 
front end is re-branded for each JU and data 
segregation is guaranteed. Best practices are 
shared and it is the most efficient, economic 
and effective solution to put in place for the 
other JUs for their absences management and 
electronic recruitment. 
 
In addition, the IMI Events Registration 
application has been extended and 
customised to allow shared events of the JUs. 
It helped greatly the management of 
registrations for an event at the European 
Parliament which was jointly organised by the 
JUs. 
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  Procurement and contracts 5.4
 
The large majority of IMI’s procurement in 
2013 was done under existing multi-annual 
framework contracts. Of the framework 
contracts, the most significant in volume, 
namely in IT services, audits and interim staff 
provision, were concluded jointly with other 
JUs to avoid duplication and minimise 
administrative effort.  
Where possible, IMI has made use of the 
European Commission’s framework contracts 
to which it is party. In 2013, the most 
significant of these in usage volume terms 
were in software licenses and in 
communications consultancy services. 
One open procedure was carried out in 2013, 
for a service contract under the operational 
budget, for consultancy services to set up a 
platform for stakeholder involvement to 
optimise project outcomes.  
On the administrative side, an open procedure 
was launched for a framework contract for the 
organisation and management of events. 
However, during the course of the procedure, 
the European Commission’s Directorate-
General (DG) for Research and Innovation 
invited IMI to join a procedure it was to launch 
for a similar contract. IMI therefore decided to 
abandon its own procedure, judging it more 
efficient and economical to join the 
Commission’s procedure.  
The table below gives the details of these 
activities, including the procedure used in 
each case, the publication date, the award 
date, and the name of the contractor(s). Only 
tenders with a value exceeding €60 000 are 
listed here.  
s 
Tender procedures in 2013 
Reference and subject Procedure Publication date Award date Contractor 
IMI/2013/FWC/029:  
Service contract for the 
organisation and management 
of events 
Open procedure 
– framework 
contract  
16/04/2013 Not awarded; 
procedure 
abandoned on 
04/09/2013 
 N/A 
 
IMI/2013/SC/154:  
Consultancy services to set up 
a platform for stakeholder 
involvement to optimise 
project outcomes 
Open procedure 
– service 
contract 
17/08/2013 05/12/2013 University 
of Oxford, 
United 
Kingdom  
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  Data protection and access to documents 5.5
 
Data protection 
 
In 2013, IMI achieved maturity in the implementation of data protection principles within its 
activities involving the processing of personal data. The General Report of the European Data 
Protection Supervisor (EDPS) on ‘Measuring compliance with Regulation (EC) 45/2001 in European 
Union institutions’ of 24 January 2014 presents the results of a survey carried out in 2013 in all 
institutions. In terms of compliance with the notifications required by Articles 25 and 27 of the 
Regulation, IMI is one of the 5 best EU institutions, with a 100% compliance rate. All notifications on 
the existing processing operations of IMI were submitted to the EDPS. Internal administrative 
notifications were also prepared for all the existing processing operations. Regular communication 
with IMI staff, with the network and the JUs’ data protection officers, and with the EDPS services, 
enabled the effective implementation of data protection principles. In particular, there were regular 
internal consultations with the data protection officer (DPO) in the areas of science, human 
resources, communication and IT. 
 
Prior checking activities 
 In July 2013 IMI concluded the 
notifications to the EDPS related to all 
existing processing operations. 
 
 Only notifications related to new 
processing operations are being 
developed from that date, in line with the 
recommendation of the EDPS to all EU 
agencies and bodies. 
 
 There is no specificity on the IMI 
processing of personal data to report. 
 
 Recommendations from the EDPS as an 
outcome of IMI notifications were all 
implemented. 
 
Notifications to the DPO 
 By December 2013, the DPO had received 
17 notifications from staff members 
responsible for the processing of personal 
data within IMI. This covers all IMI 
activities including communication with 
IMI bodies, organisation of meetings, 
remuneration schemes, audits, grants and 
procurement schemes, business trips, 
conflicts of interest & confidentiality, HR 
matters, and invitations of experts. 
 
Consultations 
 There were no formal consultations of the 
EDPS in 2013. 
 
Inspections 
 There were no site visits by the EDPS in 
2013. 
 
Complaints 
 There were no complaints to the EDPS in 
relation to IMI processing of personal data 
to report in 2013. 
 
Network activities 
 In 2013, the IMI DPO participated in two 
meetings of the network hosted by the 
EU’s Judicial Cooperation Unit EUROJUST 
and the EDPS. 
 
 The network meetings are an important 
forum to exchange best practices among 
DPOs and to learn more about EDPS 
activities, such as developments related to 
the new data protection directive. 
 
 IT and DPO participated in two workshops 
on e-communication (June) and EU 
websites and mobile devices (September). 
 
Trainings/Communication activities 
 The DPO participated in a course 
organised by the EDPS on the tasks of 
DPOs & reporting to the EDPS. 
 
 Information on developments in data 
protection activities was provided to the 
staff during internal meetings. 
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Other  
Inventory & register 
 IMI has updated its inventory of 
processing operations and the register 
established under article 26 of Regulation 
45/2001. 
 
 
DPO mandate 
 The mandate of the DPO was renewed 
until 2016. 
 
EDPS Surveys  
 IMI participated in the following surveys: 
-general monitoring exercise; 
-cloud computing; 
-guidelines on EU websites and mobile 
devices; 
-transfer of data from permanent 
representations. 
 
 The findings of the surveys were used as a 
basis to prepare the EDPS guidance in 
those areas. Guidelines on EU websites 
and mobile devices are expected soon. 
 
Data Protection Day 
 IMI participated in the activities related to 
Data Protection Day 2013 and information 
was provided to all IMI staff members. 
 
 
 
Thematic guidelines 
Follow-up table 
EDPS GUIDELINES NOTIFICATION 
TO EDPS 
STATUS OF 
PROCEDURE 
COMMENTS 
Tasks, duties and powers of 
the DPO 
YES concluded  
Recruitment YES concluded  
Health data at work YES Final stage  
Staff evaluation YES Final stage  
Leave & flexitime YES Final stage  
Conflict of interest YES awaiting feedback Pending adoption by EDPS of specific guidelines 
Anti-harassment procedures NO preparatory work Procedures being developed in IMI 
Administrative inquiries and 
disciplinary proceedings 
NO preparatory work Procedures being developed in IMI 
Video surveillance  NO not applicable  IMI is not the controller of the data  
 
 
 
Access to documents 
 
During 2013 IMI continued to promote transparency and access to information and documents 
through the IMI Infodesk (see Section 4.2). IMI also implemented the guidance regarding access to 
data related to IMI projects.  
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  Internal control strategy and environment 5.6
IMI implements a clearly defined framework 
of 16 Internal Control Standards (ICS) designed 
to maintain an efficient and effective internal 
control system that corresponds to IMI’s 
strategic objectives and lifespan, its 
governance structure and resources, as well as 
to the degree of maturity, risk and change 
across its operational and support systems 
and processes.  
In 2013, the robustness of the internal 
controls continued to rely on an efficient and 
effective combination of ex ante and ex post 
controls, adequate segregation of duties, 
established and documented processes and 
procedures, the promotion of ethical 
behaviour, and sound management. These are 
embedded across IMI’s administrative, 
support and grant management systems and 
workflows.  
Within IMI, internal control issues and actions 
are systematically discussed and reviewed on 
a regular basis through weekly management 
meetings. In parallel, the internal control 
coordinator monitored on a quarterly basis 
(including a mid-year formal self-assessment) 
the progress made towards achieving 
compliance with and effectiveness of the 
internal controls system. In addition, at the 
end of 2013, an assessment of the compliance 
with and effectiveness of the ICS was 
performed in order to identify opportunities 
for action and improvement for the following 
year.  
Risks that pose a threat to the achievement of 
IMI’s mission and objectives were also 
systematically identified, assessed and 
managed through the annual risk assessment 
exercise (RAE).  
The 2013 RAE identified 14 corporate risk 
areas which were recorded in the IMI Strategic 
Risk Register, together with a list of mitigating 
actions that have been or will be taken by the 
Executive Office to reduce the impact of risks 
to an acceptable level.  
Concrete actions taken during the year to 
strengthen internal controls and focus on the 
prioritised standards included: 
 the implementation of a new policy 
on conflict of interest and an 
operating procedure concerning the 
selection of independent experts (ICS 
8);  
 new measures to enhance the quality 
of accounting information through 
new procedures on reimbursement, 
negotiation, acceptance of periodic 
reports and payments, year-end 
financial closure and financial ex post 
audits (ICS 13);  
 the establishment of an internal 
scorecard to better monitor 
performance and report on 
achievements (ICS12/ICS 9);  
 more emphasis on fraud prevention 
and detection (ICS 2). 
Ex post control of operational expenditure has 
continued to play an important role in the 
overall internal control framework. By the end 
of 2013, 70 audits of beneficiaries had been 
finalised since the launch of the first such 
audits in November 2011. In addition, the first 
three audits of EFPIA participants were 
concluded during 2013 (for more information, 
see Section 6.2). Errors detected through 
these audits are progressively corrected and 
followed up, and when found to be systematic 
in nature, also extended to unaudited claims 
from the same participant. Preventive 
measures are also in place to reduce the risk 
of errors from occurring in the first place, 
particularly through ongoing training and 
guidance for participants as well as through 
rigorous ex ante procedures.      
In conclusion, IMI’s internal control system 
can be considered having reached an 
advanced level of maturity and is working as 
intended, given also the particular nature and 
limited size of the organisation. Within this 
context, the efficiency and effectiveness of 
internal control systems will be further 
enhanced in 2014 as part of a process of 
continuous improvement, as highlighted in the 
Annual Implementation Plan 2014. 
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 6. ELEMENTS LEADING TO THE DECLARATION OF ASSURANCE 
 
 Background 6.1
 
IMI, as a European Union body, is required to 
include in its Annual Activity Report a 
structured assessment of the effectiveness of 
internal controls and on other elements 
supporting the Declaration of Assurance by 
the Executive Director in his capacity as 
Authorising Officer.  
 
The Declaration is intended to provide 
reasonable assurance, and possible 
reservations, on the accuracy and 
completeness of the information included in 
the report, on the use of resources for their 
intended purpose, as well as on the legality, 
regularity and sound financial management of 
the underlying transactions.   
 
For this evaluation, the relevant management 
information and reports on the following were 
used:   
 the performance and results of the JU and 
the projects it supports; 
 risk management, governance and 
internal control issues; 
 findings and conclusions of audits and 
independent reviews on the JU’s systems, 
individual processes and the underlying 
transactions; 
 stakeholders’ feedback. 
 Assessment by management 6.2
Implementation of operational and administrative budgets 
The budgets for 2013 were adopted by the Governing Board together with the corresponding Annual 
Implementation Plan on 21 December 2012. 
Operational budget 
At the end of 2013, 54 operational payments were made for a total of €121.5 million. Budget 
execution was therefore 99.4% (100.0% in 2012).  
 
During the first five months of the year, IMI JU experienced a significant delay in the receipt of the 
annual financial contribution from the European Commission to cover the year’s running and 
operational costs.  This led to a cash shortfall for IMI JU and delayed payments for both pre-financing 
and interim payments.  The first instalment of €65.0 million from the European Commission was 
transferred to IMI JU on 28 May 2013. 
 
The cash shortfall had a direct impact on the average time to pay for pre-financing payments. In 
2013, it took on average 18 days to process these payments (5 days in 2012). Similarly, the average 
time to pay for cost claims increased from 60 days in 2012 to 66 days in 2013. The situation also led 
to three late payments in 2013 generating late interest costs.  
Budget 
year 
No. 
payments 
Average delay for 
report submission 
from the projects  
after reporting 
deadline* 
a) 
Average 
suspension 
period 
(days) 
 
b) 
Average 
time to 
pay 
(days) 
c) 
Average 
processing 
time after 
report 
submission 
(days) 
b) + c) 
% of 
payme
nts on 
time 
% 
beyond 
time 
limit 
2011 16 28 62 54 117  94 6 
2012 26 16 65 60 125 96 4 
2013 33 14 44 66 110 91 9 
*after the 60 contractual days for submission 
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 Each payment represents the end of a complex validation procedure that consists of an operational 
review of the periodic report and the validation of all financial claims and certificates of financial 
statements submitted by participants in the project (including any adjustments for previous 
reporting periods and for audit findings). As expected, a significantly larger number of payments 
were made in 2013 when compared to the previous year (from 26 in 2012 to 35 in 2013 – an increase 
of 34.6%), with the receipt of the first claims from an additional 12 projects from Call 3 and Call 4.   
 
Despite the increase in the number of projects and participants’ claims to be validated by IMI and the 
challenging situation experienced with the cash shortfall in the first half of the year, the average 
processing time (from the date of report submission to the IMI bank execution date for the payment 
of the cost claims) actually decreased from 125 days in 2012 to 110 days in 2013. This is the result of 
a number of proactive initiatives IMI took in the past two years to facilitate and streamline the 
process for project participants and IMI staff, including: 
 the publication of guidance and the organisation of workshops for participants on the applicable 
financial rules and the correct completion of the financial statements; 
 the simplification of internal workflows and key documents; 
 the development and enhancement of IMI’s core business application SOFIA to automate and 
further support project-related processes.  
These measures were also particularly critical in view of the increasing workload related to the 
processing and payment of cost claims. 
 
As a result, shorter average timelines were registered in 2013 in all critical stages of the process, 
including a reduction in the time needed for projects to submit reports after each reporting period; 
shorter average suspension periods; and overall less time for IMI to review and process for payments 
throughout 2013.   
 
Administrative budget (running costs) 
As of 31 December 2013, payments were made for a total of €5.9 million, resulting in a 
budget execution of 69.6% (as compared to 60.2% in 2012).  
 
Time to pay has continued to improve when compared to 2011 and 2012. The table 
below only shows administrative payments with maximum time limits. 
 
Maximum 
payment 
time limit 
% paid on time % paid beyond time limit Average  time to pay (days) 
Year 2011 2012 2013 2011 2012 2013 2011 2012 2013 
30 days 51 85 92 49 15 8 39 17 15 
45 days 60 90 92 40 10 8 44 23 19 
60 days 71 84 100 29 16 0 47 25 14 
All16  N/A N/A 92.5 N/A N/A 7.5 N/A N/A 18 
 
16 Since January 2013, IMI has had to comply with the payment time limits set out in the new Financial Regulation. 
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 Control systems 
IMI’s ex ante controls form an integral part of 
the respective procedures, workflows and 
financial circuits for both the administrative 
and operational budgets. These controls are 
documented and enforced through internal 
policies, management decisions, documented 
procedures and templates as well as by a 
series of established internal checks and 
balances aimed primarily at preventing errors 
from entering the process and also detecting 
and correcting errors in case these occur.  
 
In the case of payments to beneficiaries, the 
ex ante controls cover the whole project 
lifecycle, from the initial validation and 
approval of the pre-financing payments to the 
initiation and verification of interim and 
eventually final payments. Grants are paid on 
the basis of the beneficiaries’ declarations of 
eligible costs, the submitted Periodic Reports, 
and where applicable, certificates on the 
financial statements. The operational and 
financial agents perform initiation and 
verification tasks. As FP7 reporting is based on 
self-declarations, at the moment the payment 
is authorised, IMI is not able to fully ensure 
that the amount paid is accurate and in 
compliance with the applicable legal and 
contractual provisions. This can only be 
achieved through ex post audits carried out at 
the beneficiaries' premises, after the costs 
have been incurred and declared (see below). 
 
Internal controls are also embedded in the 
Call and grant award process, including the 
eligibility screening of the EoIs and the FPPs; 
the selection of experts; the ethical reviews of 
the proposals performed by independent 
external experts; the controls to ensure 
conformity with IMI rules, procedures and 
checks carried out during the negotiation; and 
grant preparation and signature processes.  
 
In 2013, independent observers compiled four 
reports on the publication of IMI Calls, the 
selection of independent experts and the 
evaluations of the 7th Call (Stage 2), 8th Call 
(Stages 1 and 2) and 9th Call (Stage 1). They list 
their observations and also make 
recommendations for further fine-tuning of 
the processes. The independent observers 
concluded that for these evaluations:  
 these processes were all according to the 
established procedures and regulations 
and there were no violations of the rules of 
the published evaluation guidelines;  
 the evaluators were of high quality, 
possessed the relevant expertise for each 
of the topics and displayed the utmost 
professionalism; 
 all evaluators fulfilled the stipulated 
criteria including not being involved in any 
of the applicant consortia and not being 
subject to any kind of conflict of interest; 
 the processes were well organised and 
managed from the initial publication and 
promotion of the Calls and the organisation 
of submissions to the evaluation of 
proposals; 
 the evaluation of the proposals was 
exhaustive, fair, impartial and transparent; 
 the consensus evaluation reports 
generated by all panels incorporated the 
opinions of all experts and truly 
represented the consensus opinions of the 
panels; 
 further improvements from previous Calls 
recommended by independent observers 
had been implemented. 
 
Furthermore, an appeal procedure provides 
applicants with the possibility of formally filing 
a complaint if they think that there were 
shortcomings in the handling of their proposal 
during the evaluation. No appeal requests 
were submitted in 2013 and this provides a 
further indication of the robustness of the 
grant award process and the effectiveness of 
the internal controls. 
 
IMI also actively monitors the progress of the 
funded projects through the systematic 
review of technical reports and through 
interim reviews of each project. In 2013, six 
interim reviews were held and these had 
positive conclusions on the early 
achievements of Call 2 projects (see section 
2.1 for more information).  
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 Ex post controls: audit and corrective actions 
Ex post audits are used extensively by IMI to independently measure and assess, on a multi-annual 
basis, the legality and regularity of interim (and eventually) final payments made to beneficiaries. 
Findings from the ex post audits are carefully analysed by the Executive Office and used for recovery 
and corrective actions, as well as to reinforce and fine-tune the preventive measures put in place by 
the Executive Office to minimise the occurrence of errors in cost claims submitted by beneficiaries.  
 
Ex post audits are outsourced to external audit firms as the lean structure of IMI does not allow for 
the setting up of an internal team of auditors for these purposes. Nevertheless, IMI staff remain 
responsible for the management of ex post audits, namely: 
 
 the selection of audits; 
 coordination with the EC; 
 the preparation of the audit input files; 
 contract management and the monitoring of the external audit firms’ progress and deliverables 
(regular follow up of the audit status, interaction with audit firms on technical questions and 
quality checks of audit reports); 
 the analysis of detected errors and the implementation of audit results. 
 
Important changes and improvements were made to the ex post audit process in 2013, including: 
 the creation of a new position of Ex post Audit and Finance Officer (see Section 5.2) to dedicate 
more time and resources to the above activities;  
 the introduction of additional quality review stages to further improve the quality of the 
reporting in the audit reports;  
 the approval in October 2013 of a comprehensive standard operating procedure for the 
operational planning and management of outsourced financial audits of beneficiaries as well as 
the main processes and procedures relating to the follow-up of audits.  
These initiatives will be continued in 2014, inter alia with the updating of the model audit report and 
other continuous improvement measures, to improve the efficiency and effectiveness of IMI’s ex 
post audit process. 
 
Beneficiaries 
 
The main legality and regularity indicators for payments made to beneficiaries, as defined in the Ex 
post Audit Strategy approved by the Governing Board in December 2010, are the representative and 
residual error rates detected by ex post audits: 
• The representative error rate is the error rate resulting from the representative audits. It 
provides a reasonable estimate of the level of error in the population relating to the 
accepted IMI JU contributions on completion of the audits, but does not take into account 
the corrections and follow-up undertaken by IMI. It is calculated as the average error rate 
(AER) according to the following formula:  
      ∑ (err)   
    AER%= ----------------------- = RepER% 
        n 
Where:  
∑ (err) = sum of all individual error rates of the sample (in %). Only errors in favour of the JU 
(i.e. overstated amounts) are taken into consideration. 
n = sample size (i.e. number of audited financial statements) 
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 • The residual error rate is the level of error remaining in the population after deducting 
corrections and recoveries made by IMI. This includes the extension of audit results to non-
audited financial statements of the audited beneficiaries to correct systematic errors. The 
formula for the residual error rate is: 
 
  (RepER% * (P-A) – (RepERsys% * E) 
ResER% = --------------------------------------------------------- 
    P 
Where:  
ResER%   =   residual error rate, expressed as a percentage. 
RepER%  = representative error rate, or error rate detected in the representative sample, in the form 
of the Average Error Rate, expressed as a percentage and calculated as described above (AER%). 
RepERsys% = systematic portion of the RepER% (the RepER% is composed of complementary 
portions reflecting the proportion of systematic and non-systematic errors detected) expressed 
as a percentage. 
P =  total amount in euros of the auditable population relating  to accepted IMI JU contribution.  
A = total value of audited IMI JU contribution, expressed in euros.  
E = total non-audited amounts of IMI JU contributions of all audited beneficiaries. This will 
consist of the total JU's share, expressed in euros, of all non-audited cost statements received for all 
audited beneficiaries.   
 
The calculation of the error rates is performed on a point-in-time basis, i.e. all the figures are 
provided as of a certain date.  
 
In addition, due to its multiannual nature, the effectiveness of IMI’s ex post audit strategy can only 
be fully measured and assessed during the final stages of IMI, once the ex post control strategy has 
been fully implemented and systematic errors have been detected and corrected in the relevant 
claims. For this purpose, the weighted average residual error rate for the entire cumulative period 
covered by ex post audits during the execution of the IMI programme will be applied once sufficient 
audits from each representative sample have been concluded. 
 
Periodic representative samples of beneficiaries to be audited have been extracted each year since 
2011. The methodology for selecting the representative sample is established in the Ex Post Audit 
Strategy. A combination of the largest beneficiaries and randomly selected entities are included in 
each sample. The first three samples covered payments to beneficiaries made between 22 December 
2010 (when the first and only interim payment to an IMI project was made in 2010) and 23 October 
2013 (cut-off date of the last extracted sample). 
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The following table gives an overview of the status as at 31 December 2013.  
Representative samples Number of ex post audits Selected Launched  Ongoing Finalised 
1st Rep. Sample  
(Q4 2011) 
60 60 4 56 
2nd Rep. Sample  
(Q4 2012) 
40 34 20 14 
3rd Rep. Sample  
(Q4 2013) 
35 0 0 0 
Total 135 94 24 70 
 
135 different beneficiaries participating in Call 1, 2 and 3 projects have so far been selected for ex 
post audit. This represents more than 40% of all beneficiaries participating in these projects. The 
initial broad coverage of beneficiaries is in line with the current strategy approved by the Governing 
Board.   
 
A total of 70 IMI ex post audits had been concluded by the end of 2013 and are used as a basis for 
determining the error rates in this Annual Activity Report: 
 56 of the 60 audits from the first representative sample (93.3%) were concluded between Q3 
2012 and Q2 2013. The remaining four audits from this sample were extended in scope in 2013 
due to important additional information being provided by the beneficiary during the report 
drafting stage.  
 14 of the 40 audits from the second representative sample (35.0%) launched in February and 
March 2013 were finalised by the end of the year. As for the remaining 26 audits: 
− 20 are ongoing and are at different stages of implementation. Results cannot as yet be 
used for the calculation of the error rate. Seven of these audits were launched later in the 
year (four engagements in June and three in October) after the closure of audits with the 
same beneficiaries by the EC and/or the European Court of Auditors (ECA).  
− Two audits from this sample were on hold as all external audit firms available through the 
IMI JU framework contract for external audit services reported a conflict of interest with 
the beneficiaries in question. These audits will now be outsourced in 2014 to other 
contractors using alternative European Commission framework contracts for audit services 
to which IMI JU has access for cases like this.   
− Four audits from this sample were still on hold at the end of 2013 due to recently-closed or 
ongoing audits by the EC with the same beneficiaries, and close coordination is being 
maintained with audit teams of the relevant EC services. 
 
The 35 planned audits resulting from the 3rd representative sample were selected in December 2013 
from an audit population of payments made between December 2012 and October 2013. The audits 
have been assigned to the external audit firms and the first set of these engagements will be 
launched in the first quarter of 2014, with results expected at the end of the year.  
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Representative and Residual Error Rates as at 31 December 2013 
 
First Representative Sample 
The average error rate (AER) resulting from the 56 concluded audits of the first representative 
sample was estimated at 5.8 % as at 31 December 2013.  
 
The residual error rate (ResER), after corrections on the audited claims are made (but at this stage 
prudently excluding the impact of corrected systematic errors on non-audited amounts of all audited 
participants until the extension of audit results is undertaken in 2014), was estimated at 3.6% as at 
31 December 2013. 
 
When analysing these results, three elements need to be taken into consideration: 
 The 56 audits cover a substantial 37.3% of the accepted IMI JU’s contribution of the audit 
population. 
 The audits in this first sample were by design focused in most cases on new or unaudited 
beneficiaries under the EU research programmes. In fact, the majority of detected errors clearly 
arose from misunderstandings of the rules or a lack of attention to the detail of the provisions of 
the Grant Agreements by these beneficiaries.  
 Several concrete preventive actions have since been undertaken to mitigate as much as possible 
the risk of these errors since the validation and payment of these claims in 2010 and 2011 (see 
Section 6.4 below). 
 
Second Representative Sample 
 
The 14 audits from the 2012 sample which were finalised by December 2013 register a significantly 
lower representative error rate than that recorded from the first representative sample. The error 
rate on the basis of these audit reports was estimated at 2.3% as at 31 December 2013. This estimate 
will continue to evolve with the completion of the remaining audits in the second representative 
sample. 
 
The residual error rate (ResER) will be calculated after further analysis is carried out on these results 
and the corrective and recovery actions are launched in 2014. 
 
The initial error rate from these first 14 audits, nonetheless, already shows a very encouraging early 
indication that the error rate is being reduced over time as envisaged in the Ex Post Audit Strategy.  
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 Further analysis of detected error rate levels using the year when the payments were made as a basis 
for comparison 
 
With a substantial number of audits having already been carried out on the first interim payments 
made to beneficiaries in the initial years of IMI (i.e. covering the financial years 2010, 2011 and 
2012), the following chart shows the gradual but clearly steady reduction in error rate over time 
since the first interim payment of 22 December 2010. 
 
 
 
Implementation of audit results 
IMI is very advanced in concluding the recovery and offsetting against subsequent claims of the same 
beneficiaries of the unduly paid IMI JU funds on the basis of concluded audits from the first 
representative sample. The vast majority of financial errors identified in these audits where 
adjustments were needed were relatively small sums (less than €5 000 in favour of IMI JU), and 
therefore in most cases the decision was taken to efficiently offset the amounts against the next 
payments to the beneficiaries concerned. There are no open controversial issues with these 
beneficiaries and this will duly lead to a 100% correction by the end of the process.  
 
The table below provides an overview on the implementation of ex post audit results from the first 
representative sample in favour of IMI JU as at 31 December 2013: 
 
Status as at 31/12/2013 Amount (EUR) % 
Negative adjustments in IMI JU contribution 251 102.27  
Implemented 170 347.00 67.84 
Recoveries - not yet cashed 68 382.21 27.23 
To be offset:   
Reports currently under analysis 7 520.61 3.00 
Reports due in January 2014 3 150.56 1.25  
Reports due in February 2014 1 701.89 0.68 
 
On the basis of these audits, in 2014, the process will also start for extending the systematic errors 
identified in the first representative sample to unaudited IMI JU claims by the same beneficiary for 
the same project and also for other projects in which the beneficiary is a participant.  
 
In addition, the same corrective actions (implementation of audit result and extension of audit 
findings) will also be taken on the first audit results from the second representative samples which 
were received in December 2013.  
6.5% 
5.6% 
2.6% 
0.0%
2.0%
4.0%
6.0%
8.0%
2010 2011 2012
Average detected error rate on the basis of 70 audits concluded by 31/12/2013, using the year 
when the payments were made as a basis for comparison 
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A balanced and risk-based approach to ex post control 
 
IMI remains committed to managing its funding to beneficiaries through a trust-based approach 
whilst ensuring sufficient control and accountability. The risk-based preventive and corrective actions 
already taken by IMI provide a sufficient basis for sound financial management and the gradual 
reduction of the risk of error in interim payments to beneficiaries on a multi-annual basis.  
 
With many projects only starting to generate expenditure, particularly in the case of projects from 
Call 3 onwards, the full impact of IMI’s actions can only be seen in the longer term, once more 
projects submit cost claims and ex post audits cover a greater part of the total population of 
beneficiaries. 
 
EFPIA Companies 
 
In addition to the ex post audits covering the 
IMI JU share of the funding to beneficiaries, 
2013 also saw IMI conduct the first in a series 
of ex post reviews and audits on the declared 
in kind contributions by EFPIA companies 
participating in IMI projects following the 
reporting of the first declarations of in kind 
contributions in 2012 
 
These companies do not receive any IMI 
funding, but contribute in kind to the projects 
in which they participate and benefit from. 
The purpose of the IMI audits is to 
independently measure and assess, on a 
sample basis and using a risk-based approach, 
the legality and regularity of the in kind 
contributions accepted by IMI.   
 
Each exercise consisted of two key elements.  
 
1. A review of the in kind methodology used 
by the EFPIA company to declare in kind 
contributions for all the IMI projects in which 
it participates, applying agreed-upon 
procedures to confirm the factual basis of the 
responses and descriptions provided in the 
submitted certificate on in kind contribution 
methodology. On this basis, the auditors 
conclude whether:  
a) the approach and basis of the actual 
calculations were as originally described in 
the accepted methodology;  
b) there were mathematical errors or other 
inconsistencies in the actual calculations 
made relating to the direct personnel full 
time equivalent (FTE) daily cost rate;  
c) the in kind methodology was consistently 
applied by the EFPIA company across all 
research and business activities and in 
accordance with its usual accounting and 
management principles and practices;  
d) the basis of the methodology and 
calculation is consistent with Article II.13.4 
of the Grant Agreement and excludes 
prescribed ineligible costs. 
 
2. A financial audit of a sample of in kind 
contributions declared in the Financial 
Statements submitted by EFPIA companies to 
IMI in order to assess and present an opinion 
on whether these meet the conditions of the 
Grant Agreement. 
 
By the end of 2013, the first three ex post 
selected reviews and audits of EFPIA 
companies were finalised. and with the 
following outcomes: 
 
 For two of the audited companies, the 
auditors reported no exceptions, based on 
the agreed-upon procedures, in their 
review of the submitted in kind 
methodology. 
 
 For the other EFPIA company, the auditors 
reported specific one-off human errors in 
the calculations made, leading to 
significant understatement of the FTE rate 
and the resulting in kind contributions 
declared in the projects. In addition, for 
this case, the auditors identified two cost 
statements not yet approved and eligible 
under Clause 13 of the Grant Agreement 
in relation to time recorded in the US.  
 
 With regard to the audit of sampled in 
kind declarations, in the case of one EFPIA 
company, the auditors found errors of a 
systematic nature, of both additional 
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 allowable amounts and disallowances. The 
impact of this was a significant increase in 
the allowable amount that could be 
declared by the EFPIA company. 
  
 For the other two companies, the auditors 
identified a few isolated errors, none of 
which were systematic or had a major 
impact on the declared amounts of in kind 
contributions, leading to adjustments in 
the total declared contributions. 
 
The calculated individual error rates for 
these three companies, on the basis of the 
audited declared contributions, were a 
negative adjustment of 3.52%, and two 
positive adjustments of 0.02% and 
39.89%..  
 All three companies accepted the findings 
and adjustments of the auditors and have 
already adjusted their claimed 
contributions or are in the process of 
doing so in the next reporting periods. In 
addition, one of the audits also led to the 
revision of the certificate on in kind 
methodology being updated and re-
submitted for acceptance by IMI. 
 
 The auditors also made recommendations 
for improving internal controls and for 
ensuring that the contractual obligation 
concerning the type and level of evidence 
kept on time-recording by staff working 
on IMI projects is sufficiently addressed. 
 
 
In addition to the above three finalised audits, 
a new on-the-spot review of applied in kind 
methodology and audit of a sample of 
declared contributions was launched by IMI in 
the third quarter of 2013 and this exercise is 
expected to be finalised in 2014.  
 
This approach will also be continued with 
other sampled EFPIA companies in order to 
obtain, on a multi-annual basis and over the 
lifetime of IMI, sufficient risk-based coverage 
of declared in-kind contributions.  
 
Collectively the first four EFPIA companies 
selected for an IMI ex post exercise account 
for a significant 23% of all committed in-kind 
contributions in IMI projects launched so far. 
 
In addition, at the end of 2013, two further 
EFPIA ex post exercises were being prepared 
for launch in the first half of 2014. These two 
companies account for a further 24% of all 
committed in-kind contributions in IMI 
projects launched so far. 
 
Fraud prevention and detection  
Since its inception, IMI has ensured that 
procedures to fight against fraud at all stages 
of the management process are applied across 
the organisation. In October 2008, the 
Governing Board adopted a decision 
concerning the terms for internal 
investigations in relation to the prevention of 
fraud, corruption and any illegal activity 
detrimental to the European Community’s 
interests.  
 
Anti-fraud measures are embedded in various 
ex ante and ex post controls for prevention 
and detection purposes, and a policy on 
sensitive posts is in place. The Executive Office 
has also collaborated closely with the 
European Commission on this matter over the 
years, and its staff has participated actively in 
training on fraud awareness, ethics, integrity 
and good conduct. In 2013, management gave 
prioritisation to the internal control standard 
on ethical values, and a policy on conflicts of 
interest was developed and implemented 
during the year.  
 
Moreover, IMI has also started the process of 
developing a consolidated Anti-Fraud Strategy 
for the whole organisation. The main purpose 
of this strategy will be to translate the 
strategic anti-fraud priorities into concrete 
operational measures addressing risks that are 
particularly relevant for the operations 
managed by IMI. It is expected that the 
Strategy will be finalised in early 2014. 
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  Results from audits and the second interim evaluation of IMI during the 6.3
reporting year 
 
Second Interim Evaluation of IMI 
The second interim review was carried out in 2013 by an independent expert group appointed by the 
EC. The expert panel was highly positive on the effectiveness, efficiency and quality of research and 
on the progress of IMI towards achieving its set objectives. The experts also reported on the 
considerable achievements and acquired strengths of IMI since the first interim evaluation and 
highlighted areas where more attention can be given in order to maximise the impact of IMI. These 
recommendations focused on communication activities, the measurement of the socio-economic 
impact of IMI, opportunities for increased engagement from a wider range of industry stakeholders, 
the possibility of more flexible funding mechanisms to ensure the sustainability of current and future 
projects; finding ways of reducing bureaucracy and ensuring that IMI has the optimal organisational 
structure for the tasks ahead, and on the Commission’s proposals for IMI 2 under Horizon 2020. IMI 
is implementing the relevant actions arising from these recommendations. 
 
Internal Audit 
In 2013, the Internal Audit Service of the European Commission (IAS) carried out two risk 
assessments at IMI, one on the common IT infrastructure shared among five JUs located in same 
building in Brussels and another on IMI’s own applications. The reports on these two risk 
assessments were finalised in November 2013. 
 
On the common IT infrastructure, the IAS risk assessment concluded that the five JUs showed a good 
level of control of all the risks in the area of IT management except for two risk areas, namely that 
implemented security management measures do not necessarily correspond with the business 
needs, and that specific contracts with IT service providers do not give adequate details about the 
procedures and controls the contractors have to follow. The JUs will take the necessary joint 
mitigating measures to address these risks. 
 
With regard to the IMI applications, the IAS risk assessment concluded that IMI also showed a good 
level of controls for all the risks in the area of applications except for the need for better descriptions 
in the contracts on the minimum project controls IMI expects from IT service providers.  
The IAS nonetheless also concluded that adequate project management controls are applied in 
practice and that the issue is to better enhance the descriptions in the contracts. IMI has in the 
meantime addressed this risk and introduced detailed clauses on project management controls in its 
new contracts with service providers. 
 
In the fourth quarter of 2013, the IAS also launched an internal audit on project monitoring and the 
reporting of operational performance at IMI. The main objective of the audit was to assess whether 
the JU has set up effective and efficient systems to monitor projects and to report on operational 
performance. The audit resulted in three recommendations, none of which were flagged as ‘critical’. 
Two of the recommendations were classified as ‘very important’ and the other as ‘important’.  
 
The IAS acknowledged in the report the considerable efforts of IMI to put in place KPIs and the 
challenges faced within the pioneering context in which IMI operates. The IAS recommend that 
objective setting and performance measurement and reporting be further developed by IMI by 
creating a more structured link in the Annual Implementation Plan to strategic objectives and by 
defining more clearly related objectives, quantitative targets and criteria for measuring and reporting 
progress and achievements. The auditors also make recommendations on how to strengthen and 
enhance the internal practices, tools and procedures applied by IMI for project monitoring and 
reporting. 
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The final audit report was received in February 2014 and IMI will use the conclusions and 
recommendations of the auditors to draw up a plan to implement the accepted actions for 
improvement. 
 
During 2013, the Internal Audit Manager of IMI, who also acts as the Internal Audit Capability (IAC) 
supported management through consultancy activities related to governance, internal control, ex 
post audits and risk management issues. The Internal Audit Manager also coordinated the various 
visits of the ECA and the IAS, providing additional support to the auditors in the conduct of their 
work.  
 
External audit 
In its report on the 2012 accounts issued in November 2013, the European Court of Auditors (ECA) 
provided a ‘clean opinion’ on the reliability of the accounts.  
 
On the legality and the regularity of the transactions underlying the accounts, the Court considered 
all transactions to be, in all material respects, legal and regular, except for a qualification on the basis 
of the preliminary error rate detected ex post by IMI’s own audits on a sample of intermediate 
payments made to Call 1 beneficiaries in the years prior to the one under review (that is, 2010 and 
2011). At the time of the ECA audit, IMI was in the process of taking corrective and recovery actions 
and had also launched additional audits to cover more recent claims validated between July 2011 
and November 2012.  
 
Furthermore, in its opinion, the Court also concluded that IMI JU’s ex post audit strategy was a key 
tool for IMI JU for assessing the legality and regularity of such payments. 
 
Several preventive and corrective actions have since been taken by IMI to mitigate the risk of errors 
in financial statements submitted by beneficiaries. More information on these measures can be 
found in the sections on financial operations (section 5.1), on ex post controls and recoveries (section 
6.2) as well and the analysis and action plan (section 6.5).  
 
Without calling into question its opinions as outlined above, the ECA also provided in its report on 
the financial year 2012 comments on budgetary and financial management. These issues have been 
superseded by later developments and the actions taken by IMI in 2013. The Court commented on: 
 the implementation of the budget in terms of both commitment and payment appropriations 
(see the financial tables and graphs in section 5.1 on the achievements in 2013 and previous 
years);  
 the degree of utilisation of the total EC contribution for IMI at the end of 2012 (refer to the 
most recent strategic achievements in section 1);  
 IMI’s adequate and comprehensive internal control systems and the areas where further 
work was being done at that time (an update on internal controls is presented in sections 
5.6, 6.2 and Annex C); 
 the internal audit of the IAS in 2012 and the actions of IMI to address the auditors’ 
recommendations (reported in 6.4 below); 
 the information to be available for the monitoring report that is regularly produced for FP7 
(see section 5.3 on the automatic export to CORDA); 
 the implementation of recommendations resulting from the validation of the accounting 
system of 2012 (refer to Annex C). 
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 Audits from previous years 6.4
 
Follow-up of the 2011 reservation 
The Declaration of Assurance for the 2012 Annual Activity Report was qualified for the first time with 
one reservation concerning the rate of the residual errors with regard to the accuracy of cost claims 
submitted by IMI project participants. This reservation was made on the basis of the findings from 
the first IMI ex post audits concluded in 2012 on payments made to beneficiaries in 2010 and 2011 
and on the conclusion that it was not possible to state with certainty that the residual error rate 
would fall below the materiality threshold of 2% at the end the IMI programme.  
 
The following steps were taken by IMI in 2013 in line with the action plan set out in the 2012 Annual 
Activity Report. 
 
 The continued systematic launch of ex post audits of beneficiaries and EFPIA participants 
together with the resulting corrective and recovery actions (see section 6.2 above). 
 
 The improvement of checklists and internal procedures for the validation and acceptance of 
cost claims in 2012 (see overview in Annex C). These are periodically reviewed and updated 
in line with the internal control standards and the principal of continuous improvement. 
 
 Training actions in 2013, through guidance and workshops, for beneficiaries and EFPIA 
participants on the provisions of the IMI model Grant Agreement and the most common 
errors. Actions to raise the awareness included the publication of updated IMI Financial 
Guidelines in June 2013 (first issued in January 2012) and the organisation of four financial 
workshops for participants throughout the year (following the successful launch of the first 
workshops in 2012). Both measures will continue to be conducted and updated. 
 
 Monitoring of the financial impact of identified errors, which might be lower, over the multi-
annual period (see section 6.2 above and Annex B). 
 
Follow-up of the European Court of Auditors’ comments from previous years 
All recommendations from the ECA from the report on the 2011 Accounts issued in November 2012 
were fully addressed by IMI between 2012 and 2013. These concerned: 
• the ongoing implementation of the action plan to mitigate the risk of errors in financial 
statements submitted by beneficiaries (details provided above and in section 6.5);  
• significant improvements in the implementation of the budget in terms of both commitment 
and payment appropriations (see the financial tables and graphs in section 5.1 on the 
achievements in 2013 and previous years)  and more clarity in the subsequent Governing Board 
decision on the approval of carry-overs; 
 the timely launch of Calls for Proposals and the full utilisation of the total EC contribution for IMI 
by end of 2013 (refer to the most recent strategic achievements in section 1); 
 the continued strengthening of internal controls and follow-up actions (an update on internal 
controls is presented in sections 5.6, 6.2 and Annex C); 
• the work and role of the IAS as IMI’s Internal Auditor  (described in section 6.3),  
• the continued formalisation of IT policies and systems (reported in section 5.3), and  
• the introduction of a reservation in the Declaration of Assurance to reflect the limited results of 
ex-post controls (documented in section 6.5, 6.6 and 7). 
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 Follow-up of the internal audit recommendations of 2012 
During 2012, the IAS carried out its first internal audit assurance engagement at IMI. The audit 
covered the negotiation, Grant Agreement preparations and pre-financing processes of IMI JU and  
resulted in 11 recommendations, none of which were flagged as ‘critical’. Three of the 
recommendations were classified as ‘very important’ and the others as ‘important’.  
 
The IAS recommendations were namely to:  
1. develop and implement a comprehensive policy to manage potential conflicts of interests of 
staff involved in the negotiation process;  
2. to formalise and implement a documented procedure and guidelines covering all aspects of 
the negotiation process;  
3. to develop SOFIA further in order to manage the technical negotiation as well as allow an 
accurate online information trail of changes made to financial and legal data by the project 
participants. 
 
All recommendations were accepted by IMI and were implemented between 2012 and 2013.  
 
In the third quarter of 2013, IAS also validated and closed the implementation of 10 of these 11 
recommendations; the remaining action will be closed by the IAS after they have conducted an on-
the-spot verification of the supporting evidence. 
 
 Reservations 6.5
 
For claims submitted by beneficiaries: 
 
• The representative error rate resulting from 56 audits (65 cost claims accepted in 2010 and 
2011) finalised from the first representative sample (93.3% completed) is 5.8%. The 
estimated residual error rate based on these concluded audit results is 3.6%.  
 
• The initial error rate resulting from 14 audits (19 cost claims accepted in 2011 and 2012) 
finalised in December 2013 from the second representative sample (35.0% completed) is 
2.3%. The residual error rate will be calculated once more results from other audits are 
received and implemented. 
 
The representative and residual error rates will continue to develop as more audits are closed and 
more corrections and recoveries are undertaken.  
 
Taking into account the first audit results as well as the similar experience of the European 
Commission in the management and control of research grants, it is not possible at this stage to state 
that by the end of the programming period the residual error rate will be below the materiality 
threshold as defined in Annex B ‘Materiality Criteria’. 
 
 With regard to the declared in kind contributions, it is still early in the ex post audit process to draw 
aggregate conclusions on the basis of the first risk-based sample of three audits of EFPIA participants. 
 
For these reasons, IMI JU maintains the reservation it introduced last year for its research 
programme. 
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Action plan to address the reservation 
The reduction of errors will continue to be addressed through the following actions.  
 
• The continued systematic launch of ex post audits of beneficiaries and EFPIA participants 
together with the resulting corrective and recovery actions. 
 
• Monitoring and fine-tuning of ex ante control procedures to optimise the detection and 
correction of errors before acceptance without increasing unduly the complexity and the 
processing time taken to pay beneficiaries and accept declarations of in kind contributions from 
EFPIA companies. 
 
• Training actions through guidance and workshops for beneficiaries and EFPIA participants on 
IMI’s financial rules. 
 
• Monitoring of the financial impact of identified errors, which might be lower, over the multi-
annual period.  
 
Title of the reservation, 
including the scope 
Reservation concerning the rate of the residual errors with regard to 
the accuracy of cost claims submitted by IMI JU participants. 
Domain IMI JU projects. 
Activity and amount Payment appropriations related to intermediate payments made to 
beneficiaries in 2013: €59.4 million. 
 
Estimated in kind contribution by EFPIA companies accrued under 
operational expenditure in 2013 : €106.2 million 
Reason for the reservation At the end of 2013 it is not possible to state with certainty that the 
residual error rate of the level of the financial impact of identified 
errors will fall below the materiality threshold at the end of the multi-
annual period. 
Materiality 
criterion/criteria 
The materiality criterion is the residual error rate which is the level of 
errors that remain undetected and uncorrected by the end of the IMI 
JU programme. 
 
The control objective is to ensure that the residual error rate on the 
overall population is below 2% at the end of the IMI JU programme.  
 
As the control objective is set to be achieved in the future, it is 
therefore not sufficient to assess the effectiveness of controls only by 
looking at the error rate determined during the year under review.  
 
The analysis must also include an assessment of whether:  
• the scope and results of the audits carried out until the end of the 
reporting year were sufficient and adequate to meet the multi-
annual control strategy goals; 
• the preventive and remedial measures in place are adequately 
effective in order lead to the expected reduction in the target error 
rate by the end of the programme. 
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 Quantification of the 
impact 
In the case of beneficiaries, the maximum impact is calculated on the 
basis of the best available information by multiplying the estimated 
residual error rate of 3.6% in favour of IMI JU (currently based on the 
more complete audit results of the first representative sample) by the 
amount of intermediate payments made to them in 2013. The 
estimated impact on interim payments made to beneficiaries in 2013 is 
€2.1 million. 
 
With regard to the declared in kind contributions, it is still early in the 
ex post audit process to quantify and determine the impact of the 
reservation on the basis of the first three audits of EFPIA participants. 
 
Impact on the assurance 
 
This reservation has an impact on the legality and regularity of the 
affected transactions, i.e. intermediate payments made by IMI JU 
against submitted cost claims from beneficiaries. It can also lead to 
adjustments in the total reported in kind contributions. 
 
Responsibility for the 
weakness and its 
correction 
The principal underlying reason for this issue is the complexity of the 
eligibility rules as laid down in the basic acts decided by the legislative 
authorities. IMI JU is responsible for the management and control 
systems. Participants and certifying auditors are responsible for the 
declaration of costs and for certificates on the financial statements, 
respectively. Within these parameters, IMI JU’s remedial action is 
carried out through ex ante controls, ex post audits, and the systematic 
correction of detected errors, as well as through ongoing guidance, 
workshops and feedback to participants and certifying auditors. 
Corrective action The reduction of errors will be addressed through the following 
actions:  
• the continued systematic launch of ex post audits as well as 
corrective and recovery actions; 
 
• the monitoring and fine-tuning of ex ante control procedures 
to optimise the balance between on one hand the effective 
detection and correction of errors before acceptance of cost 
claims and on the other hand the avoidance of undue 
complexity and delays in the processing time needed to pay 
beneficiaries and accept declarations of in kind contributions 
from EFPIA companies; 
 
• initiatives to pre-empt and stem the occurrence of errors in 
financial statements and certificates on the financial 
statements submitted by participants through guidance and 
workshops for beneficiaries and EFPIA participants;  
 
• monitoring the actual financial impact of the identified errors, 
which can ultimately be lower, over the multi-annual period, 
than what is indicated by the current estimated error rates 
based on the first audit results on cost claims received from 
beneficiaries of Call 1 and Call 2 projects. 
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 Overall conclusions on the combined impact of the reservations on the 6.6
Declaration as a whole 
 
 No qualification is to be made on IMI JU’s policy activities. There is also no reservation on the 
procedures relating to the selection of participants for IMI JU projects and the corresponding 
underlying financial operations (legal and financial commitments). This is also the case for IMI JU 
payments relating to administrative expenditure and procurement, as well as for pre-financing 
payments for grants. 
 The accounts that may be affected by the errors are expenditure against cost claims of IMI JU 
participants. 
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 7. STATEMENT OF REASONABLE ASSURANCE 
 
 
 
 
STATEMENT OF REASONABLE ASSURANCE 
 
I, the undersigned, Michel Goldman, Executive Director of the Innovative Medicines Joint 
Undertaking in my capacity as authorising officer, 
 
- declare that the information contained in this report gives a true and fair view; 
 
- state that I have reasonable assurance that the resources assigned to the activities  described in 
this report have been used for their intended purpose and in accordance with the principles of 
sound financial management, and that the control procedures put in place give the necessary 
guarantees concerning the legality and regularity of the underlying transactions; 
 
- state that this reasonable assurance is based on my own judgement and on the information at 
my disposal, such as the results of the self-assessment, ex post controls, the work of the internal 
audit capability, the observations of the Internal Audit Service and the findings from the reports 
of the European Court of Auditors for the years prior to the year of declaration;  
 
- confirm that I am not aware of anything not reported here which could harm the interests of the 
Joint Undertaking. 
 
However the following reservation should be noted: 
 
The reservation concerning the rate of residual errors with regard to the accuracy of cost claims 
submitted by participants of IMI JU projects. 
 
 
Signed in Brussels, on 14 February 2014 
 
 
Michel Goldman, MD, PhD 
Executive Director  
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ANNEX A – FINANCIAL INFORMATION 
 
In accordance with the Financial Rules of the IMI JU art. 41, the Annual Activity Report shall include 
financial information for the year under review. This Annex provides a detailed overview of the 
Budget and its execution in 2013. 
 
BUDGET 
Budget of IMI JU is divided in three titles: 
 Title I covers staff expenditure such as salaries, training, costs associated with recruitment 
procedures and staff well-being; 
 Title II covers the costs associated with functioning of IMI JU such as renting of premises, IT needs, 
expenses related to external communication, expert fees and costs of ex-post audits; 
 Title III covers operational activities of IMI JU. 
The 2013 budget was approved by the Governing Board on 21 December 2012 and adjustments were 
made based on the Decision of the Governing Board on carry over amounts of 4 February 2013.  
 
On 2 December 2013, the Governing Board approved an amending budget 2013. The following 
changes were introduced: 
 Cancelled commitment appropriations were re-entered in the budget in order to use available 
appropriations for Calls for proposals launched in 2013; 
 Payment appropriation for Title III was lowered following the cut of the EU contribution for 2013 
operational payments by the budgetary authority; 
 Correction of bank interest was made for both payment and commitment appropriation. 
Budget 2013 (in EUR) 
 Commitment appropriation Payment appropriation 
Original budget  226,945,440 134,974,655 
Amending budget No 1 255,715,919 130,558,622 
 
Budget transfers 
No budget transfer between Titles was done during 2013.  
 
Five budget transfers between chapters were authorised out of which three were formalised during 
the amending budget. Two budget transfers made after the adoption of amending budget led to the 
following changes: 
 
Chapter Amending Budget 
No 1/2013 
Budget transfer Budget after transfers 
Chapter 11 4,131,000 (-) 16,000 4,115,000 
Chapter 14 200,000 (+) 16,000 216,000 
Chapter 26 500,000 (-) 25,873 474,127 
Chapter 28 800,000 (+) 25,873 825,873 
 
Twenty six budget transfers were made between different budget lines of the same Chapter without 
any impact on voted budget.  
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 Budget execution 
Details on budget execution are reported in section 5.1. 
 
REVENUE 
IMI JU's revenue for the year:  
 
 
Source of revenue 
Amount (in EUR) 
2013 2012 
EU Contribution from 
European Commission 125,829,159.00 97,783,960.00 
Contribution from EFPIA 2,742,987.80 4,067,578.15 
Bank interest 95,796.81 474,655.28 
Miscellaneous income  100,112.92  
TOTAL 128,768,056.53 102,326,193.43 
 
Overview of EFPIA contribution to IMI JU running costs 
 
Year Payments from EFPIA 50% of payments executed C1+C4 
50% of 
payments 
executed C8 
Balance 
31/12/2013 
2008  171,974.04 n/a  
2009 711,167.90 397,989.50 n/a  
2010 2,126,460.00 1,408,297.53 164,906.28  
2011 1,660,162.00 2,221,660.11 440,540.59  
2012 4,067,578.15 2,830,223.22 312,764.58  
2013 2,742,987.80 2,925,226.85 411,704.20  
Total 11,308,355.85 9,955,371.25 1,329,915.65 *(23,068.95) 
*The amount due to IMI will be paid by EFPIA together with the first instalment 2014 
 
 
EXPENDITURE 
Administrative expenditure (Title I and Title II) 
 
Title I 
In 2013 IMI JU had 29 temporary agents and 7 contract agents. Following expenditure is reported 
under Title I: salaries, insurance, taxes, allowances, training costs, mission costs, medical service fees, 
entertainment and representation.  
 
Title II 
Other administrative expenditure is reported under Title II including: 
 rent and related charges;  
 development of IT tools (SOFIA, DORA, etc.);  
 ABAC fees; 
 purchase, rent and maintenance of equipment;  
 purchase of software;  
 postage and telecommunications fees;  
 office supply; 
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 costs of formal meetings, workshops, call evaluations and interim reviews including renting 
of facilities and payments of experts; 
 costs of ex-post audits; 
 studies, etc. 
Procurement 
The majority of IMI JU’s tendering needs are in the field of external communication, IT and ex-post 
audit services. The tender and contract management is being simplified as far as possible through the 
use of multiannual framework contracts. IMI JU also cooperates with other Joint Undertakings in 
tendering services in order to avoid duplication of administrative work. Where possible, IMI JU is 
party to European Commission’s framework contracts to reduce administrative burden created by 
proprietary contract management.  
In 2013, IMI mainly relied on these existing contracts for its procurement needs. No major new 
procurement procedures were launched under IMI’s administrative budget in 2013. The only larger 
procurement procedure was carried out for a service contract for consultancy services to set up a 
platform for stakeholder involvement to optimise project outcomes. This contract was concluded 
against IMI’s operational budget.  
 
 
Administrative expenditure per Chapter 
 
 
Administrative budget was executed applying principles of sound financial management. As an 
example, IMI planned to improve working conditions in an open space for its staff which would 
require some works and purchase of furniture. For this activity, budget was foreseen under Chapter 
22. These plans were postponed taking into consideration the proposal of IMI2 with estimated start 
date in 2014.  
Meetings were mostly organised in Brussels or in parallel with other meetings which considerably 
lowered costs of formal meetings (Chapter 25), workshops (Chapter 26) and events (Chapter 27). 
For Title I, it was expected that the indexation of salaries (2011) will have to be paid at the end of 
2013. The information that the indexation will not be paid in 2013 came only the last days of 
December when it was too late to use the reserved funds for other purposes. 
It is important to note that the EU part of unused appropriations for running costs will be made 
available for operational activities under 2014 budget.  
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  Report on C1 
Running 
costs 
Budget  
(PA/CA)  Committed Not used  Paid 
To be carried 
forward 
(RAL) 
To be 
carried 
over to  
Title III C2 
(50%-EC)* 
Title I 4,541,000 3,781,745.77 759,254.23 3,722,901.56 58,844.21 379,627.12 
Title II 3,859,000 3,337,439.72 521,560.28 2,126,126.80 1,220,915.53 260,780.14 
Total 8,400,000 7,119,185.49 1,280,814.51 5,849,028.36 1,279,759.74 640,407.26 
*The amount transferred from Title I & II to Title III and carried over to 2014 following decision of the Governing Board 
 
Report on C8 
 Carried 
forward RAL 
from 2012 
Paid 
in 2013 
To be 
cancelled To be carried over to  Title III C2 (50%-EC)* 
Title I 115,491.69 71,384.45 44,107.24 22,053.62 
Title II 1,104,798.03 752,023.94 352,774.09 176,387.05 
TOTAL 1,220,289.72 823,408.39 396,881.33 198,440.67 
*the amount transferred to Title III and carried over to 2014 following decision of the Governing Board. 
 
Report on C4 
 C4 
2013 
Paid 
in 2013 
To be carried 
forward to 2014 
Title I 2,234.00 0 2,234.00 
Title II 15,810.88 1,425.33 14,385.55 
TOTAL 18,044.88 1,425.33 16,619.55 
 
 
Operational expenditure (Title III) 
Operational expenditure on Title III covers all the expenses linked to the Research Agenda of IMI JU. 
In 2013, intermediate payments for Call 1, 2, 3 and 4 projects have been made as well as pre-
financing for projects of Call 7, Call 8 and one project of Call 6. These payments consumed 99.43% of 
the payment appropriation available for 2013.  
 
Commitment appropriation was fully consumed by launching Call 9, Call 10, Call 11 and ENSO Call 
2013 (global commitments) and one individual commitment for consultancy service to set up a 
platform for stakeholder involvement to optimise IMI projects’ outcomes (€ 200,000).  
 
Report on C1 
Research 
Title III Budget 
Amending 
Budget No 1  Committed Not used  Paid 
**To be 
carried 
over 
Commitments *196,379,206 *197,311,368 197,311,368 0 n/a 0 
Payments *126,150,000 *121,733,967 n/a 266,547.55 121,467,419.45 266,547.55 
*Including budgeted bank interest 
** The amount carried over to 2014 following decision of the Governing Board 
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 Report on C2 
Research 
Title III Budget 
Amending 
Budget No 1  Committed Not used  Paid 
*To be 
carried 
over 
Commitments 22,166,234 50,004,551 50,004,551 0 n/a 0 
Payments 424,655 424,655 n/a 424,655 0 424,655.00 
* The amount carried over to 2014 following decision of the Governing Board 
 
Report on C4 
 C4 
2013 
Committed 
in 2013 
To be carried forward to 2014 
Title III 16,823.34 0 16,823.34 
 
Report on C8 - carried forward contractual obligations (on-going projects/calls) 
Title III  
Commitment Appropriation 
RAL 
 carried forward to 2014 
Call 1 15,389,481.05 
Call 2 30,044,211.47 
Call 3 65,890,685.04 
Call 4 57,499,181.33 
Call 5 58,793,232.30 
Call 6 74,812,972,73 
Call 7 6,399,872.00 
Call 8 84,980,808.00 
Call 9 63,120,000.00 
Call 10 6,100,000.00 
Call 11 171,424,773.00 
ENSO 2013 6,471,146.00 
Service contract 200,000.00 
Total 641,126,362.92 
 
Overview of appropriations carried over to 2014 
Title Commitment appropriation Comment 
Title I & II → Title III 640,407 Non-used EU contribution in 2013 
Title I & II → Title III 198,441 Appropriation cancelled in 2013 
Title III 42,055 Bank interest – Q4 2013 
TOTAL 880,903  
 
Title Payment appropriation Comment 
Title III 266,547 Non-consumed appropriation 2013 – C1 
Title III 424,655 Non-consumed appropriation 2013 – C2 
Title III 42,055 Bank interest – Q4 2013 
TOTAL 733,257  
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BUDGET OUTTURN ACCOUNT 
 
 
 2013 2012 
Revenue EUR EUR 
EU contribution – European Commission DG RTD 
EFPIA contribution for running costs 
Bank interest 
Interest on pre-financing 
Miscellaneous income 
125,829,159.00 
2,742,987.80 
95,796.81 
54,072.68 
100,112.92 
97,783,960.00 
4,067,578.15 
474,655.28 
52,864.52 
Total revenue (a) 128,822,129.21 102,379,057.95 
Expenditure EUR EUR 
Personnel expenses – Title I 
Payments on current year appropriations (C1) 
Payments on previous year appropriations (C8) 
Administrative expenses – Title II 
Payments on current year appropriations (C1) + (C4) 
Payments on previous year appropriations (C8) 
Operational expenses – Title III 
Payments on current year appropriations (C1) 
Payments on previous year appropriations (C2) 
3,794,286.01 
3,722,901.56 
71,384.45 
2,879,576.07 
2,127,552.13 
752,023.94 
121,467,419.45 
121,467,419.45 
0 
3,718,444.28 
3,677,389.78 
41,054.50 
2,567,531.31 
1,983,056.66 
584,474.65 
103,809,163.00 
93,133,960.00 
10,675,203.00 
Total expenditure (b) 128,141,281.53 110,095,138.59 
Outturn for the financial year (a-b) 680,847.68 -7,716,080.64 
Cancellation of unused appropriations (+) 396,881.33 (+) 160,656.06 
Appropriations carried over/forward 
(Title I and II) 
 
(-) 2,135,227.22 
 
(-) 2,560,589.67 
Appropriations carried over 
(Title III) 
(-) 424,655.00 (-) 424,655.28 
Balance of the outturn account for the financial year -1,482,153.21 -10,540,669.53 
  
 
 
 
 
 
  
ANNUAL ACTIVITY REPORT 2013 INNOVATIVE MEDICINES INITIATIVE  page 97 of 118 
 
 
 
 
ANNEX B - MATERIALITY CRITERIA 
 
 
The Executive Director assessed the 
significance of any weaknesses or risks that 
could lead to a formal reservation in the 
annual declaration of assurance. This annex 
provides an explanation of the materiality 
threshold that was applied as a basis for this 
assessment. 
 
The control objective is to ensure that the 
residual error rate of payments made to 
beneficiaries, i.e. the level of errors which 
remain undetected and uncorrected, does not 
exceed 2% by the end of the research 
programme. The guidance of the European 
Court of Auditors as well as the applicable EC 
standards were taken in account for defining 
the 2% threshold. In addition, a qualitative 
and quantitative judgment was applied to 
assess and quantify any significant 
weaknesses: 
 
− in qualitative terms, the following 
factors are considered as part of the 
materiality criteria: nature, scope, 
duration, mitigating controls, 
existence of corrective actions;  
 
− in quantitative terms, the potential 
financial impact is taken into account. 
The assessment of weaknesses was done by 
identifying their potential impact and judging 
whether any weakness was material enough 
that its non-disclosure could influence the 
decisions or conclusions of the users of the 
declaration of assurance.  
 
The following considerations were, therefore, 
taken into account: 
 
 Due to its multiannual nature, the 
effectiveness of IMI’s control strategy can 
only be fully measured and assessed at 
the final stages in the life of the IMI 
programme, once the ex post audit 
strategy has been fully implemented and 
systematic errors regarding beneficiaries 
have been detected and corrected.   
 
 As the control objective is set to be 
achieved in the future, it is therefore not 
sufficient to assess the effectiveness of 
controls only by looking at the error rate 
determined during the year under review. 
The analysis must also include an 
assessment of whether (1) the scope and 
results of the audits carried out until the 
end of the reporting year were sufficient 
and adequate to meet the multi-annual 
control strategy goals; and (2) whether 
the preventive and remedial measures in 
place are being deemed to be adequately 
effective in order lead to the expected 
reduction in the error rate by the end of 
the programme. 
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 ANNEX C - INTERNAL CONTROL FOR BUDGET IMPLEMENTATION 
 
 
Key figures 
Details on budget execution and time to pay for administrative and operational expenditures are 
provided in sections 5.1 and 6.2. 
  
Management and control systems: stages and main actors 
 IMI applies the simple financial circuit 
model in the Accrual Based Accounting (ABAC) 
system, but the respective role of Operational 
Initiating Agent and Operational Verifying 
Agent are taken into account - where relevant 
- during the process (as defined in the routing 
sheet). This financial circuit, together with the 
management and accounting systems, 
segregation of duties and procedures, internal 
controls, reporting structures and control 
functions were established in line with the 
requirements of the IMI financial rules.  
 The Executive Director acts as Authorising 
Officer, with authority being delegated to the 
Head of Administration and Finance and, 
when necessary as backup, to another 
member of staff. In accordance with its 
financial rules, IMI uses the four-eye principle: 
all operational and financial aspects of an 
operation have to be verified by a second staff 
member before it is authorised. This 
verification is used to ensure compliance with 
rules and good financial management. The 
Executive Office also has an Internal Control 
Coordinator (ICC), an Internal Audit Capability 
(IAC) and an Internal Auditor (the Internal 
Audit Service of the European Commission, 
IAS) to monitor and independently assess 
governance, management and control 
systems. 
 
Selection process 
 The selection process for participants in 
IMI projects is based on a two-stage 
evaluation process which includes a public Call 
for proposals, official rules of participation, 
eligibility screening of the EoIs and FPPs; 
ethical reviews of the proposals performed by 
independent external experts; and controls to 
ensure conformity with IMI rules as well as 
procedures and checks carried out during the 
negotiation, grant preparation and signature 
processes. Each key stage is endorsed by a 
decision of the Governing Board. 
 
 In the case of the selection of experts, 
individuals are chosen on the basis of a list of 
appropriate experts according to their specific 
expertise. The experts are appointed for the 
duration of each specific Call process. A 
Scientific Officer ensures that the proposed 
experts have the necessary expertise and 
prepares a dossier with the required 
information to support the decision of the 
Executive Director. IMI has a documented 
standard operating procedure and controls for 
the selection of experts. 
 
 For the procurement of services and 
supplies, the preventive measures in place for 
each procurement activity include: a clear 
evaluation of needs; the volume and cost of 
the required services or supplies; verification 
that the services or work cannot be executed 
in house or on the basis of any framework 
contracts of the European Commission to 
which IMI is associated or on the basis of 
service level agreements; and a decision on 
the choice of procurement procedure. 
Standard procurement procedures apply 
depending on established thresholds of the 
estimated value of the contract. 
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Communication and information 
 Internally: The main internal mechanisms 
for communication and the dissemination of 
information are senior management briefings 
and updates to the Governing Board, 
Management Team meetings, Management of 
Scientific Activities meetings, Finance and 
Administration meetings, internal briefings 
and newsletters as well as horizontal and ad 
hoc meetings. These channels are important 
for ensuring effective communication and 
sharing of information between financial, 
administrative and scientific staff. 
 Externally: Published information (such as 
the Call text, guidelines for applicants and 
participants and information on the website); 
the organisation of meetings with 
stakeholders such as the SRG, ILG, and 
stakeholders, special information sessions 
linked to the different calls; meetings and 
workshops; and a wide range of 
communication tools are used to support the 
management processes and for the collection 
and reporting of information and data. 
 
Detective and corrective controls 
 Projects submit periodic reports which 
include financial statements and an 
explanation on the use of resources for all 
participants including EFPIA companies. 
The current cumulative threshold for the 
presentation of a certificate on the financial 
statements issued by an independent external 
auditor is €375 000. This requirement is 
waived (except at the end of the project) for 
those project participants that declare their 
costs according to certified methodologies 
that have already been accepted by the EC or 
IMI. 
 
Before a payment is authorised, all relevant 
operational and financial aspects are verified 
by at least two independent members of staff. 
 
 Scientific Officers verify that the work 
carried out by the participant is in all respects 
in compliance with the Grant Agreement by 
evaluating the periodic reports and 
deliverables and by assessing the plausibility 
of declared spending in relation to reported 
progress. 
 
 Financial Officers carry out checks to 
ensure financial statements and certificates of 
financial statement (CFS) have been submitted 
in accordance with the provisions of the Grant 
Agreement. 
 
 The Authorising Officer ascertains that 
these checks on the supporting documents 
have been carried out and validates the 
expenditure. 
 
 Since 2011, interim reviews have also been 
systematically used to complement the 
detective and corrective controls. In 2013, six 
interim reviews were organised. 
 
 
 
 
 
Corrective controls and audit 
 Ex post audits are a key element of 
corrective controls. IMI follows the JUs’ ex 
post audit strategy which was approved by the 
IMI Governing Board following harmonisation 
with the corresponding FP7 strategy. 
 
 The main objective of the ex post audit 
activity is to provide an adequate indication of 
the effectiveness of ex ante controls as well as 
on the accuracy, legality and regularity of the 
underlying transactions on a multi-annual 
basis. 
 
 At any time during the project 
implementation period, the European 
Commission, the ECA and IMI can carry out on 
the spot checks and/or audits of beneficiaries. 
In addition, IMI can also carry out on the spot 
checks and/or audits of EFPIA companies 
providing in kind contributions to the projects. 
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  The selected financial statements to be 
audited are based on a sampling strategy that 
ensures comprehensive coverage of the audit 
population. This sampling includes primarily 
representative sampling to estimate error 
rates in the total population of beneficiaries, 
and systematic coverage of the largest 
beneficiaries (with due consideration to any 
overlapping activity by the EC). It can also 
include risk-based sampling from the overall 
population of participants including EFPIA 
companies. 
 
 The first ex post audits of beneficiaries 
were concluded in 2012 and new audits are 
continuously being launched to cover new 
cost claims. In parallel, follow-up corrective 
actions are taken to recover amounts found to 
have been paid in excess. Systematic errors 
detected on the audited contracts are also 
extended and corrected in the relevant non-
audited claims. This ensures that a substantial 
share of funding is largely free from 
systematic errors. 
 All audit results are implemented by the 
authorising officer and errors detected are 
corrected by issuing recovery orders or 
deducting amounts wrongly paid from future 
payments to the same beneficiary.  
 
 Preventive measures, such as workshops 
and guidance to participants and auditors, and 
further strengthening of ex ante controls are 
also being implemented. 
 
 In addition, in 2013, the first sample of 
three independent ex post reviews of the 
accepted in kind methodologies of EFPIA 
companies together with audits of a sample of 
declared in kind contribution were concluded. 
This approach is being continued with other 
sampled EFPIA companies particularly the 
largest contributors of in kind contributions to 
IMI projects. 
 
 
 
Anti-fraud measures 
Anti-fraud measures are embedded in various 
ex ante and ex post controls for prevention 
and detection purposes. In addition, in 2014, 
IMI will build on the Anti-Fraud Strategy of the 
European Commission and experience 
acquired by Commission services to develop 
its own Anti-Fraud Strategy in line with 
guidance from OLAF (the European Anti-Fraud 
Office) and good practices applied across the 
European Commission’s research family. In 
2013, the initial work for the preparation of 
this strategy was started and consultations 
were held with the European Commission. The 
main purpose of this strategy will be to 
translate the strategic anti-fraud priorities into 
concrete operational measures addressing 
risks that are particularly relevant for the 
operations managed by IMI. 
 
 
Feedback which enables control activities to be optimised 
Verification that processes are working as designed 
 Arrangements are in place to ensure 
adequate management supervision and 
the proper segregation of duties. These 
measures prevent any control overrides or 
deviations from policies and procedures 
unless there is prior approval. Procedures 
are also in place for rigorous reporting and 
registration of exceptions to internal 
policies and standard operating 
procedures and processes that have been 
assessed and accepted by management. In 
2013, 13 exceptions were registered by 
management. These related to processes 
and workflows concerning grant 
management (2 registered exceptions), 
call coordination (1), financial 
management (5), contract management 
(5) and ex-post audit (1). 
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 Management at all levels supervises the 
activities they are responsible for and keeps 
track of main issues identified. A system of 
checklists and routing sheets document the 
processes and the work carried out. Activities 
involving potentially critical risks (e.g. aspects 
of legality, regularity and operational 
performance) are also adequately 
documented and, when necessary, also 
discussed and addressed during regular 
management or team meetings.   
 The effectiveness and efficiency of 
management supervision is also systematically 
evaluated during each annual risk assessment 
exercise and by other planned or ad hoc 
examinations, assessments, audits and checks 
carried out by the ICC and the IAC. 
 As from 2012, independent verifications 
and follow-up examinations on the 
implementation of recommendations have 
also been carried out by the IAS on IMI’s 
processes. These can be in the form of an 
audit assurance engagement or as a 
performance audit. 
 Two in-depth and comprehensive 
exercises were carried out in 2011 and 2012 
by the Accounting Officer to validate the 
system of underlying processes supporting the 
accounting system. Moreover, the Accounting 
Officer can launch at any time additional 
validations, particularly of new or modified 
processes or procedures that are assessed as 
having a significant impact on reliability of the 
accounting system, 
 Independent observers are also engaged 
by IMI to monitor each evaluation of EoIs or 
FPPs. Their role is to report on the degree of 
compliance with the established rules, the 
extent to which proceedings were fair, 
exhaustive and transparent, as well as on the 
level of organisation and the quality of the 
evaluations. In their report they also propose 
recommendations for further improvement 
and fine-tuning of the processes. These 
reports are made public and identified actions 
are followed up and implemented by IM in 
subsequent evaluations. In 2013, there were 
four independent observers’ reports. 
 Ex post audits also provide an important 
source of information on the extent to which 
internal ex ante control and verification 
systems are functioning as intended and 
effectively.  
 In parallel, the ECA carries out financial 
and compliance audits of IMI and provides 
draft and final audit reports on the reliability, 
legality and regularity issues. It also highlights 
any concerns and observations resulting from 
its audits. 
 
 
 
Monitoring of performance 
 On a day-to-day basis, progress against 
objectives/deadlines and performance is 
discussed and monitored through regular 
team, management and cross-functional 
meetings. Issues and risks (e.g. on Call 
management status) are flagged and followed 
up. Additional systematic monitoring and 
tracking is also undertaken by management, 
the ICC and the IAC on prioritised areas of 
activity or concern. Critical strategic or 
governance issues are also monitored and 
followed up in Governing Board meetings. 
 
 
 
 In addition, throughout the year, metrics, 
indicators and qualitative evaluations on the 
scientific achievements and results of IMI as 
well as on the operational efficiency of the 
organisation are systematically compiled 
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 and reported. The latter cover critical issues 
such as time-to-pay, time-to-grant and budget 
execution.  
 
 An internal audit was also launched in the 
fourth quarter of 2013 by the IAS to assess 
IMI’s performance monitoring and reporting 
systems. The conclusions and 
recommendations of this audit are expected in 
2014 and these will used by management to 
refine and improve the overall approach and 
the underlying processes for measuring and 
monitoring performance.  
 Moreover, two external interim reviews 
by independent panels of experts were carried 
out on behalf of the European Commission in 
2010 and 2013 to assess the effectiveness, 
efficiency and quality of research generated 
through IMI, and to evaluate the progress of 
IMI towards the objectives set and the level of 
implementation of recommendations from 
the first interim evaluation.  
 
 
 
 
 
 
High-level management reporting 
 The Annual Implementation Plan includes 
planned actions, initiatives and priorities relative to 
the implementation of the budget.  
 
 The Executive Director reports to the 
Governing Board on progress and achievements 
through regular briefings and communications as 
well as during at least two meeting of the Board 
which are held every year. 
 
 In addition, the Annual Activity Report outlines 
the activities, achievements and progress made 
during the year, including issues related to budget 
implementation. 
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 ANNEX D – MEDIA COVERAGE 
 
The following list sets out some media highlights from 2013. Articles appearing in national media in 
the EU are arranged by country. A more exhaustive list can be found on the Media Coverage page of 
the IMI website. 
 
European  
 European Files, December 2013 
IMI: Delivering results for patients 
 MedNous, 23 December 2013 
Genetic variants affect cognition 
 Science Business, 12 December 2013 
Health in Horizon 2020 – A move towards personalised healthcare 
 PharmaNews, 12 December 2013 
IMI launches €371 million call with focus on Alzheimer's, arthritis, cancer, and more 
 European Biotechnology News, 11 December 2013 
First adaptive Alzheimer trials 
 European Biotechnology News, 15 August 2013  
A Bioeconomy PPP – the next generation in collaboration  
 Euronews, 25 June 2013 
Developing a treatment for autism 
 EurActiv, 13 March 2013 
EU body may provide ‘solution’ to antibiotics resistance threat, says UK medical chief 
 European Files, February-March 2013 
IMI – Towards a new ecosystem for healthcare in Europe 
 
International 
 Wall Street Journal, 30 December 2013 
Researchers Aim to Speed Cures to Patients 
 BioCentury, 13 December 2013 
IMI launching project for adaptive Alzheimer's trial 
 Scrip, 11 December 2013 
IMI to revolutionize the hunt for Alzheimer's drugs as part of €371m call 
 BioCentury, 27 November 2013 
Stakeholders launch pan-Europe vaccine monitoring project 
 Scrip, 29 October 2013 
IMI offers €12.2m for better ways of testing effectiveness of flu vaccines 
 FierceBiotech, 15 July 2013 
Europe eyes social media and mobile for data on bad drug reactions 
 Science, 12 July 2013 
E.U. Commission Beefs up Research Partnerships with Industry 
 Scrip, 21 April 2013 
INTERVIEW: Goldman's dreams of competitive collaboration as IMI 2 considered 
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  Fierce Biotech, 7 February 2013 
€196 million pan-European drug discovery platform launched 
 Reuters, 7 February 2013 
Drugmakers, academics pool R&D in $265 mln EU project 
 BioCentury, 24 January 2013 
IMI's collaborative chemistry 
 
Belgium 
 Belga Agency, 2 December 2013 
Europees project wil system ontwikkelen om veiligheid vaccins te kunnen onderzoeken 
(European project wants to develop system in order to be able to research vaccine safety) 
 RTBF, 14 May 2013 
Sur les traces de l'autisme génétique (Investigating genetic autism) 
 La Dernière Heure, 21 March 2013 
Une pandémie d’ici peu! (A pandemic coming soon!) 
 De Standaard, 8 February 2013 
Europese farmareuzen delen onderzoek (European pharma giants share research) 
 
Bulgaria 
 Meditsinski Digest, 28 July 2013 
Increasing antibiotic resistance, fewer antibiotics under development 
 
Czech Republic 
 Zdravotnické noviny, 16 December 2013 
Inovativní farmaceutické společnosti nabízejí českým vědcům pomocnou ruku (Innovative 
pharmaceutical companies offer Czech scientists a helping hand) 
 Medical Tribune, 20 May 2013 
Krátce ze světa farmacie (Short world of pharmacy) 
 Medical Tribune, 11 February 2013 
IMI – cesta k partnerství při výzkumu i realizaci (IMI - the path to partnership in research 
and implementation) 
 
Denmark 
 MedWatch, 11 December 2013 
Trecifret millionbeløb bag IMI-satsning på Alzheimers (Three-digit million figure behind IMI 
focus on Alzheimer's) 
 
Germany 
 Focus, 20 December 2013 
Werden künftig Stammzellen am Fließband produziert? (Will stem cells be made on a 
production line in the future?) 
 Die Welt, 19 December 2013 
Geschäft mit der Hoffnung bei Stammzellforschung (Promising business in stem cell 
research 
 Ärzte Zeitung, 11 December 2013 
Personalisierte Medizin rückt in den Vordergrund (Personalised medicine comes to the fore) 
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 Ärzte Zeitung, 4 October 2013 
EU gibt Innovationen Schub (EU gives innovations a boost) 
 Arzt Aspekte, 25 September 2013 
Schmerztherapie: so früh wie möglich – um Veränderungen des Gehirns vorzubeugen (Pain 
treatment: as early as possible – to prevent changes in the brain) 
 Deutsche Welle – Spectrum, 4 March 2013 
Make drugs not war 
 
Estonia 
 Eesti Päevaleht, 23 May 2013 
Euroopa Liit koondab joud ajuhaiguste vastu (The European Union joined forces on brain 
disease) 
 
Ireland 
 Medical Independent, 6 June 2013 
AD pre-diagnosis window crucial 
 Medical Independent, 23 May 2013 
Paternal age may have autism link 
 Independent, 11 March 2013 
Resistance to antibiotics risks health 'catastrophe' to rank with terrorism and climate 
change 
 
Greece 
 EKT, 29 July 2013 
Περισσότερα από 22 δισ. ευρώ επενδύουν η ΕΕ και η ευρωπαϊκή βιομηχανία στην έρευνα 
και την καινοτομία (More than 22 billion invested by the EU and European industry in 
research and innovation) 
 Pharma Market Journal, 20 February 2013 
Ανθεκτικότητα στα αντιβιοτικά: Συνεργασία 5 φαρμακευτικών εταιριών στις έρευνες 
(Antibiotic resistance: 5 pharmaceutical companies in research) 
 
Spain 
 La Voz de Galicia, 23 December 2013 
Los medicamentos que nos cambiarán la vida (The medicines that will change our lives) 
 Diario Medico, 27 May 2013 
Los emprendedores son esenciales (Entrepreneurs are essential) 
 
France 
 Europe Nouvelles, 23 December 2013 
Les variantes génétiques liées à la schizophrénie ont un impact chez les porteurs sains 
(Genetic variants link to schizophrenia have an impact in healthy carriers) 
 Les Echos, 2 April 2013 
Un plan européen de 195 millions d'euros pour inventer de nouveaux antibiotiques (A EUR 
 195 million European plan to invent new antibiotics) 
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 Italy 
 Agora Magazine, 2 December 2013 
Nasce ADVANCE, progetto europeo per il monitoraggio dei benefici e rischi dei vaccine 
(ADVANCE, European project for vaccines benefits and risks monitoring, was created) 
 Corriere Della Sera, 26 November 2013 
Vaccini, progetto europeo per monitorare benefici e rischi 
 
Latvia 
 Latvijas Avīze, 7 June 2013 
Postošais Alcheimers joprojām mīkla zinātniekiem (Devastating Alzheimer's is still an 
enigma for scientists) 
 Latvijas Avīze, 31 May 2013 
ES kā galvenos izvirza pētījumus un inovācijas neirozinātnēs  (The EU supports 
neuroscience research and innovation) 
 
Lithuania 
 Lietuvos Rytas, 6 December 2013 
Vaistų gamintojams kryptį rodo mokslas (Pharmaceutical manufacturers' direction of science) 
 
Hungary 
 HaziPatika.com, 13 June 2013 
A jövő gyógyszereit ma fejlesztik (The future of medicines being developed today) 
 
Netherlands 
 De Telegraaf, 26 November 2013 
Effect vaccinatie sneller in kaart (Effects of vaccination mapped faster) 
 De Volkskrant, 7 February 2013 
Bundeling kennis voor nieuwe medicijnen (Bundling knowledge for new medicines) 
 
Poland 
 Gazeta dla Lekarzy, May 2013 
Innovative Medicine Initiative Stakeholder Forum 
 
Slovakia 
 Quark, 2 April 2013 
Spolupraca je všetko (Cooperation is everything) 
 Pravda, 5 March 2013 
Univerzita Komenského prispieva k špičkovému vzdelávaniu o liekoch (University 
contributes to excellent medicines education) 
 
Finland 
 Talouselämä, 11 March 2013 
Globaali aikapommi uhkaa terveydenhoidossa - "samanlainen kansakunnan uhka kuin 
terrorismikin" - Global time bomb threatening to health care - "similar to the nation as the 
threat of terrorism" 
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Sweden 
 SverigesRadio - Kropp & Själ, 29 October 2013 
Bakteriekriget (Bacterial war) 
 
United Kingdom 
 Nature, 16 December 2013 
Man versus microbe: warfare at its worst 
 ITV, 10 December 2013 
Dementia replaces cancer as disease people fear most 
 Financial Times, 6 December 2013 
Science: High-tech drug research gives us a fuller picture 
 Financial Times, 17 October 2013 
Doctor prescribes boost for biomedicine in EU 
 Financial Times, 12 August 2013  
Pharmaceuticals: Back to the lab  
 Financial Times, 21 April 2013 
Healing the UK pharma industry 
 Chemistry World, 13 March 2013 
Antibiotic resistance is a ‘ticking time bomb’ 
 The Guardian, 11 March 2013 
New wave of 'superbugs' poses dire threat, says chief medical officer 
 BBC, 11 March 2013 
Antibiotics resistance 'as big a risk as terrorism' - medical chief 
 Scottish Government, 7 February 2013 
Lanarkshire and Dundee in £100M life science project 
 Nature, 7 February 2013 
Europe bets on drug discovery 
 BBC, 7 February 2013 
Scottish consortium wins £100m drug research contract 
 Nature Biotechnology, 7 February 2013 
Industry backs biocatalysis for greener manufacturing 
 Nature Biotechnology, January 2013 
Banking iPS cells 
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 ANNEX E - TABLE OF ONGOING IMI PROJECTS AS AT 31 DECEMBER 2013 
Project 
acronym 
Full project title Website Subject area 
ABIRISK Anti-biopharmaceutical immunization: prediction 
and analysis of clinical relevance to minimize the 
risk 
www.abirisk.eu drug safety 
ADVANCE Accelerated development of vaccine benefit-risk 
collaboration in Europe 
 vaccines 
AETIONOMY Organising mechanistic knowledge about 
neurodegenerative diseases for the 
improvement of drug development and therapy 
 Alzheimer's disease 
and Parkinson's 
disease 
BioVacSafe Biomarkers For enhanced vaccine safety www.biovacsafe.eu vaccines 
BTCure Be the cure www.btcure.eu rheumatoid 
arthritis 
CHEM21 Chemical manufacturing methods for the 21st 
century pharmaceutical industries 
www.chem21.eu green chemistry 
COMBACTE Combatting bacterial resistance in Europe www.combacte.com antimicrobial 
resistance 
COMPACT Collaboration on the optimisation of 
macromolecular pharmaceutical access to 
cellular targets 
www.compact-
research.org 
drug delivery 
DDMoRe Drug disease model resources www.ddmore.eu knowledge 
management 
DIRECT Diabetes research on patient stratification www.direct-diabetes.org diabetes 
EBiSC European bank for induced pluripotent stem 
cells 
 stem cells 
EHR4CR Electronic health record systems for clinical 
research 
www.ehr4cr.eu knowledge 
management 
EMIF European medical information framework www.emif.eu knowledge 
management, 
Alzheimer's 
disease, metabolic 
syndromes 
EMTRAIN European medicines research training network www.emtrain.eu education and 
training 
ENABLE European Gram negative antibacterial engine  antimicrobial 
resistance 
eTOX Integrating bioinformatics and chemoinformatics 
approaches for the development of expert 
systems allowing the in silico prediction of 
toxicities 
www.e-tox.net knowledge 
management, drug 
safety 
eTRIKS Delivering European translational information & 
knowledge management services 
www.etriks.org knowledge 
management 
Eu2P European programme in pharmacovigilance and 
pharmacoepidemiology 
www.eu2p.org education and 
training 
EU-AIMS European autism interventions - a multicentre 
study for developing new medications 
www.eu-aims.eu autism 
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Project 
acronym 
Full project title Website Subject area 
ELF European lead factory www.europeanleadfactory
.eu 
drug discovery 
EUPATI European patients' academy on therapeutic 
innovation 
www.patientsacademy.eu education and 
training 
Europain Understanding chronic pain and improving its 
treatment 
www.imieuropain.org chronic pain 
GetReal Incorporating real-life clinical data into drug 
development 
 relative 
effectiveness 
IMIDIA Improving beta-cell function and identification of 
diagnostic biomarkers for treatment monitoring 
in diabetes 
www.imidia.org diabetes 
K4DD Kinetics for drug discovery www.k4dd.eu drug discovery 
MARCAR Biomarkers and molecular tumor classification 
for non-genotoxic carcinogenesis 
www.imi-marcar.eu safety, cancer 
MIP-DILI Mechanism-based integrated systems for the 
prediction of drug-induced liver injury 
www.mip-dili.eu drug safety 
NEWMEDS Novel methods leading to new medications in 
depression and schizophrenia 
www.newmeds-
europe.com 
schizophrenia, 
depression 
OncoTrack Methods for systematic next generation 
oncology biomarker development 
www.oncotrack.eu cancer 
Open PHACTS The open pharmacological concepts triple store www.openphacts.org knowledge 
management 
OrBiTo Oral biopharmaceutics tools www.orbitoproject.eu drug delivery 
Pharma-Cog Prediction of cognitive properties of new drug 
candidates for neurodegenerative diseases in the 
early clinical development 
www.alzheimer-
europe.org/Research/Phar
maCog 
Alzheimer's disease 
PharmaTrain Pharmaceutical medicine training programme www.pharmatrain.eu education and 
training 
PRECISESADS Molecular reclassification to find clinically useful 
biomarkers for systemic autoimmune diseases 
 rheumatoid 
arthritis and lupus 
PREDECT New models for preclinical evaluation of drug 
efficacy in common solid tumours 
www.predect.eu cancer 
PreDiCT-TB Model-based preclinical development of anti-
tuberculosis drug combinations 
www.predict-tb.eu tuberculosis 
PROactive Physical activity as a crucial patient reported 
outcome in COPD 
www.proactivecopd.com chronic obstructive 
pulmonary disease 
(COPD) 
PROTECT Pharmacoepidemiolocal research on outcomes 
of therapeutics by a European consortium 
www.imi-protect.eu pharmacovigilance 
QuIC-ConCePT Quantitative imaging in cancer: connecting 
cellular processes with therapy 
www.quic-concept.eu cancer 
RAPP-ID Development of rapid point-of-care test 
platforms for infectious diseases 
www.rapp-id.eu infectious diseases 
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 Project 
acronym 
Full project title Website Subject area 
SafeSciMET European modular education and training 
programme in safety sciences for medicines 
www.safescimet.eu education and 
training 
SAFE-T Safer and faster evidence-based translation www.imi-safe-t.eu drug safety 
StemBANCC Stem cells for biological assays of novel drugs 
and predictive toxicology 
www.stembancc.org stem cells 
SUMMIT Surrogate markers for vascular micro- and 
macrovascular hard endpoints for innovative 
diabetes tools 
www.imi-summit.eu diabetes 
TRANSLOCATI
ON 
Molecular basis of the outer membrane 
permeability 
www.translocation.eu antimicrobial 
resistance 
U-BIOPRED Unbiased biomarkers for the prediction of 
respiratory disease outcomes 
www.ubiopred.eu asthma 
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List of acronyms
Acronym Meaning 
3D three-dimensional 
ABAC Accrual Based Accounting 
ABPI Association of the British Pharmaceutical Industry  
AchEi acetylcholine esterase inhibitor 
AD Alzheimer's disease 
ADR adverse drug reaction 
AER average error rate 
API active pharmaceutical ingredient 
ASD autism spectrum disorder 
ASL-FMRI arterial spin labelling functional magnetic resonance imaging 
ATLA  Alternatives to Laboratory Animals  
BIT Booking of IT material application 
BLA beta-lactamase inhibitor  
BRIDG Biomedical Research Integrated Domain Group 
CAD Carcinogenicity Assessment Document  
CAMD Coalition Against Major Diseases  
CDA confidential disclosure agreement 
CDASH Clinical Data Acquisition Standards Harmonization 
CDISC Clinical Data Interchange Standards Consortium  
CFAST Coalition for Accelerating Standards and Therapies  
CFS Certificate of Financial Statement 
CHMP Committee for Medicinal Products for Human Use  
CNS central nervous system 
CNV copy number variation 
COPD chronic obstructive pulmonary disease 
CORDA Common Research Data Warehouse 
COST European Cooperation in Science and Technology  
C-Path Critical Path Institute 
CPD continuing professional development 
CPTR Critical Path to TB Drug Regimens 
CSF cerebrospinal fluid  
CTMM Center for Translational Molecular Medicine 
DG Directorate-General 
DIA Drug Information Association 
DIKI drug-induced kidney injury 
DILI drug-induced liver injury 
DIVI drug-induced vascular injury 
DN diabetes neuropathy  
DORA Document Registry Application 
DPO data protection officer 
E&T education and training 
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 Acronym Meaning 
EACPT European Association for Clinical Pharmacology and Therapeutics  
EAPM European Alliance for Personalised Medicine  
EASD European Association for the Study of Diabetes 
EC European Commission 
ECA European Court of Auditors 
eCDR electronic Career Development Report application   
eCORDA External Common Research Data Warehouse 
EDPS European Data Protection Supervisor  
EEG electroencephalograph 
EFPIA European Federation of Pharmaceutical Industries and Associations  
EHR electronic health record 
EMA European Medicines Agency 
ENSO Exploring New Scientific Opportunities 
EoI Expression of Interest 
ERA European Research Area 
EU European Union 
FCH Fuel Cells and Hydrogen 
FDA Food and Drug Administration  
FP7 Seventh Framework Programme 
FPP Full Project Proposal 
FTE full time equivalent 
GEMM genetically-engineered mouse model 
GMP good manufacturing practice 
GWAS genome-wide association study  
HL7 Health Level Seven International  
HR human resources 
HTS high throughput screening 
IAC Internal Audit Capability  
IAS Internal Audit Service of the European Commission 
ICC Internal Control Coordinator 
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
ICI International Congress of Immunology  
ICS Internal Control Standards  
ICT Information and communication technology  
IHC immunohistochemistry 
ILG Industry Liaison Group 
IMI Innovative Medicines Initiative 
IP intellectual property 
ISA Information System for Absences 
ISO International Organization for Standardization  
IT  information technology 
ITI-PF&S innovative therapeutic interventions against physical frailty and sarcopenia  
IVC International Venture Club 
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Acronym Meaning 
JAMA Journal of the American Medical Association 
JDRF Juvenile Diabetes Research Foundation 
JTI Joint Technology Initiative  
JU Joint Undertaking 
KPI key performance indicator 
KU Leuven Katholieke Universiteit Leuven  
LSE London School of Economics 
MAPP medicines adaptive pathways to patients 
MCI mild cognitive impairment 
MDL modelling description language  
MEP Member of the European Parliament 
MoU memorandum of understanding 
MRC Medical Research Council 
MRI magnetic resonance imaging 
NCATS National Center for Advancing Translational Sciences 
ND4BB New Drugs for Bad Bugs 
NFAT Nuclear Factor of Activated T-Cells 
NGC non-genotoxic carcinogen 
NIA-AA National Institute on Aging–Alzheimer's Association 
NIH National Institutes of Health 
OLAF European Anti-Fraud Office 
PDX patient-derived xenograph  
PET positron emission tomography 
PharmML pharmacometrics markup language  
phMRI pharmacological magnetic resonance imaging  
PM² Project Management Methodology 
PMDA Pharmaceuticals and Medical Devices Agency  
POCT point of care test  
PPP public-private partnership 
PR  public relations 
PRO patient-reported outcome 
PRRE Private Remote Research Environment  
PSTC Predictive Safety Testing Consortium  
Q&A question and answer 
R&D research and development 
RA rheumatoid arthritis  
RAE risk assessment exercise 
RepER representative error rate 
ResER residual error rate 
SDTM Study Data Tabulation Model 
SLE systemic lupus erythematosus 
SME small and medium-sized enterprise 
SOFIA Submission of Information Application 
SRA Strategic Research Agenda 
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 Acronym Meaning 
SRG States Representatives Group 
SSRI selective serotonin reuptake inhibitor  
SWP Safety Working Party 
TB tuberculosis 
TMA tissue microarray 
TraIT Translational Research Information Technology   
UML unified modelling language 
US United States 
UVB ultraviolet B 
VC venture capital 
VCF variant call format  
ZDF Zucker diabetic fatty  
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Innovative Medicines Initiative 
IMI JU Governing Board 
Analysis and Assessment of the Innovative Medicines Joint 
Undertaking 
Annual Activity Report 2013 (IMI JU AAR) 
Legal Basis 
Article 41 (2) of the IMI Financial Rules states that ‘by no later than 15 June each year, the Governing 
Board shall send the budgetary authority and the Court of Auditors an analysis and assessment of the 
authorizing officer’s annual report on the previous financial year. This analysis and assessment shall 
be included in the Annual Activity Report of the IMI Joint Undertaking, in accordance with the 
provisions of Article 18 of the Statutes’. 
Analysis 
The Innovative Medicines Initiative Annual Activity Report 2013 (Authorising Officer’s report) was 
presented to the IMI JU Governing Board in March 2014 and it is planned to have it approved by the 
Governing Board in June 2014. 
 
The Governing Board is of the opinion that the IMI JU AAR 2013 covers the main achievements of the 
IMI JU in 2013 in relation to the objectives set; clearly identifies the risks associated with the IMI JU 
operations; duly reports on the use made of the IMI JU resources provided; and indicates the 
efficiency and effectiveness of the IMI JU internal control system. 
 
The Governing Board recognizes the progress made by the IMU JU towards achieving the objectives 
set for year 2013 and notes in particular that: 
• The Annual Implementation Plan 2013 was approved on 22 December 2012. 
• With the launch of the last three Calls for Proposals under IMI 1 and the kick-off of 6 new 
projects, IMI continued to implement key strategic objectives of its Scientific Research 
Agenda and IMI committed entire of its available budget. This has been possible thanks to 
efficient collaboration between EC and EFPIA with the support from IMI SC and SRG and the 
entire JU office. 
• Continued analysis of projects deliverables indicates outstanding scientific performance with 
uptake of results in research processes, regulatory and clinical practice. The bibliometric 
analysis of IMI projects demonstrated impact factor higher than world and EU ‘s average 
confirming scientific excellence. 
• The second Interim Evaluation of IMI performed by independent experts documented the 
added value of IMI for the European Union. The expert panel was positive on the 
effectiveness, efficiency and quality of research and on the progress of IMI towards its 
objectives. 
 
 
 
 
Innovative Medicines Initiative (IMI) 
Postal mail: IMI JU, TO 56, Office 6/5 1049 Brussels  
Visiting address: Avenue de la Toison d'Or, 56-60, 1060 Brussels 
tel: +32 (0)2-221 81 81 – fax: +32 (0)2-221 81 74  DORA_2014-01939 
www.imi.europa.eu 
  
  
• Communication activities have been enhanced in particular towards scientific audiences, 
patient organisation and other possible applicants. 
• In 2013 IMI increased its focus on fostering cross-project interactions and collaboration as 
well as creating new relationships between multiple stakeholders, particularly with regards 
to promoting collaboration beyond IMI and Europe to achieve global impact. 
• The execution of 2nd Call projects was adequately followed up, including ex-ante and ex-post 
financial and scientific verifications. All 6 interim reviews expected in 2013 took place. 
• In 2013, IMI JU finalised 3 ex post reviews and audits (risk-based audits) on the declared in-
kind contribution of 3 EFPIA companies. 
• 70 ex-post audits of beneficiaries were finalised by the end of 2013. 
• IMI’s IT project management tool (SOFIA) was further developed to better support all Call 
processes. Since the third quarter of 2013 SOFIA is integrated with EC IT architecture for 
reporting on Call and project data, which is now available in Common Research Data 
warehouse (CORDA). 
• Simplification of call, application and reporting processes was put in place and implemented 
as of the 4th Call. Time to grant has improved (more than 400 days for call 3 to less than 150 
days for Call 6). 
• In 2013, the budget execution improved slightly compared to 2012, with 95.5% execution in 
commitment appropriations and 97.52% in payment appropriations. 
• The authorised maximum ceiling of 36 staff members was reached on 1 July 2012. Following 
the departure of staff members 4 new staff members joined IMI during 2013 (3 project 
officers and 1 administrative assistant). 
• IMI continued to promote SME participation in IMI projects. The SME involvement in IMI 
projects (Call 1 to 8) represents 15.2% and receiving 18.4 % of the IMI JU funding. 
• IMI JU enhanced communication activities and coverage in specialized/scientific press and in 
newer EU Member States and it focused on promoting IMI’s successes.  
 
Most of the key objectives were achieved in the expected time frame in a satisfactory manner.  
 
During 2013 the monitoring tools were fully operational and the IMI JU AAR 2013 provides 
information on the effectiveness of the internal controls implemented and on the main results of 
monitoring and supervision controls.  
 
Based on the information provided, the key objectives set up for 2013 have been met in compliance 
with legality, regularity and sound financial management. 
 
The technical and operational information provided in the report reflects the situation at the end of 
2013 in a realistic way. 
 
As recommendations for improvements, IMI should work further on the communication strategy to 
reach different groups with targeted messages, thus addressing the lack of visibility of IMI among 
specific groups within the scientific, healthcare and patient community.  
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The KPIs should be further developed to better measure and reflect Innovative Medicines Initiative’s 
overall objectives. There is also a need for the long-term strategy to better evaluate the general 
impact of IMI on the biopharmaceutical industry, the healthcare system and the European economy. 
 
Further work on sustainability of projects and uptake of results from IMI projects should also be 
undertaken. 
 
 
Assessment 
 
The declaration of the Executive Director’s and the IMI Annual Activity Report 2013 gives a fair 
assessment (clear, unambiguous, congruous) of operational and financial management in relation to 
the achievement of objectives, and the legality and regularity of the financial operations of the IMI JU 
in the year 2013.  
 
However, the reservation concerning the rate of residual errors with regard to the accuracy of cost 
claims submitted by participants of IMI JU projects should be noted. 
 
Therefore, the IMI JU Governing Board hereby adopts this assessment of the IMI Annual Activity 
Report 2013 of the authorizing officer. This assessment will be included into the IMI Annual Activity 
Report 2013. 
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